A

Abbadessa S, 797
Abe M, 2049
Abeles M, 2152
Abernethy ML, 1380
Abraham GE, 953
Abrahamowicz M, 1602, 2078
Abu-Shakra M, 241, 1259, 1265, 1386, 2100
Accardo S, 1802
Achenbach G, 554
Achkar AA, 93, 360
Acquaviva PC, 844
Adamashvili I, 1025
Adams ME, S43-94
Adebajo AO, 1434
Aerssens J, S43-98
Afek A, 1068
Afshari S, 2344
Agarwal SS, 2349
Aguado JM, 2193
Agudelo CA, 344
Ahern M, 2065
Ahmad S, 915
Ahmed N, 1235
Aho H, 16
Aho K, 1065, 2186, 2213
Aiach M, 1215
Aigner T, S43-152
Airio A, 1300
Al Dalaan A, 904, 2008
Al Swailem R, 1601
Al-Balaa SR, 904
Al-Janadi MA, 904
Al-Mousily F, 2344
Al-Sedairy S, 904
Alaeddine N, 1599
Alarcon-Segovia D, 1894, 1899
Albert DA, 1646
Albrecht M, 109
Aledort D, 2177
Alexandre C, 2183
Alfa M, 1602, 1947
Algert C, 1663
Allegue F, 2009
Allen GL, 180
Allen SH, 1577, 2084
Alonso-Ruiz A, 501
Altman RD, 1442 S43-42, S43-56, S43-146
Altmeyer P, 1286
Altomonte L, 649
Ameis A, 372
Ammerman S, 544
Amoroso K, 1166
Anagnostopoulos I, 252
Ananjeva LP, 689
Anastassiades P, 1600
Anastassiades T, 440, 1598, 1600, 1600, 1605
Anaya J, 557, 595, 1152
Anderson J, 151
Anderson JJ, 218, 432
Andersson-Gare B, 295, 308
Andreu M, 572
Angles-Cano E, 1688
Anichini E, S43-120
Anthony JM, 432
Aosaki N, 1483
Aramburu JM, 792
Aramini L, 1574
Arana RM, 1352
Aranason A, 1862
Aringer M, 926
Arinoviche Schenker R, S43-2
Armstrong S, S43-155
Arndt JW, 1461
Arner EC, 1338
Arnold WJ, 1722
Arostegui J, 792
Arriagada M, 1352
Arthur AB, 1601
Arvanitis A, 252
Asano G, 1624
Asherson RA, 621, 669
Askar MA, 1235
Astion ML, 571
Athreya BH, 1149
Atkinson K, 1809
Atra E, 270
Augustine AJ, 1740
Autran B, 2006
Avina-Zubieta A, 625, 1600, 1603
Awad M, 702
Ayling-Campos A, 326
Ayoub EM, 1075
Azzini M, 103

B

Babyn P, 1747
Bachmeyer C, 1384
Backman E, 1159
Badley EM, 204, 573, 733, 959, 1934, S43-19
Baethge BA, 450
Baglioni AJ, 1141
Bahabri S, 904
Bailey D, 1604
Bailey S, 1356
Baker PR, 1420
Bakker C, 1197, 1304, 1536
Balk RA, 1043
Bambara L, 103
Banares AA, 413, 1112
Bar-Khayim Y, 2366
Bargman JM, 5
Baron M, 1271
Barras C, 1224
Barskova VG, 689
Barth J, 1286
Bartoli E, 1060 ,1442, 1674
Baruffo A, 797
Bas J, 1891
Bas S, 1224
Bateman JF, S43-37
Batista N, 1352
Battistel B, 1499
Baum J, 164
Bayeux M, 1771
Beardmore TD, 1844, 2192
Beaufils H, 791
Beaulieu A, 915
Beckers C, 850
Belanger R, 1971
Belhorn LR, 2226
Bell M, 218, 617, 915
Bellamy N, 617, 915, 1203, 1271, 1442, S43-49
Belza BL, 639
Ben David D, 2366
Ben-Yehuda A, 2166
Ben-Yehuda D, 2166
Benazet JF, 607
Benitez-del-Castillo JM, 1112
Bennett K, 1536
Bennett RM, 133, 372, 1393
Bensen WG, 617, 915
Benucci M, S43-120
Beraneck L, 1804
Berenbaum F, 1804
Berg E, 2208
Berglund J, 695
Berglund K, 569
Berman A, 2148
Bernet VJ, 574
Berry H, 1941
Berthelot J, 2135
Bertouch JV, 469
Bianchi G, 571
Bijlsma JW, 644, 1466, 1766
Binder A, 1825
Biousse V, 1215
Bisagni-Faure A, 255, 1230
Bisighini G, 1499
Bitter T, 2371
Bjarnason D, 1097
Bjelle A, 1559
Black CM, 1217
Blackmore M, 886
Blanche P, 1384
Blanco A, 2238
Blanco F, S43-104
Blanco-Rodriguez J, 566
Bland JM, 214
Blank M, 1068
Blaser J, 2285
Blasum C, 1286
Bleasel JF, 255, S43-34
Bletry O, 1215, 2103
Blocka K, 1600, 1604
Bloom BJ, 320, 1953
Blotman F, 2189
Blumberg H, 782
Blyth T, 552
Boers M, 980, 1185, 1203, 1420, 1431, 1783
Bogoch E, 1604, 2114
Boiocchi M, 1674
Boire G, 789, 1352, 1599
Boki K, 2046
Bologna C, 1829
Bolwijn P, 1304, 1536
Bombardier C, 617, 989, 1193
Bonafede R, 133
Bonnin MR, 1455, 2238
Bookman AA, 617, 1604
Borah B, 855
Borg G, 2208
Borg Y, 1586
Bortolon C, 533, 541
Borzy MS, 332
Bosch X, 2038
Boulange M, 1315
Bourke BE, 214, 370
Bowyer SL, 165, 790
Boyce JT, 855
Braganza JM, 374
Brahn E, 177
Brama TT, 469, 494
Brancos M, 1504
Brandt DA, 109
Brandt KD, 109, 201, 1442, 1732, S43-149
Brandwein SR, 462
Brauner M, 876
Bravo-Gatica GC, 45
Breedveld FC, 34, 385, 611, 1461
Brennan P, 1277
Brenner M, 394
Bresnihan B, 1211
Bressot N, 1829
Bretal-Laranga M, 566
Briancon S, 1834
Brittain DC, 1947
Britz P, 482
Broadwell LH, 450
Brodin U, 2208
Brooks PM, 85, 980, 982, 998, 1420, 1431, 1809
Brouillard D, 440, 1598
Brucato A, 533, 541
Bruhlmann P, 473
Bruyn GA, 1373
Bryant G, 1097
Bryant L, 1527
Buchanan W, 915
Buckelew SP, 2307
Buckland-Wright C, 937
Buckley LM, 1055
Buckwalter J, S43-13
Buday M, 1514
Budinger TF, S43-62
Buffrini L, 571
Bulow P, 1544
Burgos-Vargas R, 2331
Burnell RH, 548
Burns R, 1124
Buskila D, 525
Byron M, 1694

C

Caamano-Freire M, 566
Cabiedes J, 1894, 1899
Cabral AR, 497, 1894, 1899

A

Abbadessa S, 797
Abe M, 2049
Abeles M, 2152
Abernethy ML, 1380
Abraham GE, 953
Abrahamowicz M, 1602, 2078
Abu-Shakra M, 241, 1259, 1265, 1386, 2100
Accardo S, 1802
Achenbach G, 554
Achkar AA, 93, 360
Acquaviva PC, 844
Adamashvili I, 1025
Adams ME, S43-94
Adebajo AO, 1434
Aerssens J, S43-98
Afek A, 1068
Afshari S, 2344
Agarwal SS, 2349
Aguado JM, 2193
Agudelo CA, 344
Ahern M, 2065
Ahmad S, 915
Ahmed N, 1235
Aho H, 16
Aho K, 1065, 2186, 2213
Aiach M, 1215
Aigner T, S43-152
Airio A, 1300
Al Dalaan A, 904, 2008
Al Swailem R, 1601
Al-Balaa SR, 904
Al-Janadi MA, 904
Al-Mousily F, 2344
Al-Sedairy S, 904
Alaeddine N, 1599
Alarcon-Segovia D, 1894, 1899
Albert DA, 1646
Albrecht M, 109
Aledort D, 2177
Alexandre C, 2183
Alfa M, 1602, 1947
Algert C, 1663
Allegue F, 2009
Allen GL, 180
Allen SH, 1577, 2084
Alonso-Ruiz A, 501
Altman RD, 1442 S43-42, S43-56, S43-146
Altmeyer P, 1286
Altomonte L, 649
Ameis A, 372
Ammerman S, 544
Amoroso K, 1166
Anagnostopoulos I, 252
Ananjeva LP, 689
Anastassiades P, 1600
Anastassiades T, 440, 1598, 1600, 1600, 1605
Anaya J, 557, 595, 1152
Anderson J, 151
Anderson JJ, 218, 432
Andersson-Gare B, 295, 308
Andreu M, 572
Angles-Cano E, 1688
Anichini E, S43-120
Anthony JM, 432
Aosaki N, 1483
Aramburu JM, 792
Aramini L, 1574
Arana RM, 1352
Aranason A, 1862
Aringer M, 926
Arinoviche Schenker R, S43-2
Armstrong S, S43-155
Arndt JW, 1461
Arner EC, 1338
Arnold WJ, 1722
Arostegui J, 792
Arriagada M, 1352
Arthur AB, 1601
Arvanitis A, 252
Asano G, 1624
Asherson RA, 621, 669
Askar MA, 1235
Astion ML, 571
Athreya BH, 1149
Atkinson K, 1809
Atra E, 270
Augustine AJ, 1740
Autran B, 2006
Avina-Zubieta A, 625, 1600, 1603
Awad M, 702
Ayling-Campos A, 326
Ayoub EM, 1075
Azzini M, 103

B

Babyn P, 1747
Bachmeyer C, 1384
Backman E, 1159
Badley EM, 204, 573, 733, 959, 1934, S43-19
Baethge BA, 450
Baglioni AJ, 1141
Bahabri S, 904
Bailey D, 1604
Bailey S, 1356
Baker PR, 1420
Bakker C, 1197, 1304, 1536
Balk RA, 1043
Bambara L, 103
Banares AA, 413, 1112
Bar-Khayim Y, 2366
Bargman JM, 5
Baron M, 1271
Barras C, 1224
Barskova VG, 689
Barth J, 1286
Bartoli E, 1060 ,1442, 1674
Baruffo A, 797
Bas J, 1891
Bas S, 1224
Bateman JF, S43-37
Batista N, 1352
Battistel B, 1499
Baum J, 164
Bayeux M, 1771
Beardmore TD, 1844, 2192
Beaufils H, 791
Beaulieu A, 915
Beckers C, 850
Belanger R, 1971
Belhorn LR, 2226
Bell M, 218, 617, 915
Bellamy N, 617, 915, 1203, 1271, 1442, S43-49
Belza BL, 639
Ben David D, 2366
Ben-Yehuda A, 2166
Ben-Yehuda D, 2166
Benazet JF, 607
Benitez-del-Castillo JM, 1112
Bennett K, 1536
Bennett RM, 133, 372, 1393
Bensen WG, 617, 915
Benucci M, S43-120
Beraneck L, 1804
Berenbaum F, 1804
Berg E, 2208
Berglund J, 695
Berglund K, 569
Berman A, 2148
Bernet VJ, 574
Berry H, 1941
Berthelot J, 2135
Bertouch JV, 469
Bianchi G, 571
Bijlsma JW, 644, 1466, 1766
Binder A, 1825
Biousse V, 1215
Bisagni-Faure A, 255, 1230
Bisighini G, 1499
Bitter T, 2371
Bjarnason D, 1097
Bjelle A, 1559
Black CM, 1217
Blackmore M, 886
Blanche P, 1384
Blanco A, 2238
Blanco F, S43-104
Blanco-Rodriguez J, 566
Bland JM, 214
Blank M, 1068
Blaser J, 2285
Blasum C, 1286
Bleasel JF, 255, S43-34
Bletry O, 1215, 2103
Blocka K, 1600, 1604
Bloom BJ, 320, 1953
Blotman F, 2189
Blumberg H, 782
Blyth T, 552
Boers M, 980, 1185, 1203, 1420, 1431, 1783
Bogoch E, 1604, 2114
Boiocchi M, 1674
Boire G, 789, 1352, 1599
Boki K, 2046
Bologna C, 1829
Bolwijn P, 1304, 1536
Bombardier C, 617, 989, 1193
Bonafede R, 133
Bonnin MR, 1455, 2238
Bookman AA, 617, 1604
Borah B, 855
Borg G, 2208
Borg Y, 1586
Bortolon C, 533, 541
Borzy MS, 332
Bosch X, 2038
Boulange M, 1315
Bourke BE, 214, 370
Bowyer SL, 165, 790
Boyce JT, 855
Braganza JM, 374
Brahn E, 177
Brama TT, 469, 494
Brancos M, 1504
Brandt DA, 109
Brandt KD, 109, 201, 1442, 1732, S43-149
Brandwein SR, 462
Brauner M, 876
Bravo-Gatica GC, 45
Breedveld FC, 34, 385, 611, 1461
Brennan P, 1277
Brenner M, 394
Bresnihan B, 1211
Bressot N, 1829
Bretal-Laranga M, 566
Briancon S, 1834
Brittain DC, 1947
Britz P, 482
Broadwell LH, 450
Brodin U, 2208
Brooks PM, 85, 980, 982, 998, 1420, 1431, 1809
Brouillard D, 440, 1598
Brucato A, 533, 541
Bruhlmann P, 473
Bruyn GA, 1373
Bryant G, 1097
Bryant L, 1527
Buchanan W, 915
Buckelew SP, 2307
Buckland-Wright C, 937
Buckley LM, 1055
Buckwalter J, S43-13
Buday M, 1514
Budinger TF, S43-62
Buffrini L, 571
Bulow P, 1544
Burgos-Vargas R, 2331
Burnell RH, 548
Burns R, 1124
Buskila D, 525
Byron M, 1694

C

Caamano-Freire M, 566
Cabiedes J, 1894, 1899
Cabral AR, 497, 1894, 1899

Cabral DA, 548
Cabrera GE, 236, 557
Cairns RA, 548
Calabozo M, 501
Calabrese LH, 662, 2370
Caldwell JR, 1757
Calin A, 740, 794, 1609
Callahan LF, 1434, 1435, 1983
Callen JP, 1380
Calore EE, 2246
Camargo-Corone AC, 45
Campbell J, 915, 1271
Cannon GW, 207
Cantatore FP, 1913
Capell HA, 224
Carbone A, 1674
Carbotte RM, 863
Careless D, 1598, 1602
Carette S, 590, 617, 1271
Caricchio R, 649
Carlson B, 1601
Carpenter MT, 1527
Carrasquillo JA, 478
Carter CS, 478
Carthy D, 2203
Cartularo KS, 1055
Cassidy JT, 1577
Castell M, 124
Castello-Sendra J, 73
Castellote C, 124
Catalin J, 844
Caton J, S43-133
Caughey DE, 1005
Cavaliere MJ, 2246
Cedoz JP, 1884
Cervera H, 1867
Cervera R, 62
Chaibi P, 375
Chakravarty KK, 1694
Challa VR, 344
Chalmers A, 617, 1311, 1391, 1802, 2163
Chalmers IM, 1271, 1601, 1967
Chan C, 1605
Chan D, S43-37
Chan RM, 1321
Chaouni I, 394
Chartier S, 868
Chaudhry-Ahluwalia V, 1604
Chavanon P, 1208
Cheevers WP, 8
Chen CC, 478
Chen J, 1450, 2034
Chen T, 1704
Cheng H, 2006
Chennebault JM, 2191
Chermat-Izard V, 1651
Chernoff MC, 218
Cheseaux JJ, 766
Cheung NT, 2004
Chikanza IC, 600
Chiu B, 1598
Chivers T, 85
Chmiel JF, 762
Choi E, 1356
Cholewczynski JG, 1757
Chopra RK, 1605
Choquette D, 78
Chrischilles EA, 2142
Chu-Lee A, 2372
Cimmino MA, 1802
Cisnal del Mazo A, 246
Citera G, 347
Cividino A, 617
Clarke AE, 189, 1602
Clauw DJ, 161
Clements PJ, 1281
Clerc D, 1803
Cloutier J, 1599, S43-109
Cobb R, 2152
Cochand-Priollet B, 1174
Coffey JW, 1922
Coggon D, 1509
Cohen LM, 1722
Cohen M, 1097
Cohen MG, 575
Cohen P, 876
Cole B, 207
Cole WG, S43-37
Coll J, 1488
Col!ado A, 1504, 2038
Collantes-Estevez E, 246
Collier DH, 1281
Collin JF, 1315
Collins RC, 1338
Coluccio E, 541
Combe B, 188, 790
Conaghan PG, 983
Conant E, 881
Conca W, 782, 2188
Connell D, 1311, 1605
Conrad K, 1286
Constant F, 1315
Contreras M, 1891
Coodley GO, 174
Cooper C, 1509, S43-10
Cooper KD, 29
Cooper SM, 1055
Cope AP, 382
Copperman N, 1347
Cornu O, 262
Corominas Torres JM, 1488
Corrigall V, 1020
Corrocher R, 103
Cossermelli W, 633
Coste J, 1230
Cox D, 881
Coyte PC, 1209
Crausman RS, 554
Creed F, 2187
Creemers M, 1104
Cremonesi T, 1499
Crilly A, 224
Criswell LA, 829
Crofford LJ, 2159
Croker BP, 1075
Cron RQ, 1962
Cross AR, 1747
Crotty M, 1934
Crowson CS, S43-23
Cruz TF, 117, 1714
Cuadrado MJ, 1589
Cuellar ML, 236, 347, 1710
Cunningham K, 1825
Cush JJ, 187
Cuvelier C, 680, 2266, 2273, 2279

D

d'Agay MF, 1174
D'Agosto A, 1674
d'Anglejan G, 1174
D'Cruz D, 1669
da Costa T, 2374
Daft L, 1514
Dagenais P, 789
Dales P, 1271
Dalinka MK, 976
Damade R, 1771
Danneskiold-Samsoe B, 1138
Danoff D, 1602, 2078
Darras-Joly C, 876
David MJ, S43-133
Davis P, 915, 1603, 1762
Davis WC, 8
Dawes PT, 1800, 2004
Day RO, 983, 998, 2295
De Bandt M, 1395
De Benedetti F, 1581
de Bois MH, 1461
De Clerck LS, 2279
De Clercq L, 2266, 2273
de Crombrugghe B, S43-140
De Juli E, 533, 541
de Koning M, 1520
de la Vega G, 497
de Lourdes Sanchez ML, 45
De Re V, 1674
De Sole P, 649
De Vita S, 1442, 1674
De Vos M, 680, 2266, 2273, 2279
de Wilde EJ, 751
Deal CL, 1757
DeBari VA, 2233
DeInocencio J, 1438
Dekker JJ, 1326, 1766
del Olmo J, 183
Del Rosso A, S43-120
Del Rosso M, S43-120
Dellhag B, 1559
Demers DJ, 1365
Demers ML, 1214
DeNardo BA, 790
Denburg JA, 863
Denburg SD, 863
Denko CW, 2191
Dennis GJ, 188
Dequeker J, 1013, S43-98
Derfus BA, 1514
Dersimonian H, 394
Derumeaux G, 1586
Des Rosier KF, 1527
DeShane PJ, 944
Despres N, 789
Dewar CL, 1604
Di Munno O, 1492
Diamond HS, 817
DiBattista JA, 1599, S43-123
Dick T, 67
Dieppe PA, 201, 2132, S43-136
Dieudonne D, 1726
Dijkmans BA, 34611
DiMeo TM, 1338
Dinant HJ, 1766
Dines K, 109
Dixon M, 1281
Doeglas D, 1834
Doherty M, 2013
Doherty PJ, 1220
Dolan AL, 1020
Dolcetti R, 1674
Dombret H, 1174
Domenech P, 1891
Donald F, 1604
Dong Y, 659
Dostal, Sr. C, 2055
Dourado GS, S43-94
Douwes N, 611
Downey DC, 133
Doyle DV, 1118, 1509
Doyle JJ, 574
Dreyfus F, 1384
Driscoll DJ, 2346
Drosos AA, 2046
Druetz-Van Egeren A, 262
Drummond M, 1403, 1408, 1418
Duarte C, 2331
Dubois T, 1230
Duchemin J, 1215
Ducloux J, 2135
Dudler J, S43-104
Duffy DA, 1214
Duke O, 1608
Duku E, 1420
Duna G, 662, 2370
Dunckley H, 85
Dupuis L, 1570
Dupuis M, 1599
Dupuy d'Angeac A, 394
Durand A, 844
Durk H, 2194
Duro JC, 572
Dwolatzky T, 713

E

Earle L, 881
Eastwood BJ, 55, 2009
Eberhardt KB, 1037
Ebringer A, 1825
Eckman JM, 1001
Edmonds JP, 1241
Edworthy SM, 617
Eggelmeijer F, 561
Egger P, 1509
Egsmose C, 2208
Ehle B, 1998
Ehrlich LS, 1646
Eisman JA, 921, 932
Eitrem R, 695
El-Kadi HS, 2233
Elewaut D, 680, 2266, 2273, 2279
Ellis CN, 894
Elramahi K, 904
Elston RC, 227
Elwood R, 1321
Emery H, 1171
Emori T, 1681
Endo H, 791
Engelbrecht J, 1097
Englert H, 85, 469
Enkerlin HL, 1867
Erlacher L, 926

Erlendsson K, 1862
Ermini M, 1438
Escalante A, 1844, 2192
Esdaile JM, 78, 189, 915, 1211, 1602, 1603, 1604, 2062
Esgleyes-Ribot T, 73
Espinoza LR, 236, 347, 557, 595, 1710
Esseveld F, 751
Eto S, 2049
Ettinger WH, 1124
Evans CH, 1922
Evans TI, 2226
Eyre DR, S43-82

F

Falach-Vaknin E, 1086
Falcini F, 1438
Faltin, Jr. K, 1956
Faltynek CR, 1581
Fam AG, 1621
Farewell V, 241, 675, 886, 1601
Farhey YD, 1179
Farrera-Gamboa H, 2120
Fast M, 745
Fasth A, 295, 308
Favaro L, 899
Fawcett PT, 684
Fedorak RN, 1603
Feldman B, 326
Feldman M, 799
Felipe O, 347
Felson DT, 201, 218, 1203, S43-7
Feltes TF, 768
Fenton P, 1604
Fernandez M, 1867
Fernandez-Gutierrez B, 413, 1112
Ferraccioli GF, 1060, 1442, 1674, 1800
Ferraro G, 533
Ferraz MB, 270, 908, 1408, 1618
Ferri S, 899
Ferri W, 1478
Festen JJ, 338
Feuer J, 2170
Fex E, 1037
Fibbi G, S43-120
Fidler WK, 1600, 1604
Fielder M, 1825
Fijen CA, 1389
Fine PR, 505
Finger DR, 188, 574, 796, 2188, 2189
Fink CW, 1566
Fink SD, 967
Fisher GW, 817
Fishman P, 1086
Fiter J, 569
Fitzcharles M, 1603, 1604
FitzGerald O, 1211
FitzGerald OM, 2226
Fjalarsson M, 1862
Flaisler F, 188
Flanigan M, 1335
Flaster ER, 1872
Flechas JD, 953
Foldes K, 1441
Font J, 2038
Ford PM, 802
Ford SE, 802
Formiga F, 2238
Forre O, 143
Fort JG, 1335
Fortin L, 1971
Fortin PR, 78, 1602, 2078
Fosang AJ, S43-86
Fossdal R, 1862
Foster HE, 548
Fotino M, 1872
Fraenkel L, 1602
Fraga A, 1867
Frances C, 791, 1208, 1215
Franceschini F, 533
Franch A, 124
Francis H, 2295
Francis MD, 855
Frank K, 1286
Franssen M, 1104
Fraser DD, 1803
Fraser KJ, 1442
Fraser P, 1025
Frasson de Azevedo M, 1956
Fredrickson D, 1166
Free SM, 1757
Fried LP, S43-16
Frieden IJ, 1171
Fries JF, 995, 1203
Frigo A, 103
Fritzler M, 73, 521, 1688, 2371
Fu YZ, 2307
Fuchs HA, 1983
Fujimoto M, 563
Fujimoto N, S43-123
Fukuda K, 1483
Furst DE, 218, 1203, 1281
Fuster J, 1395

G

Gabriel SE, 93, 360, 1412, S43-23
Gahunia HK, 1747
Galianova A, 2055
Galindo-Rodriguez G, 1603
Gallay P, 1224
Gamez-Nava JI, 2120
Gamsu G, 455
Garcia CO, 1710
Garcia J, 1112
Garcia-Corbeira P, 2193
Garcia-De La Torre I, 73, 1688
Gardner GC, 1929
Garofalo S, S43-140
Garrett SL, 1609
Garry RF, 236
Gasparini M, 533, 541
Gatfosse M, 791
Gay RE, 275
Gay S, 275
Gazarian M, 2156
Gedalia A, 525
Geiler T, 275
Geisslinger G, 2295
Gelder F, 1025
Geltner D, 2007, 2366
Genant H, 2291
Gendron M, 1599
Geng Y, S43-104
Genth E, 67
Gerster JC, 371, 766, 1212, 2007
Ghessi A, 533
Ghirardo G, 571
Ghosh P, S43-155
Giannikos N, 252
Giannini EH, 1149, 1356
Giardina B, 649
Gibney KM, 684
Gibofsky A, 379
Gibson G, 1605
Gibson KR, 482
Girelli D, 103
Gishen P, 1941
Galbraith W, 1338
Gladman DD, 241, 675, 886, 1247, 1259, 1265, 1601, 1601, 1601, 1604, 2369
Glass DN, 1356
Glauser MP, 1224
Glickstein SL, 1141
Gloghini A, 1674
Godeau P, 187, 791, 1208, 2103
Goei The HS, 34
Goemaere S, 680, 2266, 2273, 2279
Golan TD, 376
Gold W, 455
Goldberg I, 1068
Goldberg V, S43-91
Golden HE, 1043
Golden M, 1043
Goldenberg DL, 2313
Goldenberg J, 1956
Goldlist BJ, 617
Goldman D, 1365
Goldsmith CH, 617, 944, 1420
Golub LM, 1726
Gomez-Mora P, 2331
Gomez-Reino JJ, 282
Gomez-Vargas A, 2120
Gonzalez F, 1112
Gonzalez-Lopez L, 2120
Gorordo JM, 792
Gottschalk R, 1603
Gotze O, 24
Gough J, 241, 1259, 1265
Gough JR, 1967
Goupille P, 2188, 2369
Gourley MF, 1812, 2159
Graham K, 174
Graham M, 654
Granger D, 1599
Granger D, 444
Graninger WB, 926
Grassanovich JL, 1631, 1636
Gratacos J, 1504
Greaves C, 1603
Green R, 1193
Greene MG, 529
Greenwald RA, 1726, 2004
Gregorio DI, 1663
Gribnau FW, 1104
Griffiths CE, 29
Griffiths MM, 207
Grober JS, 29, 894
Grom AA, 1356
Grondin C, 617
Grouix B, 1816, 2114
Grumbles RM, S43-146
Guarini P, 103
Guccione AA, 432
Guerra P, 1060
Guerrerosantos J, 73
Guillemin F, 1315, 1834
Guillevin L, 876
Guinot P, 1651
Gupta AK, 894
Gutierrez J, 1369
Gutierrez-Urena S, 1710
Guyatt GH, 1188
Guzman J, 2331
Guzman-Guzman JL, 2120
Gyselbrecht L, 680, 2279

H

Haafiz AB, 2344
Haanen HC, 1466
Haapasalmi K, 16
Haberman H, 3
Hachiya T, 1681
Hackshaw KV, 462
Haga M, 1600, 1604
Halko GJ, 2152
Hamilton JA, 1809
Hamilton R, 384, 1630, 2072
Hamilton TA, 894
Hammer HB, 24
Hammoudeh M, 1377
Hanly JG, 617, 1091, 1271
Hannema A, 1389
Hansen BU, 695
Hansten PD, 708
Haqqi TM, 255, S43-34
Harboe M, 24
Hardingham TE, S43-86
Harisdangkul V, 796
Harland C, 1608
Harman JG, 1631, 1636
Harris E, 227
Harris RR, 1338
Harrison LC, 654
Harrison M, 1277
Hart DA, 1688
Hart DJ, 1118, 1509, S43-46
Hart DN, 1326
Hart LE, 617, 944
Harth M, 722, 1608
Hashimoto H, 2173
Haslock I, 574
Hatzinikolaou P, 1108
Hauselmann HJ, S43-68
Hauta SA, 2337
Hawker G, 959, 1193
Hay E, 2187
Hayslett JP, 1211
Hazleman BL, 1434, 1694
Hearth-Holmes M, 450
Heer AH, 275
Heikkinen A, 427
Heilman J, 617
Heinegard D, S43-71
Heino J, 16
Helders PJ, 751

Helin H, 427
Heliovaara M, 2186
Hellio MP, S43-133
Hellmann DB, 455
Henderson DR, 803
Henke CJ, 829
Henriksen O, 1544
Henry D, 1203
Herborn G, 1976
Hermabessiere J, 2010
Herman JH, 1179
Hernandez MV, 183, 2008
Hernandez-Garcia C, 413, 1112
Hernandez-Rodriguez I, 2009
Herrero A, 501
Herrick AL, 374
Hershman E, 525
Hertzman PA, 161
Heumann D, 1224
Heuser MD, 1124
Hewett JE, 2307
Heywood G, 2188
Hickman Pepmueller P, 1577
Hidding A, 1304
Hilario MO, 1956
Hilkens PH, 342
Hilliquin P, 1651
Ho AC, 1365
Ho E, 1209
Hochberg MC, 488, 1445, 2291, S43-16
Hoffman E, 557
Hoffman GS, 478
Hoffman KC, 1757
Hoffman RA, 1922
Hoffman RW, 586
Hofler E, 406
Hogasen K, 24
Holbert C, S43-155
Holderbaum D, 255, S43-34
Holland N, 344
Holleman, Jr. DR, 727
Holman AJ, 1929
Holt PA, 1757
Holthofer H, 2046
Holthuysen AE, 2250
Hong C, 1091
Hooper M, 1820
Hori T, 2020
Houtman PM, 1373
Hovancik K, 855
How AR, 1321
Howard GA, S43-146
Howell DS, S43-146
Hoy MS, 1326
Hu C, 2006
Huang D, S43-94
Huang G, 371
Huang S, 617
Hubscher O, 1352
Hudson MJ, 1825
Hudson N, 1603
Huffman G, 1075
Hughes GR, 1589 1669
Hultquist R, 569
Humphrey SM, 970, 1602
Hunder GG, 93, 360, 1097
Hungerford DS, 1757
Hunter JA, 552
Hunter T, 2008
Huskisson EC, 1941
Husted J, 886, 1601
Huttenlocher A, 1171
Huyser B, 2307

I

Iakovou I, 252
International Group on Assessment of Disease Outcome in Scleroderma, 1277
Ihn H, 563
Ike RW, 29
Ikeda M, 1681
Ikemoto M, 2020
Iliopoulos A, 252
Ilowite NT, 758, 1347
Imbimbo B, 1492
Ingelmo M, 2038
Ingenito F, 1281
Inman RD, 970, 1598, 1602, 1602
Inoue K, 421
Inoue T, 812
Insua-Vilarino S, 566
Ioakimidis D, 252
Ishiwata T, 1624
Isola L, 2356
Isomaki HA, 1065, 1300, 2213
Ivaskova E, 2055
Iwamoto I, 2092

J

Jacenko O, S43-39
Jacobs JW, 1466
Jacobs MA, 1757
Jacobsen S, 1138
Jacobson MS, 1347
Jaffe IA, 2372
Jamali F, 1603
Jamar F, 850
James H, 55, 1091, 2009
James P, 1124
James WH, 794, 1607
Janoff HB, 976
Janosky J, 1478
Janzen LM, 1967
Jara LJ, 1867
Jasani M, 937
Jaspers PJ, 561
Jawaheer D, 1032
Jayson MI, 374
Jeandel C, 793
Jeffery JR, 1967
Jennings CA, 554
Jimenez SA, 881, S43-28
Jimenez de Anta M, 1504
Jimenez-Gil F, 2120
Johansen P, 1852
Johnson JC, 2307
Johnsson B, 1660
Jolicoeur FC, S43-115
Jones AC, 2013
Jones E, 55
Jones G, 921, 932
Jones JG, 186, 2007
Jones JV, 55, 1091, 2009
Jones K, 462
Jones SD, 1609
Jongen PJ, 576
Jonsdottir S, 1862
Jonsson T, 570, 2186
Joosten P, 1373
Jorgensen C, 394, 1829
Joseph AE, 214, 370
Joseph JM, 1365
Joseph L, 1211, 2062
Jover JA, 413, 1112
Juanola X, 1891
Jubb RW, 1941

K

Kaburaki J, 1210
Kaditis AG, 2346
Kageyama Y, 812
Kahaleh BM, 881
Kahn M, 1395, 2017
Kajiyama G, 1130
Kaklamanis P, 1108
Kalovidouris AE, 1698
Kaminska EA, 1271
Kamo Y, 2049
Kaneko K, 1483
Kano S, 668, 1681
Kaplan FS, 976
Kaplan G, 1804
Kaplan H, 2197
Kaplan S, 191
Karbowski A, S43-152
Karmochkine M, 375
Karras D, 252
Karsh J, 1208
Kashgarian M, 1211
Kasper J, S43-16
Katayama I, 1806
Kato S, 1483
Kato T, 2092
Kato Y, S43-158
Katona IM, 529, 1369
Katsu M, 1483
Katz A, 2114
Katz RS, 1043
Katzenstein P, S43-140
Kaufman LD, 157, 161, 282, 1776
Kaufman MA, 157
Kautiainen H, 1065
Kavanaugh A, 780
Kawai S, 1210
Kaye J, 1983
Kearney DL, 768
Keenan G, 1149
Keil LB, 2233
Keisler D, 1577
Kelley M, 1581
Kelly PJ, 921, 932
Kemppinen P, 2285
Kendall CJ, 1600, 1603
Kennedy L, 794, 1609
Keroack BJ, 29
Kerr GS, 478
Kerr LD, 2356
Kerr RG, 1714
Kessler MJ, 1747
Keysser C, 275
Keyszer GM, 275
Khamashta MA, 1589, 1669
Khanjar I, 1377
Khanna VN, 915
Kiansa K, 1599
Kieffer E, 2103
Kiely PD, 214, 370
Kiener H, 926
Kikuchi K, 563
Kim HK, 1714
Kim HA, 356
Kimoff J, 1604
Kimura K, 1806
Kingsley GH, 600
Kinoshita M, 1183
Kirkham BW, 654, 803
Kirsch CM, 455
Kiss MH, 2246
Kiuchi T, 668
Klein JP, 1636
Klinkhoff AV, 617, 915, 1601, 1655, 1657, 2163
Klipple GL, 796, 1369, 2189
Kloppenburg M, 611
Kneeland J, S43-60
Koami T, 1483
Kobayashi M, 2020
Kobayashi S, 2173
Kobayashi T, S43-78
Koeger AC, 375
Koh ET, 1386
Kohli M, 1393
Koide Y, 812
Kondo H, 791
Konrad K, 1441
Konttinen YT, 2285
Kooh SW, 2156
Koolwijk P, 385
Kopolovic J, 1068
Koren G, 1570
Korpela M, 427
Koszulinski R, 1726
Kotter I, 2194
Kovacs J, 1247
Koyama Y, 2049
Kraag G, 915
Kraaimaat FW, 644
Krafchik B, 2337
Kraus A, 497
Krause I, 1068
Krause T, 782
Kredich DW, 1166
Kremer JM, 384, 1630, 1967, 2072
Kriegsmann J, 275
Krogsgaard MR, 1660
Kroiher A, 2194
Krol B, 1834
Krupp LB, 157
Kuettner KE, S43-68
Kuis W, 751
Kuller LH, 1254
Kumar TR, 1235
Kuntz D, 1174
Kurki P, 2046
Kuroda A, 2020
Kuroda K, 2092
Kushida K, 812

Kutzer JE, 1254
Kvien TK, 514, 2218
Kwoh C, 482
Kwong T, 1347

L
La Canna R, 1913
La Montagna G, 797
Lacaille D, 1605
Lachenbruch PA, 1281
Lafage-Proust M, 2183
Lafforgue P, 844
Lai FM, 1295
Lai KN, 1295
Laing TJ, 29, 2126
Lally EV, 1281
Lamas Cedron P, 566
Lammert N, 2344
Lamour A, 2241
Landewe RB, 34
Landro NI, 137
Lane NE, 1130, 2291, S43-3
Lang BA, 168
Langlands DR, 2190
Lanting PJ, 338
Lapadula G, 1913
Larbre JP, 1436
Larjava H, 16
Larsen A, 1974, 1983
Larson MG, 78
Lassere MN, 1241
Laubenberger J, 782
Laurindo IM, 633
Laxer RM, 168, 326, 521, 1570, 2156, 2337
Le Corre R, 2241
Le Loet X, 1586
Le Roy D, 1224
Le Thi Huong D, 187, 791, 1208, 2103
Leclech C, 2191
Lederman MH, 1956
Lee M, 1604
Lee P, 1740
Lee P, 1271, 1386, 2100
Lefebvre V, S43-140
Leib ES, 1055
Leicht T, 1347
Leitman SF, 478
LeLorier J, S43-26
Lemaire C, 1747
Leners N, 850
Lentle BC, 2008
Lenz M, 262, S43-68
Lequesne M, 1442
Leroux JL, 2189
LeRoy E, 1876
Lesser RS, 2177
Lethbridge-Cejku M, 488
Leung CB, 1295
Leung MK, 1726
Lewis CG, 1757
Lewkonia RM, 186
Li EK, 575
Li PK, 1295
Li XC, 659
Liang MH, 1191, 1203
Libman BS, 351
Lie JT, 93, 186, 360, 363, 367, 774, 809, 2173, 2177, 2375
Liedvogel B, 1286
Lim KK, 2132
Lindehammar H, 1159
Link Study Group, 1941
Liote F, 1174
Littman BH, 1097
Liu H, 1450, 2034
Llena J, 2038
Lloyd M, 1589
Lo W, 1704
Lo Scocco G, 1499
Locht H, 2304
Lohmander L, 201, S43-75
Lombardi A, 1447
Long J, 241, 886, 1601
Looney RJ, 1820
Lopez JA, 1112
Lord SR, 921
Lortholary O, 876
Lotz M, S43-104
Love LA, 161
Lovell DJ, 1203, 1356, 1438
Loyau S, 1688
Lucero E, 2148
Luchi M, 799
Ludwicka A, 1876
Lugagne PM, 187
Luggen ME, 2226
Lui SF, 1295
Lund B, 1660, 2208
Luong MH, 625, 1600
Lussier A, 915
Luy L, 326
Luyrink L, 1356
Lynch JA, 937
Lynch NM, 1005

M
Macchioni P, 1499
Macen J, 1605
Macfarlane DG, 937
MacGregor AJ, 1032, 2203
Machtey I, 1607
MacKenzie T, 1211
MacLean C, 177
Madhok R, 224, 552
Maeda T, 2259
Magaro M, 649
Mageed RA, 2203
Maier R, S43-104
Maier R, 926
Main K, 1138
Maini RN, 382
Maisch SA, 768
Maisiak R, 505
Maitra SC, 2349
Maja L, 797
Maksymowych W, 625, 1600, 1605, 2027, 2120
Malemud CJ, S43-91
Malleson PN, 548
Malnick SD, 2007
Malone CC, 1075
Mandel NS, 1514
Manicourt D, 262, 850, S43-68
Mannoni A, S43-120
Manolios N, 85
Manor D, 2166
Mansilla J, 2327
Mansour M, 55, 1091, 2009
Mantovani W, 1499
Manuela Costa M, 2374
Manzi S, 1254, 1478
Marble DA, 207
March L, 1203
Marcos M, 1504
Marfeuille M, 1803
Mariette X, 1803
Marino C, 191
Marks RM, 2126
Markusse HM, 342, 1389
Marletta C, 1352
Martel-Pelletier J, 1599, 1599, S43-109, S43-115, S43-123, S43-160
Martin K, 780
Martin L, 198, 617
Martin RW, 1281
Martinez JE, 270
Martinez MI, 282
Martinez-Bonilla G, 73
Martinez-Lavin M, 2327
Martinez-Osuna P, 1000
Martini A, 1574, 1581
Maruyama M, 2020
Mason J, 1408
Mason T, 1166
Massa M, 1581
Massa M, 1281
Massari D, 533, 541
Massengill S, 1075
Masson C, 2191
Masuda K, S43-68
Masuyama J, 1681
Mata S, 2062
Matei D, 1776
Mateo L, 1455, 1891
Mathieu A, 1771
Matsumura T, 1483
Matteson EL, 1471
Mattie H, 611
Matucci A, S43-120
Matucci-Cerinic M, 1447
Matyas JR, S43-94
Maugars YM, 2135
Mautalen C, 2148
Mavougou E, 1230
Mavropoulos S, 1108
Mayes MD, 1281
Mazzantini M, 1492
McCain GA, 944
McCall S, 207
McCambridge MM, 786
McCarthy GM, 1447
McCarty DJ, 574, 578, 1631, 1636
McCarty M, 379
McCauley RG, 1953
McCloskey DA, 1281
McColl GJ, 1442
McCollum R, S43-109
McComb J, 1604
McCune JW, 894
McDermid AJ, 944
McDonald AG, 224
McDonald E, 191
McDonald JC, 1025
McFadden G, 1605
McGill NW, 494
McGuinn JL, 1380
McInnes IB, 224
McKendry RJ, 218
McKnight K, 344
McManus R, 1603
McMurray RW, 1577, 2084
McNeil JD, 335
Mease PJ, 161
Medina F, 1867
Medsger, Jr. TA, 581, 1254, 1281, 1478
Meenan RF, 432
Mehlhorn J, 1286
Meixner C, 1048
Mejjad O, 1586
Melfi CA, 1193
Mello SB, 633
Ménard HA, 789, 1352
Mengshoel AM, 143
Menkes CJ, 255, 1230, 1442, 1651
Menninger H, 1048
Menon GN, 1235
Menschik M, 926
Mensi N, 1224
Mera-Varela A, 566
Mercie P, 1440
Mercier P, 607
Meroni PL, 1086
Merry P, 1694
Mertz LE, 1097
Meschter C, 1922
Mestres CA, 183
Metsaranta M, S43-140
Metzger AL, 801
Mewa A, 915
Meyer O, 1395
Meyers K, 1922
Michalek JE, 953
Michalski JP, 227
Michel BA, 473
Michener G, 1601
Middleton G, 187
Miehlke R, 400
Mielants H, 680, 2266, 2273, 2279
Mierau R, 67
Mikdame M, 1384
Milani S, 1492
Milanino R, 103
Milford E, 1025
Miller DJ, 768
Miller JR, 1947
Miller LC, 320, 790, 1953
Miller TD, 180
Miller, III JJ, 544
Miltenburg AM, 385
Mimori A, 1681
Mineau F, S43-115
Minota S, 1681
Mintz G, 45
Miranda JM, 1867
Mirapeix E, 2038

Mirone L, 649
Misaki Y, 97
Misra R, 2349
Missioux D, 2010
Miyamoto S, 812
Mizushima Y, 1210
Moak SA, 1726
Moder KG, 180
Moga I, 2238
Mohr W, 1436
Mokassa L, S43-98
Molin MR, 1214
Molina J, 347, 1710
Molina JF, 347, 557, 1710
Mollnes TE, 24
Monjanel-Mouterde S, 844
Monteforte P, 571
Monu J, 1124
Moon RY, 529
Moore AR, 1436
Moreland LW, 1281
Morgenstern LB, 1593
Mori N, 2049
Mori S, 668
Morita A, 2361
Morse JH, 1872
Mortimer PS, 214, 370
Moskowitz RW, 255, 1442, S43-34
Mossey CJ, 2313
Moum T, 514, 2218
Moustarah F, 2027
Moutsopoulos HM, 2046
Mow VC, S43-146
Moya F, 1504
Mozes E, 1606
Muenke M, 976
Mujic F, 1589
Mukhopadhyay K, S43-140
Mukudai Y, S43-158
Mulherin D, 1211
Muller FJ, S43-146
Munn RK, 973
Munoz-Gomariz E, 246
Munoz-Gomez J, 183, 1504, 2038
Murakami S, 2049
Murata H, 2092
Murphy, Jr. WA, S43-56
Murray KH, 1356
Mustonen J, 427
Mutchinik O, 2377
Myers SL, 109, 1732
Myllykangas-Luosujärvi R, 1065, 2213

N

Nadeau C, 675
Nagashima M, 1624
Nahir AM, 702
Naidu MU, 1235
Nakamura M, 1483
Nakamura S, S43-158
Nakano K, 668
Namekawa T, 2092
Naparstek Y, 2166
Naschitz Y, 376
Nash P, 1605
Naspitz CK, 1956
Nation N, 1605
Navarro MA, 1455, 2238
Nelson AM, 2346
Nesher G, 713, 1596
Nesher R, 1596
Neumann L, 525
Neustadt DH, 190
Nevitt MC, 2291
Newkirk MM, 2055
Newman JH, 881
Nguyen T, 921, 932
Nicassio PM, 1552
Nico B, 1913
Niedbala MJ, 385
Nielson WR, 717
Nikkari L, 16
Nisar M, 572
Nishioka J, 421
Nishioka K, 1806
Nishioka K, 2092
Nishitani H, 668
Nived O, 1852
Njoo KH, 1532
Nolla y Sole JM, 569, 1455, 1891, 2238
Nomoto K, 2259
Nordstrom DM, 1000
Normand EH, 708
Norregaard J, 1544
Numeric P, 1174
Nuver-Zwart IH, 1797

O

O'Brien BM, 1200
O'Brien BJ, 908, 1399, 1418
O'Brien RF, 554
O'Dell JR, 1757
O'Donnell JL, 1326
O'Fallon W, 93, 1471, S43-23
Obata K, S43-123
Occhipinti G, 1492
Ockenhouse CF, 786
Oda S, 2049
Oddis CV, 581
Oen KG, 745
Ogawa N, 1152
Ohashi Y, 668
Ohba T, 1876
Ohishi A, 1483
Okimura A, S43-158
Olivieri I, 899
Olivieri O, 103
Ollier B, 1032, 2203
Olsen BR, S43-39
Olson N, 1602
Oppermann M, 24
Oranges GS, 899
Orbach H, 2166
Orellana C, 183
Orr K, 1602, 1947
Ostbye T, 722
Ostrow DN, 2163
Otermin I, 501
Oudshoorn M, 385

P

Pachman LM, 193, 762
Padula A, 899
Page G, 1589
Palacios-Boix A, 2377
Paleckova A, 2055
Palosuo T, 2186
Pan GX, 659
Panayi GS, 600, 1020
Pandith V, 1598, 1600
Pando JA, 2159
Panes J, 444
Pangratis N, 1108
Panush RS, 2197
Papo T, 187, 791, 1208 1215, 2006, 2103
Pardo CA, 1593
Parker BR, 544
Partsch G, 1447
Pascal R, 1599
Pasero G, 1492
Passo MH, 1356
Pasternack A, 427
Patel J, 1365
Patel S, 1608
Patrick MR, 654
Paul JE, 1193
Pauwels EK, 1461
Paz S, 2148
Pazin GJ, 1254
Peart M, 1326
Peebles C, 1872
Peen E, 2304
Pelegri C, 124
Pellegrino M, 649
Pelletier J, 1442, 1599, S43-1,S43-109, S43-115, S43-123
Peloso P, 617, 989, 1600, 1604
Penna PM, 708
Pennec YL, 2241
Perez MD, 768
Perez NM, 2246
Perez-Ruiz F, 501
Pertuiset E, 1174
Peschken CA, 1601
Peter HH, 782
Petri M, 455, 1365, 2187
Petrillo G, 3841
Pettersson H, 2208
Petty R, 548
Phelps RG, 2170
Philen RM, 161
Phillips PE, 1947
Pickard P, 494
Pierangeli SS, 227
Pierce ST, 973
Pierro A, 899
Piette J, 1208, 1215, 2006, 2103
Pignatti P, 1581
Pignone A, 1447
Pijoan C, 2327
Pincus T, 161, 1434, 1611, 1983
Pineda C, 2327
Pipitone V, 1913
Pivetta B, 1674
Pizarro S, 1867
Plant MJ, 1800
Plato CC, 488
Plotkin Z, 1698
Plotz PH, 2188
Pluss WT, 554
Pollock P, 1600
Pollock P, 1769
Pope J, 1271, 1601, 1603
Porter J, 1609
Portioli I, 1499
Portoukalian J, S43-133
Postl B, 745
Pouchot J, 1771
Pountain G, 1694
Pozzoli R, 533
Prehm P, 400
Press J, 525
Pressly TA, 1025
Pressman AR, 2291
Price GE, 1441
Prichard MG, 2190
Pritzker KP, 117, 1747, 1907
Prokopchuk PA, 2337
Prost AM, 2135
Pruijn GJ, 97
Pruzanski W, 1816, 2114
Pucci M, S43-120
Pudiak D, 1820
Puechal X, 1651
Puett DW, 2188
Pukkala E, 1300
Purvis JC, 915
Puttick MP, 1311, 1321, 1605, 2163
Pym JM, 802

Q

Qian C, 1631 1636
Quinn DI, 983
Quinzanini M, 533, 541
Quismorio, Jr. FP, 351

R

Rabinovich CE, 1166
Rabinovitch T, 1602
Radhakrisnan S, 2349
Radojevic V, 1552
Rahman P, 1601
Railan D, 29
Raiss RX, S43-152
Ramamurthy NS, 1726
Ramenghi B, 1574
Ramos J, 2193
Ramos-Remus C, 1603, 2120
Ramsey-Goldman R, 1254, 1478
Rangno KK, 1311, 1391
Rankin E, 777
Rao R, 2319
Rao UR, 1235
Rasooly I, 733
Ratcliffe A, S43-146
Rau R, 1779, 1976, 1990
Ravelli A, 1574
Read EJ, 478
Read R, S43-155
Recht MP, S43-52
Reed AM, 1166
Rehe GT, 529
Reichle R, 488
Reid GD, 1321, 1605
Reilly BJ, 168
Reinertsen JL, 1141

Reisine S, 1663
Rejeski WJ, 1124
Reme T, 394
Resnick D, 371, S43-52
Revıron D, 607
Riccobono S, 541
Rich MW, 1001
Richard F, 187
Richard M, S43-133
Richardson BC, 29, 2126
Richardson ML, 1929
Rieley F, 374
Rivero S, 1352
Rivier G, 766
Riviere LR, 1740
Rizzi V, 1060
Roberton DM, 548
Roberts-Thomson PJ, 2065
Rogers JF, S43-37
Rogers J, 2132
Rogers T, 780
Roig-Escofet D, 569, 1455, 1891
Rollman GB, 944
Romagne F, 394
Romas E, 803
Romeu JC, 2374
Roncali L, 1913
Ronchezel MV, 1956
Rooks M, 1603
Rooney PJ, 2006
Roos BA, S43-146
Rosati R, S43-140
Rose CD, 684
Rosenberg AM, 289, 2337
Rosenberg NL, 161
Rosler D, 347
Rosner IA, 376
Ross K, 151
Rossi F, 1499
Roth SH, 1, 795, 1435
Rothfield NF, 868, 1663
Rothhut B, 1230
Rothschild BM, 2370
Rothwell A, 1326
Roudier J, 607
Roux H, 607
Rovetta G, 571
Rowberg AH, 2001
Roy R, 1776
Rozenbaum M, 376
Rozenman Y, 1596
Rubenstein LM, 2142
Rubinow A, 2166
Ruckmann A, 1998
Rudniki C, 1086
Ruffatti A, 2007
Ruiz-Lucea E, 501
Ruperto N, 1574
Rush PJ, 372
Russell AS, 573, 617, 625, 836, 1209, 1600, 1603, 1605, 2027
Russell I, 151, 953
Russell JM, 444
Russo-Marie F, 1230
Rutka J, 1604
Rutten-van Molken MP, 1536
Ryan J, 915
Ryan LM, 1514

S

Saag KG, 2142
Saal J, 2194
Sadouk M, 1599
Saito E, 1183
Saitoh Y, 2092
Sakakibara N, 2361
Sakakibara S, 2361
Sakamaki T, 2092
Sakauchi M, 1483
Sakotic G, 2114
Salaffi F, 1800
Salas M, 45
Salazar-Paramo M, 1688
Salsalate-Diclofenac Study Group, 617
Salter RB, 1714
Salvarani C, 370, 1499
Samarkos M, 1108
Sambrook PN, 921, 932
Samuel MP, 1947
Samura A, S43-78
Sanderman R, 1834
Sanmarti R, 1504
Santavirta S, 2285
Sany J, 394, 790, 1829
Sarada P, 1235
Sato EI, 270
Sato S, 563
Sato T, 668
Saugen E, 143
Saunders L, 836
Sauvezie B, 2010
Saxne T, S43-71
Scaravilli F, 777
Schaller JG, 320, 790, 1953
Schatteman L, 680, 2266, 2273, 2279
Schenck P, 400
Schiller NB, 455
Schlesinger S, 976
Schleyerbach R, S43-152
Schmid CH, 2313
Schmid FR, 218
Schned ES, 1141
Schneider R, 168
Schneider S, 400
Schoenfeld-Smith K, 1552
Scholes D, 708
Schoonbrood TM, 1389
Schousboe JT, 1141
Schouten JS, S43-44
Schulman SF, 207
Schumacher, Jr. HR, S43-101
Schuman C, 1552
Schweinsberg F, 2194
Scopelitis E, 227, 236
Scott DG, 1694
Scott JC, 2291
Scott WW, 488
Seeman J, 2055
Segawa C, 2373
Segawa F, 1183
Seguchi H, 1483
Seibold JR, 1281
Seifert B, 473
Selvaggi KJ, 1478
Senecal J, 868, 1604, 1688, 1964
Seriolo B, 1802
Serni U, S43-120
Serrano JM, 282
Setton LA, S43-146
Shantaram V, 1235
Sharp GC, 586
Sharp JT, 1787, 1800
Shaw SE, 2307
Sheldon A, 1740
Sheppard D, 16
Shepstone L, 2132
Sherry DD, 1009, 1962
Shi CS, 659
Shi Y, 462
Shibata M, 1483
Shih L, 1704
Shim H, 2170
Shimazu A, S43-158
Shimizdu Y, 1183
Shimizu H, 2049
Shimmei M, S43-78
Shinozaki T, 117, 1907
Shirakawa F, 2049
Shobha U, 1235
Shoenfeld Y, 1068, 1086
Shojania K, 1391
Shomrat D, 702
Shore EM, 976
Shum DT, 1603
Shumaker S, 1124
Si-Hassen C, 1771
Siam AR, 1377
Sibley JT, 1271, 1600, 1604
Sicard D, 1384
Siddiqui S, 904
Siegel MT, 894
Sienkiewicz PJ, 578
Sienknecht CW, 1769
Silberbach GM, 332
Silman AJ, 1032, 1277, 2203
Silveira LH, 227, 236
Silver RM, 161, 1876
Silveri F, 2006
Silverman E, 168, 326, 1570, 2156, 2337
Silvestris F, 1075
Simel DL, 727
Siminovitch KA, 915
Simkin PA, 1929
Simonson J, 455
Simony-Lafontaine J, 394
Simpson J, 332
Sinacore J, 1254
Singh RR, 2349
Sinkjaer T, 1544
Skaftaddottir I, 1862
Skakkebaek NE, 1138
Skeith KJ, 1600, 1603
Skinner A, S43-16
Skogh T, 2304
Skripnikova IA, 689
Slee PH, 561
Sletvold H, 137
Sloan D, 973
Slomovic AR, 1604
Smedstad LM, 514, 1834, 2218
Smith BH, 1235
Smith EA, 1876
Smith EM, 2126
Smith J, 1335
Smith MD, 1439, 2065
Smith R, 1130
Smolen JS, 406, 1782
Study of Osteoporotic Fractures Research Group, 2291
Sokoluk C, 1602
Soma Y, 1440
Sondgen W, 1048
Song KY, 356
Song YW, 356
Songcharoen S, 796
Sonnenblick M, 713, 1596
Sonnichsen N, 1286
Sood SK, 758
Sorsa T, 2285
Soskolne CL, 836
Spector TD, 807, 1118, 1509, S43-46
Speechley M, 722
Spencer-Green G, 2226
Spiera H, 1872, 2170
Spindler AJ, 2148
Sredni B, 1086
Stahnke G, 1286
Stam HJ, 1532
Stanzial A, 103
Starr M, 1603
Staub HL, 521
Steen VD, 1281
Steere AC, 689
Stefanovic-Racic M, 1922
Stefanski E, 2114
Stein C, 1611
Stein HB, 1321
Stein LD, 1166
Steinberg AD, 1812
Steinberg M, 1514
Steiner G, 406
Steinsson K, 1862
Stergachis A, 708
Sternfeld R, 67
Stevens A, 1271, 1603, 1603, 1603
Stevens D, 326
Stewart P, 494
Sthoeger Z, 1606, 2007, 2366
Stiles TC, 137
Stimmler MM, 351
Stoll T, 473
Stoller G, 2372
Straaton KV, 505
Strand CV, 207, 1203, 1415
Strange CB, 1876
Stucki G, 473
Studnicka-Benke A, 406
Sturfelt GK, 1852
Suarez-Almazor M, 218, 836, 1600, 1603, 1762, 2027, 2120
Subair H, 1825
Suda A, 2285
Sugiyama E, 2020
Sukenik S, 525
Sumida T, 2092
Summers KL, 1326

Sutherland SE, 1876
Suurmeijer T, 1834
Swaak AJ, 1389
Swedler W, 792
Sweeney D, 1478
Symmons DP, 2200
Szachnowski P, 1722
Szer IS, 790
Szeverenyi NM, 855

T

Tabas JA, 976
Taccetti G, 1438
Takagi M, 2285
Takayasu V, 2246
Takeda A, 1681
Takehara K, 563, 1440
Taki H, 2020
Talal N, 1152
Tamai K, 1681
Tanimoto K, 668
Tannenbaum H, 617, 915
Tao S, 2027
Tardif G, 1599
Targoff IN, 762
Taylor DJ, 2004
Taylor SE, S43-62
Tayot J, 1586
Teasell R, 944
Tenenbaum SA, 236
ter Borg EJ, 561
ter Laak HJ, 576
Terrier P, 766
Terry JB, 793
Tett SE, 983
Teufel A, 1601, 1655, 1657
Task Force for Classification Criteria, 1566
Thalji K, 1646
Thomas E, 2189
Thomas T, 2183
Thomas Doyle M, 1141
Thomine E, 1586
Thompson JM, 1601
Thompson SD, 1356
Thomsen C, 1544
Thomson GT, 617, 805, 1602, 1947
Thomson W, 1032
Thonar E, 262, S43-68
Thorne JC, 241, 617
Thorsteinsson J, 1862
Thuresson B, 1852
Thylan S, 1606
Thysell H, 569
Tirri R, 797
Tiwana H, 1825
Tobin JD, 488
Todesco S, 2007
Toffoli SM, 521
Tokano Y, 2173
Tokugawa DA, 363
Tolaymat A, 2344
Tolson TF, 1141
Tomas S, 1488
Tomer Y, 1068
Tonetto S, 2007
Torrance G, 1200
Torvinen A, 16
Toth MB, 29, 2126
Tournier-Lasserve E, 1215
Towheed T, 440, 802, 1598, 1600
Trampisch H, 1998
Trang L, 2208
Travaglio-Encinoza A, 394
Tredwell SJ, 548
Treger T, 1386
Trippel SB, S43-129
Trojanowska M, 1876
Tron F, 1586
Troy K, 2356
Truedsson L, 1852
Tsai J, 1450 2034
Tsai W, 1450 2034
Tsakonas E, 1602
Tsamis N, 252
Tschesche H, 2285
Tsuji T, 2361
Tucker LB, 320, 790, 1953
Tugwell P, 980, 1241, 1420, 1431
Tunks ER, 944
Tzioufas AG, 2046
Tzonou A, 1108

U

Ueki H, 668
Ullrich R, 926
Urbano-Marquez A, 2038
Urbina-Joiro H, 2377
Urowitz MB, 790, 1007, 1247, 1259, 1265, 1439, 1604, 1816
Ushiyama T, 421
Uthman I, 1604, 1964
Utset TO, 2187
Uziel Y, 2337

V

Vacek PM, 1055
Vacher-Lavenu M, 255
Vadas P, 1816, 2114
Vaglum P, 514, 2218
Vaile JH, 2190
Vaiopoulos G, 1108
Valat J, 2188, 2369
Valdimarsson H, 570, 2186
Valencia X, 497
Valkenburg HA, S43-44
Vallance R, 552
Valverde Garcia J, 569
Van Baarlen J, 338
Van Dam-Baggen RM, 644
van de Laar MA, 338
van de Loo FA, 2250
van de Putte LB, 1797
van de Putte LB, 576, 1104, 1781, 1792
van den Bent MJ, 342
van den Berg WB, 2250 S43-143
van den Bersselaar LA, 2250
van den Heuvel W, 1834
Van der Does E, 1532
van der Heide A, 1466
van der Heijde DM, 1792, 1797
van der Hoeven H, 751
van der Korst JK, 1520
van der Linden SM, 1185, 1197, 1203, 1304, 1536
van der Net J, 751
van der Veen MJ, 1766
van der Velde EA, 1461
van Doorslaer EK, 1536
van Erck MG, 385
van Hinsbergh VW, 385
van Kampen J, 1520
van Leeuwen MA, 186, 1792
van Lent PL, 2250
van Riel P, 1104, 1792, 1797
van Rijthoven AW, 34
van Santen-Hoeufft M, 1304, 1536
van Soesbergen RM, 1766
van Venrooij W, 97
Vanden Berghe M, 850
Varga J, 161, 881, 1281
Vazquez-Del Mercado M, 1688
Veasy G, 379
Vecht CJ, 342
Vega E, 2148
Velthuysen E, 1373
Venkovsky J, 2203
Venubabu K, 1235
Vergouwen MS, 34
Verma UN, 2349
Vermeer H, 2250
Vestergaaard-Poulsen P, 1544
Veys E, 680, 2266, 2273, 2279
Vial J, 2295
Viel J, 1884
Vignati G, 533, 541
Vignon E, S43-133
Vila JL, 1504
Vilella R, 1488
Viiliger P, S43-104
Vinceneux P, 1771
Viola S, 1574
Vischer TL, 1224
Vitoux J, 2103
Vittecoq O, 1586
Vogelgesang SA, 786, 1369
Voisin L, 1586
Vojtechovsky K, 2055
Vollestad NK, 143
Von den Hoff HW, 1520
von Kempis J, S43-104
von Muhlen CA, 521
Voorhees JJ, 894
Vuorio E, S43-140

W

Wada T, 2373
Wade JP, 1311
Wakamatsu A, 2246
Walker SE, 2084
Wallace CA, 1009
Wallace DJ, 801
Wallace JL, 444
Wallace RB, 2142
Walsh SJ, 1663
Wang AY, 1295
Wang AZ, 817
Wang JC, 817
Wang LL, 659
Ward MM, 2319
Wassenberg S, 1990
Watanabe R, 1483
Watanabe Duffy KN, 2055
Watson J, 224
Watters A, 78
Weaver AL, 1097
Weaver WJ, 2192
Webster G, 733
Wechsler B, 2103
Weeks JA, 973
Wei N, 1722
Weidensaul D, 2084
Weinblatt ME, 218
Weiner EM, 67
Weiner S, 1281
Weinstein A, 788, 1281
Weisman MH, 1281
Wells GA, 1241
Wen ZX, 659
Wendling D, 1884
Wener MH, 571
Wessel HU, 762
Westcott JY, 462
Westedt M, 1461
Westhovens R, 1013
Whetsell WO, 1769
White BW, 1281
White KP, 717, 722
Whitehead J, 1941
Whitelock HC, 1609
Whiting-O'Keefe QE, 455
Whitley DM, 482
Whitman K, 1646
Whitmore SE, 50
Wiarda KS, 1461
Wigley FM, 50, 1281
Wilder RL, 2159
Wilke WS, 218
Wilkerson MJ, 8
Williams C, S43-28
Williams H, 218
Williams K, 2295
Williams WV, 799
Williams, Jr. JW, 727
Williams, Jr. RC,
Williamson J, S43-16
Willkens RF, 2001
Willoughby DA, 1436
Wilson C, 1825
Wilson D, 1688
Wilson WA, 227
Wise RA, 50
Wisnieski JJ, 1669
Wither J, 1602
Witzmann G, 406
Wloch M, 2114
Wolf RE, 444, 450
Wolfe F, 151, 570, 788, 2062
Worthley SG, 335
Wright JG, 989, 1209
Wrigley JM, 505
Wu J, S43-82

X

Xu Y, 117

Y
Yachyshyn J, 1471
Yachyshyn V, 1471
Yamada N, 563
Yamakage A, 1876
Yamamoto K, 2092
Yamamoto K, 2049
Yamaoka T, 1483
Yamashita N, 2020
Yamauchi R, 2361
Yang D, 1704
Yao QP, 659
Yeadon C, 78
Yeh L, 1740
Yen J, 1450 2034
Yendt ER, 440
Yokoyama H, 2373
York H, 494
Yoshida TO, 812
Yoshihara Y, S43-78
Yoshino S, 1624
Yoshio T, 1681
Youinou PY, 2241
Youssef PP, 469, 494, 2065

Z
Zabriskie J, 379
Zafarullah M, S43-123
Zamperini A, S43-120
Zappacosta B, 649
Zasloff MA, 976
Zavadak KH, 482
Zee B, 1598
Zeman R, 1247
Zemel LS, 758
Zhang XR, 817
Zhang Y, 1872
Zhang ZN, 659
Zhou G, S43-140
Zhu J, 1599
Zimhony O, 2366
Zizic TM, 1757
Zoli A, 649
Zonana-Nacach A, 45, 1000
Zucker S, 2004
Zwillich SH, 1947

A

Abe Shore Memorial Lecture
autoimmunity, 289
biological therapy, 289
immunogenetics, 289
joint prosthesis, 289
pediatric rheumatic diseases, 289
Achilles tendinitis
diffuse idiopathic skeletal hyperostosis, 1212
isotretinoin, 2009
suprapatellar tendinitis, 2009
Acidosis
renal, 2366
Acquired immunodeficiency syndrome
reactive arthritis, 252
Reiter's syndrome, 252
Acromegaly
archeology, 2191
arthritis, 2191
Acromioclavicular joint
calcium pyrophosphate dihydrate deposition disease, 371
cysts, 371
Activities of daily living
knee osteoarthritis, 1124
knee pain scale, 1124
pain, 1124
Acute anterior uveitis
Canadian Rheumatology Association Meeting, 1598 (ab)
Salmonella, 1598 (ab)
Yersinia, 1598 (ab)
Adenocarcinoma
Canadian Rheumatology Association Meeting, 1602 (ab)
ovarian, 1393
paraneoplastic syndromes, 1393
Raynaud's phenomenon, 1393
sacroiliitis, 1602 (ab)
unilateral sacroiliitis, 970
Adenosine triphosphate
fibromyalgia clinical trials, 953
magnesium, 953
malic acid, 953
Adhesion molecules
endothelium, 2126
8-methoxypsoralen, 2126
psoralen and ultraviolet A therapy, 2126
rheumatoid arthritis, 2126
synovitis, 2126
Adjuvant arthritis
dexamethasone, 124
disease progression, 855
flurbiprofen, 1726
metalloproteinase, 1726
murine studies, 124
Mycobacterium butyricum, 124
one dimensional proton nuclear magnetic resonance imaging, 855
rheumatoid arthritis, 124, 855
synovial membrane, 124
tenidap, 1726
tetracycline, 1726
Adrenocorticotropic hormone
beta-endorphin, 1829
Canadian Rheumatology Association Meeting, 1603 (ab)
cortisol, 1829
pigmentation, 1603 (ab)
pituitary hormones, 1829
prolactin, 1829
rheumatoid arthritis, 1829
scleroderma, 1603 (ab)
Adult Still's disease
cardiac tamponade, 180
cyclosporin A, 1391
pericarditis, 180
Adverse effects
corticosteroids, osteoarthritis, 1013
corticosteroids, rheumatoid arthritis, 1055
cyclophosphamide, 1593, 1812
gold, rheumatoid arthritis, 572, 1600 (ab)
gold sodium thiomalate, rheumatoid arthritis, 190
granulocyte colony stimulating factor, Felty's syndrome, 1179
hyaluronan, knee osteoarthritis, 1311
hydrochlorothiazide, hypertension, 1001
hylan, 1311
interferon-alpha, leukemia, 1183
lichen planus, rheumatoid arthritis, 191
lupus nephritis, 1812
methotrexate, bladder cancer, 1441
methotrexate, juvenile rheumatoid arthritis, 1009
methotrexate, rheumatoid arthritis, 218, 335, 786, 790, 796, 1009, 1043, 1174, 1373, 1439, 1766, 2189, 2356
minocycline, rheumatoid arthritis, 611
nonsteroidal antiinflammatory drugs, juvenile rheumatoid arthritis, 1149
nonsteroidal antiinflammatory drugs, osteoarthritis, 708
nonsteroidal antiinflammatory drugs, rheumatoid arthritis, 1471, 2200, 2214
norfloxacin urinary tract infections, 793
OMERACT II Conference, 982, 983, 989, 995, 998
procainamide, Hashimoto's thyroiditis, 574
propylthiouracil, Graves' disease, 803
renal function, 1812
systemic lupus erythematosus clinical trials, 1812
tamoxifen, systemic lupus erythematosus, 1606
Age
ankylosing spondylitis, 794
disease onset, 794
disease severity, 1032
genetic factors, 794
HLA, 1032
methotrexate, 218
renal disease, 218
rheumatoid arthritis, 218, 1032
risk factors, 1032
sex, 794, 1032
spondyloarthropathies, 794
Aged
bone mineral density, 921, 932
cognitive impairment, 2142
epidemiology, 2291
fractures, 921
hip osteoarthritis, 2291
HLA-B27, 899
indomethacin, 713
misoprostol, 713
nonsteroidal antiinflammatory drugs, 2142
osteoarthritis, 921, 932
osteoporosis, 921
pitting edema, 899
radiography, 2291
renal dysfunction, 713
rheumatic diseases, 713
seronegative spondyloarthropathies, 899
spine, 932
Aggrecans
bone, S43–71
cartilage, S43–71, S43–75
metalloproteinase, S43–86
osteoarthritis, S43–71, S43–75, S43–86
synovial fluid, S43–71, S43–75
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–71, S43–75, S43–86
Aging
Australia, 1934
disability, 1934
epidemiology, 1934
Europe, 1934
musculoskeletal disorders, 1934
North America, 1934
spine, 1934
Agranulocytosis
Felty's syndrome, 1803
granulocyte colony stimulating factor, 1803
sepsis, 1803
Aldolase
disease activity, 563
eosinophilic fasciitis, 563
Alkaline phosphatase
calcium pyrophosphate dihydrate crystal deposition disease, 1907
calcium pyrophosphate dihydrate crystals, 117
calcium pyrophosphate dihydrate deposition disease, 117
pyrophosphatases, 1907
spermidine, 1907
spermine, 1907
Alpha V integrin
extracellular matrix, 16
osteoarthritis, 16
rheumatoid arthritis, 16
synovium, 16
Alpha-fetoprotein
antiphospholipid antibodies, 1365
neonatal lupus, 1365
pregnancy, 1365
Alveolar hemorrhage
antineutrophil cytoplasmic antibodies, 803
propylthiouracil, 803
Ambulatory care
inflammatory arthritis, 1005
patient care team, 1005
Ambulatory surgery
arthroscopy, 1722
complications, 1722

knee osteoarthritis, 1722
American College of Rheumatology criteria
epidemiology, S43–44
osteoarthritis, S43–42, S43–44
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–42, S43–44
Amor criteria
European Spondylarthropathy Study Group, 1499
European Spondylarthropathy Study Group criteria, 246
Italy, 1499
prevalence studies, 1499
psoriatic arthritis, 1499
spondyloarthropathies, 246
Amyloidosis
ankylosing spondylitis, 2192
Canadian Rheumatology Association Meeting, 1605 (ab)
macroglossia, 1605 (ab)
methotrexate, 569
muscle weakness, 1605 (ab)
reactive systemic, 2192
rheumatoid arthritis, 569
secondary, 569
Anaerobic threshold
exercise, 1483
muscle, 1483
oxygen, 1483
systemic lupus erythematosus, 1483
Analgesic therapy
continuing medical education, 1762
family physicians, 1762
nonsteroidal antiinflammatory drugs, 1762
osteoarthritis, 1762
Anaphylactic reaction
gold sodium thiomalate, 190
rheumatoid arthritis, 190
Anemia
aplasia, 2166
erythropoietin, 2166
normochromic, normocytic, 2166
systemic lupus erythematosus, 2166
Anesthesia
cervical subluxation, 2152
Ehlers-Danlos syndrome, 2152
Aneurysm
arteritis, 2103
Behçet's disease, 2103
corticosteroid therapy, 2103
cyclophosphamide, 2103
grafting, 183
infection, 183
osteoarthropathy, 183
Angiitis
central nervous system, 662, 2371
digital subtraction angiography, 2371
primary, 662, 2371
vasculitis, 2371
Angioendotheliomatosis
central nervous system, 1769
cytoxan, 1769
lymphoma, 1769
vasculitis, 1769
Angiography
arteriography, 876
digital subtraction, 2371
hepatitis B virus, 876
microaneurysm, 876
polyarteritis nodosa, 876
primary angiitis, 662
Angiopathy
central nervous system, 780
cocaine, 780
Animal studies
See bovine studies; canine studies; caprine studies; murine studies; ovine studies; rabbit studies
Anionic phospholipids
antiphospholipid antibody syndrome, 2009
beta$_2$ glycoprotein I, 2009
Ankylosing spondylitis
age, 794
amyloidosis, 2192
antiphospholipid antibodies, 1891
atlantoaxial subluxation, 2120
Bath Ankylosing Spondylitis Metrology Index, 1609
Central America, 2327
classification criteria, 740
clinical trials, 1304
diagnosis, 740
disease onset, 794
Dunlop-Dotteridge Lecture 1994, 740
epidemiology, 1607
familial, 794
functional status, 1304
gut, 2266, 2273, 2279
heterotopic ossification, 1704
HLA-B27, 375
inflammation, 2266, 2273, 2279
inflammatory bowel disease, 2266, 2273, 2279
ligaments, 2120
methotrexate, 1104
ossification, 2120
outcome assessment, 740, 1304, 1609
paleopathology, 2327
pediatric, 165
Problem Elicitation Technique, 1304
prognosis, 2266, 2273, 2279
refractory, 1104
RS$_3$PE syndrome, 375
sex, 794
sex ratio, 1607
spondyloarthropathies, 2266, 2273, 2279
total hip arthroplasty, 1704
Annexins
autoimmune diseases, 97
enzyme linked immunosorbent assay, 97
polymyositis, 97
Raynaud's phenomenon, 97
rheumatoid arthritis, 97
Sjögren's syndrome, 97
systemic lupus erythematosus, 97
systemic sclerosis, 97
V, 1230
VI, 1230
Anorexia nervosa
fingers, 544
osteonecrosis, 544
vascular insufficiency, 544
Anterior compartment syndrome
juvenile rheumatoid arthritis, 1377
popliteal cysts, 1377
Anterior uveitis
Canadian Rheumatology Association Meeting, 1602 (ab)
HLA-B27, 1602 (ab)
spondyloarthropathies, 1602 (ab)
Anti-alpha beta T cell receptor monoclonal antibody
anti-DNA antibodies, 2259
graft versus host disease, 2259
lupus nephritis, 2259
murine studies, 2259
Anti-annexin V antibodies
anti-annexin VI antibodies, 1230
rheumatoid arthritis, 1230
Anti-annexin VI antibodies
anti-annexin V antibodies, 1230
rheumatoid arthritis, 1230
Anti-beta$_2$ glycoprotein I antibodies
anticardiolipin antibodies, 2233
antiphospholipid antibody syndrome, 1899, 2233
IgG, 2233
systemic lupus erythematosus, 2233
Antibodies
anti-beta$_2$ glycoprotein, 2233
anti-beta$_2$ glycoprotein I, 1899
anticardiolipin, 55, 62, 227, 649, 1091, 1694, 1894
anti-Clq, 1669
anti-DNA, 2259
antiendothelial cell, 1669
anti-Fc gamma receptor, 2241
anti-hY5 RNA, 1599 (ab)
anti-idiotype, 1075
anti-Jo-1, 762
antikeratin, 2046
anti-La(SSB), 868
antilipopolysaccharide, 1947
antineutrophil cytoplasmic, 791, 803, 1669, 2304
anti-NOR-90, 2371
antinuclear, 1577, 2337
antiphospholipid, 62, 1438, 1891
antiribosomal PO protein, 1681
anti-RNA polymerase III, 557
anti-Ro, 1599 (ab)
anti-Ro(SSA), 868
antitissue type plasminogen activator, 1688
anti-U1-RNP, 586
Antibody formation
disease outbreaks, 1947
immune response, 1947
lipopolysaccharide, 1947
reactive arthritis, 1947
Salmonella, 1947
Anticardiolipin antibodies
anti-beta$_2$ glycoprotein I antibodies, 2233
antiphospholipid antibodies, 62

antiphospholipid antibody syndrome, 55, 62, 227, 1091, 1380, 1894, 2233
beta$_2$ glycoprotein I, 1091, 1894
blood platelets, 649
cancer, 2007
cofactors, 1091
connective tissue disease, 227
cutaneous necrosis, 1380
C4 genotypes, 227
enzyme linked immunosorbent assay, 55
familial, 227
giant cell arteritis, 1694
HLA haplotypes, 227
IgG, 2233
kidneys, 2007
lactate dehydrogenase, 649
polymyalgia rheumatica, 1694
prevalence studies, 55
protein S, 2007
pulmonary involvement, 62
syphilis, 1894
systemic lupus erythematosus, 62, 227, 649, 1091, 2233
thrombosis, 2007
vascular thrombosis, 1380
Anti-CENP-B
anticentromere antibodies, 1286
scleroderma, 1286
silica, 1286
Anticentromere antibodies
anti-CENP-B, 1286
scleroderma, 1286
silica, 1286
Anti-Clq antibodies
antiendothelial cell antibodies, 1669
antineutrophil cytoplasmic antibodies, 1669
hypocomplementemia, 1669
systemic lupus erythematosus, 1669
urticarial vasculitis, 1669
Anti-DNA antibodies
anti-alpha beta T cell receptor monoclonal antibody, 2259
graft versus host disease, 2259
lupus nephritis, 2259
murine studies, 2259
Antiendothelial cell antibodies
anti-Clq antibodies, 1669
antineutrophil cytoplasmic antibodies, 1669
hypocomplementemia, 1669
systemic lupus erythematosus, 1669
urticarial vasculitis, 1669
Anti-Fc gamma receptor autoantibodies
Fc gamma receptor, 2241
polymorphonuclear cells, 2241
Sjögren's syndrome, 2241
Antigen induced arthritis
articular cartilage, 1714
Canadian Rheumatology Association Meeting, 1605 (ab)
continuous passive motion, 1714
inflammation, 1605 (ab)
rabbit studies, 1605 (ab), 1714
rheumatoid arthritis, 1714
SERP-1 protein, 1605 (ab)
synovitis, 1714
Anti-hY5 RNA antibodies
anti-Ro antibodies, 1599 (ab)
Canadian Rheumatology Association Meeting, 1599 (ab)
connective tissue disease, 1599 (ab)
Anti-idiotype antibodies
lupus nephritis, 1075
systemic lupus erythematosus, 1075
Anti-Jo 1 antibodies
inflammatory myopathy, 762
pulmonary fibrosis, 762
Antikeratin antibodies
Greece, 2046
HLA-DR1, 2046
rheumatoid arthritis, 2046
Anti-La(SSB) antibodies
anti-Ro(SSA) antibodies, 868, 1352
autoantibodies, 1352
congenital heart block, 1352
hydroxychloroquine, 868
hypergammaglobulinemic purpura, 868
indomethacin, 868
neonatal lupus, 1352
prednisone, 868
systemic lupus erythematosus, 868
Antimalarial therapy
azathioprine, 1636
combination therapy, 1636
methotrexate, 1636
rheumatoid arthritis, 34, 1636
Antineutrophil cytoplasmic antibodies
alveolar hemorrhage, 803
anti-Clq antibodies, 1669
antiendothelial cell antibodies, 1669
antinuclear antibodies, 2038
cytoplasmic, 376
familial Mediterranean fever, 376
hypocomplementemia, 1669
lactoferrin, 2304
myeloperoxidase, 2304
paraformaldehyde, 2038
perinuclear, 376, 2038
propylthiouracil, 803
reactive arthritis, 2304
renal failure, 791
rheumatoid arthritis, 2038
systemic lupus erythematosus, 1669
systemic sclerosis, 791
urticarial vasculitis, 1669
Anti-NOR-90 antibodies
nucleolus organizer region-90 antigens, 2371
pediatric rheumatic diseases, 2371
Antinuclear antibodies
antineutrophil cytoplasmic antibodies, 2038
autoimmunity, 73, 236
facial hemiatrophy, 73
granulocyte specific, 2038
juvenile rheumatoid arthritis, 1577
linear scleroderma, 73
morphea, 2337
paraformaldehyde, 2038
prolactin, 1577
rheumatoid arthritis, 2038
scleroderma, 2337
silicone implants, 236
Antioxidants
fatty acids, 103
psoriatic arthritis, 103
red blood cells, 103
selenium, 103
Antiphospholipid antibodies
alpha-fetoprotein, 1365
ankylosing spondylitis, 1891
anticardiolipin antibodies, 62
antiphospholipid antibody syndrome, 62, 2006
coronary disease, 1438
IgG, 2006
murine studies, 2006
neonatal lupus, 1365
pediatric systemic lupus erythematosus, 1438
pregnancy, 1365
pulmonary involvement, 62
systemic lupus erythematosus, 62
T cells, 2006
Antiphospholipid antibody syndrome
anionic phospholipids, 2009
anti-beta$_2$ glycoprotein I antibodies, 1899, 2233
anticardiolipin antibodies, 55, 62, 227, 1091, 1380, 1894, 2233
antiphospholipid antibodies, 62, 2006
aspirin, 1086
beta$_2$ glycoprotein I, 1091, 1894, 2009
coagulopathy, 2173
cofactors, 1091
cutaneous necrosis, 1380
enzyme linked immunosorbent assay, 55
factor V mutation, 1215
heart valve replacement, 802
HLA antigens, 1589
IgG, 2006, 2233
interleukin 3, 1086
intravenous gamma globulin, 1068
leukotrienes, 1086
murine studies, 1068, 2006
myocardial infarction, 768
pediatric systemic lupus erythematosus, 768
prevalence studies, 55
primary, 1068, 1215, 1589, 1894
protein C, 1215
pulmonary hemorrhage, 554
pulmonary involvement, 62
pulmonary vasculitis, 554
Raynaud's phenomenon, 768
rheumatoid arthritis, 1586
rheumatology and rheumatologists, 186
syphilis, 1894
systemic lupus erythematosus, 62, 1068, 1091, 1589, 1899, 2173, 2233
T cells, 2006
vascular thrombosis, 1380
vasculitis, 2173
Antirheumatic drugs
chondrocytes, S43–152
osteoarthritis, S43–152
proteoglycan synthesis, S43–152
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–152
Antiribosomal PO protein antibodies
central nervous system involvement, 1681

systemic lupus erythematosus, 1681
Anti-RNA polymerase III antibodies
hypertension, 557
renal failure, 557
scleroderma, 557
systemic sclerosis, 557
Anti-Ro antibodies
anti-hY5 RNA antibodies, 1599 (ab)
Canadian Rheumatology Association Meeting, 1599 (ab)
congenital complete heart block, 533
connective tissue disease, 1599 (ab)
neonatal lupus, 533
outcome assessment, 533
Anti-Ro(SSA) antibodies
anti-La(SSB) antibodies, 868, 1352
autoantibodies, 1352
congenital heart block, 1352
hydroxychloroquine, 868
hypergammaglobulinemic purpura, 868
indomethacin, 868
neonatal lupus, 1352
prednisone, 868
systemic lupus erythematosus, 868
Antitissue type plasminogen activator antibodies
fibrin, 1688
systemic sclerosis, 1688
tissue type plasminogen activator, 1688
Anti-U1-RNP antibodies
HLA, 586
immunogenetics, 586
mixed connective tissue disease, 586
Anxiety
depression, 644
rheumatoid arthritis, 644
social factors, 644
Aortic graft
hypertrophic osteoarthropathy, 2008
infection, 2008
Aortic regurgitation
HLA-B27, 332
pediatric spondyloarthropathies, 332
Apatite crystals
calcium pyrophosphate dihydrate crystal deposition disease, 2007
calcium pyrophosphate dihydrate crystals, S43–101
fingers, 2007
osteoarthritis, 2007, S43–101
synovial fluid, S43–101
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–101
Aplasia
anemia, 2166
erythropoietin, 2166
red cell, 2166
systemic lupus erythematosus, 2166
Apoptosis
cartilage, 926
osteoarthritis, 926
proto-oncogene bcl-2, 926
Aptamers
immunoglobulin G, S43–62
osteoarthritis, S43–62
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–62
Archeology
acromegaly, 2191
arthritis, 2191
Arteriography
angiography, 876
hepatitis B virus, 876
microaneurysm, 876
polyarteritis nodosa, 876
Arteritis
aneurysm, 2103
Behçet's disease, 2103
corticosteroids, 2103
cyclophosphamide, 2103
Arthralgia
monoarthritis, 497
norfloxacin, 793
panniculitis, 497
urinary tract infection, 793
vasculitis, 497
visceral larva migrans, 497
Arthritis
acromegaly, 2191
archeology, 2191
bacillus Calmette-Guérin, 2010
bacterial infection, 1504
breast cancer, 973
diagnosis, 1504
D-lactic acid, 1504
estradiol, 421
estrogen receptors, 421
fibromyalgia, 573
iritis, 2010
joint effusion, 973
metastasis, 973
musculoskeletal disorders, 573
protein 29, 421
rheumatology and rheumatologists, 573
traumatic, 421
Arthritis, Rheumatism and Aging Medical Information System
OMERACT II Conference, 995
Arthritis Impact Measurement Scales
Canadian Rheumatology Association Meeting, 1601 (ab), 1603 (ab)
disability, 1603 (ab)
Functional Index, 1603 (ab)
Health Assessment Questionnaire, 1603 (ab)
outcome assessment, 1601 (ab), 1603 (ab)
psoriatic arthritis, 1601 (ab)
scleroderma, 1603 (ab)
Arthropathy
camptodactyly, 2349
genetic factors, 2349
pleuritis, 2349
serositis, 2349
Arthroplasty
azathioprine, 1844
Hispanics, 1844
infection, 1844
methotrexate, 1844
pericarditis, 2349
predictive factors, 1844
rheumatoid arthritis, 1844
Arthroscopy
ambulatory surgery, 1722
complications, 1722
knee osteoarthritis, 1722
psoralen ultraviolet A therapy, 29
psoriatic arthritis, 1722
rheumatoid arthritis, 29, 1722
synovitis, 29
systemic lupus erythematosus, 1722
Articular cartilage
antigen induced arthritis, 1714
bovine studies, 1740
calcium pyrophosphate dihydrate crystals, 1514
Canadian Rheumatology Association Meeting, 1599 (ab), 1605 (ab)
cartilage degradation, 1514
chondrocytes, 1130
collagen genes, S43–28
continuous passive motion, 1714
doxycycline, S43–149
gangliosides, S43–133
high molecular weight anionic glycoconjugate, 1605 (ab)
hyaluronic acid, S43–155
insulin like growth factor-I, 1599 (ab)
interleukin 1, 1130
interleukin 4, 1740
interleukin 6, 1130
keratan sulfate, S43–155
knee osteoarthritis, 1747
macaca mulatta, 1747
magnetic resonance imaging, 1747, S43–52
nonsteroidal antiinflammatory drugs, 1130
osteoarthritis, 1130, 1514, 1599 (ab), 1605 (ab), 1740, 1913, S43–28, S43–52, S43–133, S43–146, S43–149, S43–155
ovine studies, S43–155
pentosan polysulfate, S43–146
proteoglycans, 1740
rabbit studies, 1714, 1913
rheumatoid arthritis, 1714
synovitis, 1714
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–28, S43–52, S43–133, S43–146, S43–149, S43–155
tissue inhibitor of metalloprotease, S43–146
transforming growth factor-beta, 1605 (ab)
vesicles, 1514
Aspirin
antiphospholipid antibody syndrome, 1086
interleukin 3, 1086
leukotrienes, 1086
Atlantoaxial subluxation
ankylosing spondylitis, 2120
juvenile spondyloarthropathies, 548
ligaments, 2120
ossification, 2120
seronegative enthesopathy and arthropathy, 548
Auranofin
chloroquine, 1235
phenytoin, 1235
rheumatoid arthritis, 1235

rheumatoid arthritis clinical trials, 2208
slow acting antirheumatic drugs, 2208
treatment, 2208
Australia
aging, 1934
disability, 1934
epidemiology, 1934
Europe, 1934
musculoskeletal disorders, 1934
North America, 1934
spine, 1934
Autoantibodies
anti-annexin V, 1230
anti-annexin VI, 1230
anticentromere antibodies, 1286
anti-Fc gamma receptor, 2241
anti-La(SSB), 1352
antinuclear antibodies, 67, 73
anti-Ro(SSA), 1352
anti-56K/annexin XI autoantibodies, 97
congenital heart block, 1352
neonatal lupus, 1352
nucleolus organizer region-90 antigen, 521
pediatric rheumatic diseases, 521
Sa autoantibodies, 789
Autoantigens
Ro(SSA), 2092
Sjögren's syndrome, 2092
T cell receptor, 2092
T cells, 2092
Autoimmune diseases
annexins, 97
enzyme linked immunosorbent assay, 97
Autoimmunity
Abe Shore Memorial Lecture, 289
antinuclear antibodies, 73, 236
facial hemiatrophy, 73
influenza, 1802
interleukin 2 receptor, 1488
linear scleroderma, 73
minor salivary glands, 1488
pediatric rheumatic diseases, 289
rheumatoid arthritis, 1802
silicone implants, 236
Sjögren's syndrome, 1488
vaccination, 1802
Avascular necrosis of bone
Canadian Rheumatology Association Meeting, 1604 (ab)
CD4, 347
diagnosis, 1604 (ab)
human immunodeficiency virus, 347
radiography, 1604 (ab)
systemic lupus erythematosus, 347, 1604 (ab)
T cells, 347
Azathioprine
antimalarial therapy, 1636
arthroplasty, 1844
combination therapy, 1636
Hispanics, 1844
infection, 1844
methotrexate, 1636, 1844
predictive factors, 1844
rheumatoid arthritis, 1636, 1844

B

Bacillus Calmette-Guérin
arthritis, 2010
bladder cancer, 1441
iritis, 2010
Staphylococcus aureus, 1441
Bacteria
beta hemolyticus streptococcus, 1710
Borrelia burgdorferi, 684, 689, 695
Cryptosporidium, 1962
Escherichia coli, 684, 1825
fishes, 1608
Moraxella, 578
Mycobacterium marinum, 1608
Mycoplasma pneumoniae, 745
Proteus mirabilis, 1825
Salmonella, 575, 1598 (ab), 1947, 2193
Salmonella typhi, 1602 (ab)
Staphylococcus aureus, 1441
Streptococcus pyogenes, 529
Yersinia, 1598 (ab)
Bacterial infection
arthritis, 1504
diagnosis, 1504
D-lactic acid, 1504
Balneology
functional status, 1315
low back pain, 1315
Bath Ankylosing Spondylitis Metrology Index
ankylosing spondylitis, 1609
Behavior therapy
fibromyalgia, 717
treatment, 717
Behçet's disease
aneurysm, 2103
arteritis, 2103
corticosteroids, 2103
cyclophosphamide, 2103
cytokines, 904
interferon-alpha, 1183
interleukin 8, 904
leukemia, 1183
nailfold capillaries, 1108
Bermuda
disease activity, 1825
Escherichia coli, 1825
Proteus mirabilis, 1825
rheumatoid arthritis, 1825
United Kingdom, 1825
Beta hemolyticus streptococcus
reactive arthritis, 1710
rheumatic fever, 1710
Beta-endorphin
adrenocorticotropic hormone, 1829
cortisol, 1829
pituitary hormones, 1829
prolactin, 1829
rheumatoid arthritis, 1829
Beta$_2$ glycoprotein I
anionic phospholipids, 2009
anticardiolipin antibodies, 1091, 1894
antiphospholipid antibody syndrome, 1091, 1894, 2009
cofactors, 1091
syphilis, 1894
systemic lupus erythematosus, 1091
Biological availability
food, 1570
juvenile rheumatoid arthritis, 1570
methotrexate, 1570
Biological products
cost-benefit analysis, 1415
OMERACT II Conference, 1415
outcome assessment, 1415
rheumatoid arthritis clinical trials, 1415
Biological therapy
Abe Shore Memorial Lecture, 289
pediatric rheumatic diseases, 289
Biomechanical factors
occupations, S43–10
osteoarthritis, S43–10
predictive factors, S43–10
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–10
Biopsy
fibromyalgia, 133
giant cell arteritis, 93
predictive factors, 93
primary Sjögren's syndrome, 133
salivary glands, 133
Sjögren's syndrome, 133
temporal artery, 93
Biostatistics
cost-benefit analysis, 1412
diagnosis, 571
disease activity, 2307
fibromyalgia clinical trials, 2307
Lyme disease, 571
McGill Pain Questionnaire, 2307
Myalgic Score, 2307
neural networks, 571
OMERACT II Conference, 1191, 1412
outcome assessment, 1412
outcome measures, 2307
quality of life, 1191
regression analysis, 2307
reproducibility of results, 2307
rheumatoid arthritis clinical trials, 1191, 1412
Tender Point Count, 2307
Blacks
Caucasians, 1663
epidemiology, 1663
mortality, 1663
systemic lupus erythematosus, 1663
Bladder
cystitis, 2373
methylprednisolone, 2373
prednisolone, 2373
systemic lupus erythematosus, 2373
vasculitis, 2373
Bladder cancer
Bacillus Calmette-Guérin, 1441
Staphylococcus aureus, 1441
Blood platelets
anticardiolipin antibodies, 649
lactate dehydrogenase, 649
systemic lupus erythematosus, 649

Bone
aggrecan, S43–71
bone mineral density, 440
cartilage, S43–71
cortical, 440
osteoarthritis, S43–71
osteoporosis, 440
rheumatoid arthritis, 440
synovial fluid, S43–71
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–71
Bone Gla protein
cyclosporin A, 1060
insulin like growth factor-I, 1060
rheumatoid arthritis, 1060
Bone marrow transplantation
allogeneic, 1809
autologous, 1809
rheumatoid arthritis, 1809
syngeneic, 1809
systemic lupus erythematosus, 1809
Bone mineral density
aged, 921, 932
calcitonin, 2238
calcium, 2148
cortical bone, 440
corticosteroid therapy, 1055
exertion, 2148
fractures, 921
glucocorticoid therapy, 1055, 2238
osteoarthritis, 921, 932, S43–98
osteoporosis, 440, 921, 1055, 1455, 2148, 2238, S43–98
PDN-21, 2238
rheumatoid arthritis, 440, 1055, 1455
sex hormone, 1455
spine, 932
subchondral bone, S43–98
systemic lupus erythematosus, 2238
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–98
vitamin D, 2148
Bone resorption
creatinine, 797
pyridinium, 797
systemic sclerosis, 797
Book reviews
Acute Rheumatic and Immunological Diseases, 377
Arthritis Surgery, 377
Bailliere's Clinical Rheumatology. Fibromyalgia and Myofascial Pain Syndrome, 2378
Color Atlas and Text of Osteoarthritis, 2378
Diagnosis and Management of Bone Infections. Infectious Disease and Therapy, 2377
Diagnosis of Bone and Joint Disorders, 1002
Management of the Critically Ill Patient, 377
Musculoskeletal Pain, Myofascial Pain Syndrome and Fibromyalgia Syndrome, 1002
Rheumatoid Arthritis - Pathogenesis, Assessment, Outcome and Treatment, 579
Textbook of Pediatric Rheumatology, 2010
Treatment of the Rheumatic Diseases, 2011
Yearbook of Rheumatology 1994, 579
Borrelia burgdorferi
epidemiology, 689, 695
Lyme disease, 689, 695
Russia, 689
Sweden, 695
treatment, 689
Bovine studies
articular cartilage, 1740
interleukin 4, 1740
osteoarthritis, 1740
proteoglycans, 1740
Bowel
ischemia, 2375
primary Sjögren's syndrome, 2375
vasculitis, 2375
Brain abnormalities
neuropsychiatric systemic lupus erythematosus, 1247
single photon emission computed tomography, 1247
Brain biopsy
primary angiitis, 662
Breast
connective tissue disease, 198
gigantism, 1214
silicone implants, 198
Sjögren's syndrome, 198
systemic lupus erythematosus, 1214
systemic sclerosis, 198
Breast cancer
arthritis, 973
joint effusion, 973
metastasis, 973
Breast feeding
juvenile rheumatoid arthritis, 1166
8-Bromo cyclic adenosine monophosphate
chondrocytes, 2114
cytokines, 2114
juvenile rheumatoid arthritis, 2114
phospholipase A_2, 2114
rheumatoid arthritis, 2114
Bromocriptine
prolactin, 2084
systemic lupus erythematosus, 2084
Bursitis
bursography, 1971
iliopsoas, 1971
pain, 1971
Bursography
bursitis, 1971
iliopsoas, 1971
pain, 1971

C

C5 deficiency
Sjögren's syndrome, 1389
Calcergy
calcinosis, 5
calciphylaxis, 5
Calcinosis
calcergy, 5
calciphylaxis, 5
Calciphylaxis
calcergy, 5
calcinosis, 5
Calcitonin
bone mineral density, 2238
glucocorticoid therapy, 2238
osteoporosis, 2238
PDN-21, 2238
systemic lupus erythematosus, 2238
Calcium
bone mineral density, 2148
exertion, 2148
osteoporosis, 2148
vitamin D, 2148
Calcium pyrophosphate dihydrate crystal deposition disease
acromioclavicular joint, 371
alkaline phosphatase, 117, 1907
apatite crystals, 2007
calcium pyrophosphate dihydrate crystals, 117
cysts, 371
fingers, 2007
osteoarthritis, 2007
pyrophosphatases, 1907
spermidine, 1907
spermine, 1907
Calcium pyrophosphate dihydrate crystals
alkaline phosphatase, 117
apatite crystals, S43–101
articular cartilage, 1514
calcium pyrophosphate dihydrate deposition disease, 117
Canadian Rheumatology Association Meeting, 1604 (ab)
cartilage degradation, 1514
cervical spine, 1604 (ab)
Charcot's joint, 1604 (ab)
gouty arthritis, 1604 (ab)
myelopathy, 1604 (ab)
osteoarthritis, 1514, S43–101
synovial fluid, S43–101
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–101
vesicles, 1514
CAMPATH-1H
phospholipase A_2, 1816
rheumatoid arthritis, 1816
tumor necrosis factor-alpha, 1816
Camptodactyly
arthropathy, 2349
genetic factors, 2349
pericarditis, 2349
pleuritis, 2349
serositis, 2349
Canada
Canadian Rheumatology Association Meeting, 1600 (ab)
cost-benefit analysis, 908
drug prescriptions, 836
Edmonton, 836
epidemiology, 722, 1600 (ab)
fibromyalgia, 722
gouty arthritis, 908
juvenile rheumatoid arthritis, 1600 (ab)

Kingston, 1600 (ab)
methotrexate, 1600 (ab)
rheumatoid arthritis, 836, 1600 (ab)
rheumatology and rheumatologists, 1600 (ab)
risk-benefits, 1600 (ab)
second line drugs, 836
treatment, 1600 (ab)
treatment outcome, 836
urate lowering drugs, 908
Canadian Rheumatology Association Meeting, 1598–1605
acute anterior uveitis, 1598 (ab)
adenocarcinoma, 1602 (ab)
adrenocorticotropic hormone, 1603 (ab)
amyloidosis, 1605 (ab)
anterior uveitis, 1602 (ab)
antigen induced arthritis, 1605 (ab)
anti-hY5 RNA antibodies, 1599 (ab)
anti-Ro antibodies, 1599 (ab)
Arthritis Impact Measurement Scales, 1601 (ab), 1603 (ab)
The Arthritis Society, 1604 (ab)
articular cartilage, 1599 (ab), 1605 (ab)
avascular necrosis, 1604 (ab)
calcium pyrophosphate dihydrate crystals, 1604 (ab)
Canada, 1600 (ab)
cell activation, 1599 (ab)
cervical spine, 1604 (ab)
Charcot's joint, 1604 (ab)
connective tissue disease, 1599 (ab)
continuing medical education, 1603 (ab)
cortical thickness, 1598 (ab)
corticosteroid therapy, 1601 (ab)
cytomegalovirus, 1599 (ab)
diagnosis, 1603 (ab), 1604 (ab)
disability, 1601 (ab), 1603 (ab)
disease activity, 1602 (ab)
dysentery, 1602 (ab)
epidemiology, 1600 (ab), 1604 (ab)
exercise, 1604 (ab)
family physicians, 1603 (ab)
fibromyalgia, 1603 (ab), 1604 (ab)
French Canadians, 1604 (ab)
Functional Index, 1603 (ab)
functional status, 1602 (ab)
fund raising, 1604 (ab)
gastroenteropathy, 1603 (ab)
gold, 1601 (ab)
gouty arthritis, 1604 (ab)
half-life, 1603 (ab)
Health Assessment Questionnaire, 1601 (ab), 1603 (ab)
high molecular weight anionic glycoconjugate, 1605 (ab)
HLA-B27, 1602 (ab)
HLA-DR4 alleles, 1601 (ab)
hydroxychloroquine, 1602 (ab)
hypermobility, 1603 (ab)
idiopathic inflammatory myositis, 1604 (ab)
inflammation, 1605 (ab)
insulin like growth factor-I, 1599 (ab)
interleukin 2, 1602 (ab)
intramuscular gold, 1600 (ab)
juvenile rheumatoid arthritis, 1600 (ab)
keratinocytes, 1599 (ab)
keratoconjunctivitis sicca, 1604 (ab)
Kingston, Canada, 1600 (ab)
macroglossia, 1605 (ab)
methotrexate, 1600 (ab)
mortality, 1600 (ab), 1601 (ab)
muscle weakness, 1605 (ab)
myelopathy, 1604 (ab)
nonsteroidal antiinflammatory drugs, 1603 (ab)
North American Indians, 1600 (ab)
NZB mice, 1602 (ab)
osteoarthritis, 1599 (ab), 1605 (ab)
outcome assessment, 1601 (ab), 1602 (ab), 1603 (ab)
pain, 1604 (ab)
patient education, 1603 (ab)
pentoxifylline, 1600 (ab)
pharmacokinetics, 1603 (ab)
pigmentation, 1603 (ab)
psoriatic arthritis, 1601 (ab)
rabbit studies, 1605 (ab)
radiography, 1598 (ab), 1604 (ab)
reactive arthritis, 1602 (ab)
rheumatoid arthritis, 1600 (ab), 1601 (ab), 1604 (ab)
rheumatoid arthritis clinical trials, 1598 (ab), 1600 (ab), 1601 (ab)
rheumatology and rheumatologists, 1600 (ab), 1603 (ab)
risk-benefits, 1600 (ab)
sacroiliitis, 1602 (ab)
Salmonella, 1598 (ab)
Salmonella typhi, 1602 (ab)
scleroderma, 1603 (ab)
self-injections, 1601 (ab)
SERP-1 protein, 1605 (ab)
Sharp, 1598 (ab)
sicca syndrome, 1604 (ab)
Sjögren's syndrome, 1604 (ab)
skin manifestations, 1599 (ab)
sleep disorders, 1604 (ab)
socioeconomic factors, 1601 (ab)
spondyloarthropathies, 1601 (ab), 1602 (ab)
sulfasalazine, 1601 (ab)
systemic lupus erythematosus, 1599 (ab), 1602 (ab), 1604 (ab)
systemic lupus erythematosus clinical trials, 1602 (ab)
Th1 cells, 1602 (ab)
toxicity, 1600 (ab), 1601 (ab)
transforming growth factor-beta, 1605 (ab)
treatment, 1600 (ab)
tumor necrosis factor receptors, 1599 (ab)
tumor necrosis factor-alpha, 1599 (ab), 1600 (ab)
typhoid vaccine, 1602 (ab)
ulcer, 1601 (ab)
xerostomia, 1604 (ab)
Yersinia, 1598 (ab)
Cancer
adenocarcinoma, 970
anticardiolipin antibodies, 2007
arthritis, 973
endometrium, 1606
joint effusion, 973
kidneys, 2007
lung, 367
metastasis, 973
sacroiliitis, 970
systemic lupus erythematosus, 1606
tamoxifen, 1606
thrombosis, 2007
Canine studies
hyaluronic acid, 262, 1732
knee osteoarthritis, 1732
osteoarthritis, 262, S43–94, S43–146, S43–149
synovial fluid, 1732
synovium, 262
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–146
Capillaries
Behçet's disease, 1108
nailfold, 1108
Caprine arthritis encephalitis virus
rheumatoid arthritis, 8
synovial fluid, 8
Caprine studies
articular cartilage, S43–155
caprine arthritis encephalitis virus, 8
hyaluronic acid, S43–155
keratan sulfate, S43–155
osteoarthritis, S43–155
rheumatoid arthritis, 8
synovial fluid, 8
T cells, 8
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–155
Capsaicin
inflammation, 1447
neuropeptides, 1447
rheumatoid arthritis, 1447
Carcinoma
calcinar cells, 2170
pancreas, 2170
panniculitis, 2170
systemic lupus erythematosus, 2170
Cardiac involvement
necrotizing vasculitis, 78
polyarteritis nodosa, 78
polymyositis/dermatomyositis, 809
predictive factors, 78
renal involvement, 78
Cardiac tamponade
adult Still's disease, 180
pericarditis, 180
Cardiovascular disease
mortality, 1065
rheumatoid arthritis, 1065
sex, 1065
Carpal tunnel syndrome
fibromyalgia, 501
Cartilage
aggrecan, S43–71, S43–75
apoptosis, 926
articular, S43–60, S43–82
bone, S43–71
chondroitinase ABC, 702
collagen, S43–82

immune complex arthritis, 2250
inflammation, 1922
interleukin 1, 2250
magnetic resonance imaging, S43–60
murine studies, 2250
nitric oxide, 1922
osteoarthritis, 702, 926, S43–60, S43–71, S43–75, S43–82, S43–91
proteoglycan degradation, 2250
proteoglycan synthesis, 2250, S43–91
proteoglycans, 702
proteolysis, S43–82
proto-oncogene bcl-2, 926
rabbit studies, 702
rheumatoid arthritis, 1922
synovial fluid, S43–71, S43–75
synovium, 1922
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–60, S43–71, S43–75, S43–82, S43–91
tumor necrosis factor-alpha, 2250
Cartilage degradation
articular cartilage, 1514
calcium pyrophosphate dihydrate crystals, 1514
interleukin 1 receptor antagonist, 1338
osteoarthritis, 1338, 1514
proteoglycans, 1338
rheumatoid arthritis, 1338
vesicles, 1514
Cartilage destruction
polymorphonuclear granulocytes, 1436
rheumatoid arthritis, 1436
synovial fluid, 1436
Cartilage thickness
osteoarthritis, 109
ultrasound, 109
Cartilage volume
osteoarthritis, S43–120
plasminogen activators, S43–120
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–120
urokinase, S43–120
Catecholamines
exercise, 143
fibromyalgia, 143
muscle fatigue, 143
Caucasians
Blacks, 1663
C4AQ0, 1862
epidemiology, 1663
genetic factors, 1852, 1862
haplotypes, 1852
HLA, 1852
major histocompatibility complex, 1852
mortality, 1663
phenotypes, 1862
systemic lupus erythematosus, 1663, 1852, 1862
Cauda equina
epidural lipomatosis, 1771
obesity, 1771
Cause of death
mortality, 1259
prognosis, 1259
systemic lupus erythematosus, 1259
CD4
avascular necrosis of bone, 347
human immunodeficiency virus, 347
systemic lupus erythematosus, 347
T cells, 347
CD5
immunoconjugates, 207
lymphocytes, 207
rheumatoid arthritis, 207
CD8
diagnosis, 1020
polymyalgia rheumatica, 1020
rheumatoid arthritis, 1020
T lymphocytes, 1020
CD14
chondrocytes, 1326
leukocyte differentiation antigens, 1326
osteoarthritis, 1326
rheumatoid arthritis, 1326
CD69
rheumatoid arthritis, 413
synovial fluid, 413
T cells, 413
Cell activation
Canadian Rheumatology Association Meeting, 1599 (ab)
osteoarthritis, 1599 (ab)
tumor necrosis factor receptors, 1599 (ab)
tumor necrosis factor-alpha, 1599 (ab)
Cell adhesion molecules
methylprednisolone, 2065
neutrophils, 2065
rheumatoid arthritis, 2065
selectins, 2065
Central America
ankylosing spondylitis, 2327
paleopathology, 2327
Central nervous system
angioendotheliomatosis, 1769
angiopathy, 780
cocaine, 780
cognitive impairment, 863
cytoxan, 1769
diagnosis, 662
digital subtraction angiography, 2371
disease activity, 863
leukoencephalopathy, 335
lymphoma, 1769
methotrexate, 335
neuropsychologic factors, 863
normal pressure hydrocephalus, 342
prednisone, 342
primary angiitis, 662, 2371
rheumatoid arthritis, 335, 342
systemic lupus erythematosus, 863
vasculitis, 1769, 2371
Central nervous system involvement
antiribosomal PO protein antibodies, 1681
systemic lupus erythematosus, 1681
Cerebral fluid examination
primary angiitis, 662
Cerebral infarction
lipoprotein(a), 1210
myocardial infarction, 1210
systemic lupus erythematosus, 1210
Cervical spine
calcium pyrophosphate dihydrate crystals, 1604 (ab)
Canadian Rheumatology Association Meeting, 1604 (ab)
Charcot's joint, 1604 (ab)
gouty arthritis, 1604 (ab)
myelopathy, 1604 (ab)
Cervical subluxation
anesthesia, 2152
Ehlers-Danlos syndrome, 2152
Charcot's joint
calcium pyrophosphate dihydrate crystals, 1604 (ab)
Canadian Rheumatology Association Meeting, 1604 (ab)
cervical spine, 1604 (ab)
gouty arthritis, 1604 (ab)
myelopathy, 1604 (ab)
Childhood Health Assessment Questionnaire
disability, 326
juvenile dermatomyositis, 326
China
epidemiology, 795
prevalence studies, 659
rheumatic diseases, 795
Sjögren's syndrome, 659
Chinese
polyarteritis, 1295
prognosis, 1295
Chingford Study
epidemiology, 1118, 1509
hand osteoarthritis, 1509
knee osteoarthritis, 1118
Chlorambucil
inclusion body myositis, 576
Chloroquine
auranofin, 1235
hydroxychloroquine, 34
phenytoin, 1235
renal function, 34
rheumatoid arthritis, 34, 1235
Cholesterol
diet therapy, 450
hyperlipidemia, 450
systemic lupus erythematosus, 450
Cholesterol crystals
nodules, 338
rheumatoid arthritis, 338
Chondrocytes
antirheumatic drugs, S43–152
articular cartilage, 1130
8-bromo cyclic adenosine monophosphate, 2114
CD14, 1326
cytokines, 2114
human vs bovine, S43–152
interleukin 1, 1130, S43–104
interleukin 6, 1130
juvenile rheumatoid arthritis, 2114
leukocyte differentiation antigens, 1326
nonsteroidal antiinflammatory drugs, 1130

osteoarthritis, 1130, 1326, S43–104, S43–152
phospholipase A_2, 2114
proteoglycan synthesis, S43–152
rheumatoid arthritis, 1326, 2114
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–104, S43–152
transforming growth factor-beta, S43–104
Chondroitin sulfate
fibronectins, S43–158
hyaluronic acid, S43–158
osteoarthritis, S43–158
proteoglycans, S43–158
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–158
Chondroitinase ABC
cartilage, 702
osteoarthritis, 702
proteoglycans, 702
rabbit studies, 702
Chronic inflammatory arthritis
outpatient care, 1141
team management, 1141
Churg-Strauss syndrome
giant cell arteritis, 2177
neoplasms, 2177
temporal arteritis, 2177
vasa vasorum vasculitis, 2177
Clinical observations
clinical protocols, 1611
rheumatoid arthritis clinical trials, 1611
treatment, 1611
Clinical protocols
clinical observations, 1611
rheumatoid arthritis clinical trials, 1611
treatment, 1611
Clubbing
fingers, 2346
hypertrophic osteoarthropathy, 2346
Takayasu's arteritis, 2346
Coagulopathy
antiphospholipid antibody syndrome, 2173
disseminated, 2173
systemic lupus erythematosus, 2173
vasculitis, 2173
Cocaine
angiopathy, 780
central nervous system, 780
Cofactors
anticardiolipin antibodies, 1091
antiphospholipid antibody syndrome, 1091
beta$_2$ glycoprotein I, 1091
systemic lupus erythematosus, 1091
Cognitive impairment
aged, 2142
central nervous system, 863
depression, 2187
disease activity, 863
neuropsychiatric systemic lupus erythematosus, 2187
neuropsychologic factors, 863
nonsteroidal antiinflammatory drugs, 2142
systemic lupus erythematosus, 863
COL2A1
collagen type II, 255
gene mutation, 255
osteoarthritis, 255
osteochondrodysplasia, 255
Colchicine
hyperuricemia, 1618, 1621
nontophaceous interval gout, 1618, 1621
treatment, 1618, 1621
Cold
complement activation, 1806
hepatitis C virus, 1806
vasculopathy, 1806
Colitis
gold, 572
rheumatoid arthritis, 572
Collagen
cartilage, S43–82
collagen genes, S43–34
gene therapy, S43–140
osteoarthritis, S43–34, S43–39, S43–82, S43–94
proteoglycans, S43–94
proteolysis, S43–82
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–34, S43–82, S43–94, S43–140
transgenic mice, S43–140
type II, S43–34, S43–37, S43–82, S43–94
type IX, S43–39, S43–82
type XI, S43–82
Collagen genes
articular cartilage, S43–28
collagen, S43–34
murine studies, S43–39
osteoarthritis, S43–28, S43–34
osteochondrodysplasia, S43–39
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–28, S43–34, S43–39
Collagen type II
COL2A1, 255
gene mutation, 255
osteoarthritis, 255
osteochondrodysplasia, 255
Collagenases
metalloproteinases, 2285
prosthesis, 2285
total hip arthroplasty, 2285
Combination therapy
methotrexate-azathioprine-antimalarial therapy, 1636
methylprednisolone-prednisolone, 2373
rheumatoid arthritis, 1636
Comorbidity
corticosteroid therapy, 1601 (ab)
mortality, 1601 (ab)
rheumatoid arthritis, 1601 (ab)
socioeconomic factors, 1601 (ab)
Complement activation
cold, 1806
hepatitis C virus, 1806
vasculopathy, 1806
Complications
ambulatory surgery, 1722
arthroscopy, 1722
knee osteoarthritis, 1722
Computed tomography
juvenile rheumatoid arthritis, 1956
orthodontic assessment, 1956
temporomandibular joint, 1956
Congenital heart block
anti-La(SSB) antibodies, 1352
anti-Ro antibodies, 533
anti-Ro(SSA) antibodies, 1352
autoantibodies, 1352
complete, 533, 541
HLA, 541
neonatal lupus, 533, 541, 1352
outcome assessment, 533, 541
Congestive heart failure
polymyositis/dermatomyositis, 809
Connective tissue disease
anticardiolipin antibodies, 227
anti-hY5 RNA antibodies, 1599 (ab)
anti-Ro antibodies, 1599 (ab)
breast, 198
Canadian Rheumatology Association Meeting, 1599 (ab)
listeriosis, 796
microscopy, 2226
nailfold capillaries, 2226
Raynaud's phenomenon, 2226
silicone implants, 198
Sjögren's syndrome, 198
systemic sclerosis, 198, 2226
Continuing medical education
analgesic therapy, 1762
Canadian Rheumatology Association Meeting, 1603 (ab)
family physicians, 1603 (ab), 1762
nonsteroidal antiinflammatory drugs, 1762
osteoarthritis, 1762
rheumatology, 1603 (ab)
Continuous passive motion
antigen induced arthritis, 1714
articular cartilage, 1714
rabbit studies, 1714
rheumatoid arthritis, 1714
synovitis, 1714
Copenhagen criteria
modified San Diego criteria, 659
primary Sjögren's syndrome, 659
Core decompression
magnetic resonance imaging, 1929
osteonecrosis, 1929
Coronary disease
antiphospholipid antibodies, 1438
pediatric systemic lupus erythematosus, 1438
Cortical bone
bone mineral density, 440
osteoporosis, 440
rheumatoid arthritis, 440
Cortical thickness
Canadian Rheumatology Association meeting, 1598 (ab)
radiography, 1598 (ab)
rheumatoid arthritis clinical trials, 1598 (ab)
Sharp, 1598 (ab)
Corticosteroid therapy
adverse effects, 1013, 1055
aneurysm, 2103

arteritis, 2103
Behçet's disease, 2103
bone mineral density, 1055
Canadian Rheumatology Association Meeting, 1601 (ab)
comorbidity, 1601 (ab)
cyclophosphamide, 2103
immunosuppressive therapy, 2193
infection, 2193
interstitial lung disease, 881
low dose, 1013
lymphadenopathy, 881
mortality, 1601 (ab)
osteoarthritis, 1013
osteoporosis, 1013, 1055
rheumatoid arthritis, 1055, 1601 (ab)
Salmonella, 2193
sarcoidosis, 881
socioeconomic factors, 1601 (ab)
systemic lupus erythematosus, 2193
systemic sclerosis, 881
Cortisol
adrenocorticotropic hormone, 1829
beta-endorphin, 1829
pituitary hormones, 1829
prolactin, 1829
rheumatoid arthritis, 1829
Cost of illness
musculoskeletal disorders, 204
Cost-benefit analysis
biological products, 1415
biostatistics, 1412
Canada, 908
gouty arthritis, 908
nonsteroidal antiinflammatory drugs, 1408
OMERACT II Conference, 1399, 1403, 1408, 1412, 1415, 1418
outcome assessment, 1399, 1403, 1408, 1412, 1415
rheumatic diseases, 1399
rheumatoid arthritis clinical trials, 1403, 1408, 1412, 1415, 1418
urate lowering drugs, 908
C-reactive protein
inflammation, 1224
interleukin 6, 1224
lipopolysaccharide binding protein, 1224
rheumatoid arthritis, 1224
synovial fluid, 1224
Creatinine
bone resorption, 797
pyridinium, 797
systemic sclerosis, 797
Creatinine clearance
chloroquine, 34
hydroxychloroquine, 34
rheumatoid arthritis, 34
Cryptosporidiosis
Cryptosporidium, 1962
gastroenteritis, 1962
pediatric Reiter's syndrome, 1962
Cryptosporidium
cryptosporidiosis, 1962
gastroenteritis, 1962
pediatric Reiter's syndrome, 1962
Crystals
cholesterol, 338
Cushing's disease
pituitary microadenoma, 1964
rheumatoid arthritis, 1964
trans-sphenoidal surgery, 1964
Cutaneous necrosis
anticardiolipin antibodies, 1380
antiphospholipid antibody syndrome, 1380
vascular thrombosis, 1380
Cyclophosphamide
adverse effects, 1812
aneurysm, 2103
arteritis, 2103
Behçet's disease, 2103
corticosteroids, 2103
intravenous, 1000
lupus nephritis, 1812
methotrexate, 1000
prednisone, 1593
progressive multifocal leukoencephalopathy, 1593
pyoderma gangrenosum, 1000
renal function, 1812
rheumatoid arthritis, 1000
systemic lupus erythematosus clinical trials, 1812
Wegener's granulomatosis, 1593
Cyclosporin A
Adult Still's disease, 1391
bone Gla protein, 1060
insulin like growth factor-I, 1060
rheumatoid arthritis, 1060
Cyclosporine
disease activity, 654
interleukin 1 beta, 654
interstitial lung disease, 2163
rheumatoid arthritis, 2163
scleroderma, 654
soluble interleukin 2 receptor, 654
Cystitis
bladder, 2373
methylprednisolone, 2373
prednisolone, 2373
systemic lupus erythematosus, 2373
vasculitis, 2373
Cysts
acromioclavicular joint, 371
calcium pyrophosphate dihydrate deposition disease, 371
Cytokines
Behçet's disease, 904
8-bromo cyclic adenosine monophosphate, 2114
chondrocytes, 2114
interferon gamma, 904, 1698
interleukin 1, S43–109, S43–123
interleukin 1 receptor antagonist, S43–109
interleukin 4, 1740, 2020
interleukin 6, 224, 904, S43–109
interleukin 7, 1581
interleukin 8, 904
interleukin 10, 2020
interleukin 12, 1674
juvenile rheumatoid arthritis, 2114
lymphoma, 1674
methotrexate, 224
osteoarthritis, S43–109
phospholipase A_2, 2114
rheumatoid arthritis, 224, 2114
Sjögren's syndrome, 1674
soluble interleukin 2 receptor, 224
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–109
tumor necrosis factor-alpha, 904, 1698, S43–109, S43–115
Cytomegalovirus
Canadian Rheumatology Association Meeting, 1599 (ab)
keratinocytes, 1599 (ab)
skin manifestations, 1599 (ab)
systemic lupus erythematosus, 1599 (ab)
Cytoxan
angioendotheliomatosis, 1769
central nervous system, 1769
lymphoma, 1769
vasculitis, 1769
C4 genotypes
anticardiolipin antibodies, 227
HLA haplotypes, 227
C4AQ0
Caucasians, 1862
genetic factors, 1862
phenotypes, 1862
systemic lupus erythematosus, 1862
C5 deficiency
primary Sjögren's syndrome, 1389
C5a
lysis, 24
rheumatoid arthritis, 24

D

Danazol
Evans' syndrome, 1867
hemolytic anemia, 1867
systemic lupus erythematosus, 1867
thrombocytopenia, 1867
Deflazacort
drug administration schedule, 1492
drug dose-response relationship, 1660
methylprednisolone, 1492
polymyalgia rheumatica, 1492
polymyalgia rheumatica clinical trials, 1660
prednisolone, 1660
Denervation
distal interphalangeal joint, 1211
fingers, 1211
psoriatic arthritis, 1211
Dental amalgam
fibromyalgia, 2194
mercury, 2194
Depression
anxiety, 644
cognitive impairment, 2187
fibromyalgia, 137
mental processes, 137
neuropsychiatric systemic lupus erythematosus, 2187
rheumatoid arthritis, 644

social factors, 644
Dermatomyositis
childhood Health Assessment Questionnaire, 326
classification criteria, 581, 668
diagnostic criteria, 581, 668
disability, 326
disease activity, 193, 320
epidemiology, 668
juvenile, 193, 320, 326, 1369
magnetic resonance imaging, 193
polymyositis, 668
retinopathy, 2372
von Willebrand factor, 193, 320
Dexamethasone
adjuvant arthritis, 124
murine studies, 124
rheumatoid arthritis, 124
synovial membrane, 124
Diagnosis
ankylosing spondylitis, 740
arthritis, 1504
avascular necrosis of bone, 1604 (ab)
bacterial infection, 1504
Canadian Rheumatology Association Meeting, 1603 (ab), 1604 (ab)
CD8, 1020
central nervous system, 662
D-lactic acid, 1504
Dunlop-Dotteridge Lecture 1994, 740
enzyme linked immunosorbent assay, 684
Escherichia coli, 684
family physicians, 1532
fibromyalgia, 1603 (ab)
hypermobility, 1603 (ab)
iliac crest pain syndrome, 1532
keratoconjunctivitis sicca, 1604 (ab)
low back pain, 1532
Lyme disease, 571, 684
neural networks, 571
observer variation, 1532
outcome assessment, 740
polymyalgia rheumatica, 1020
primary angiitis, 662
radiography, 1604 (ab)
rheumatoid arthritis, 789, 1020
Sa autoantibodies, 789
sicca syndrome, 1604 (ab)
Sjögren's syndrome, 1604 (ab)
systemic lupus erythematosus, 1604 (ab)
T lymphocytes, 1020
xerostomia, 1604 (ab)
Diclofenac
disease progression, 2013
indomethacin, 2013
nabumetone, 915
nonsteroidal antiinflammatory drugs, 2013
osteoarthritis, 2013
osteoarthritis clinical trials, 915
rheumatoid arthritis clinical trials, 617
salsalate, 617
Diet therapy
cholesterol, 450
hyperlipidemia, 450
systemic lupus erythematosus, 450
Diffuse idiopathic skeletal hyperostosis
Achilles tendinitis, 1212
ligament, 1395
ossification, 1395
retinol, 1395
retinol binding protein, 1395
Digital imaging
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 2001
outcome assessment, 2001
radiography, 2001
rheumatoid arthritis clinical trials, 2001
Digital subtraction angiography
central nervous system, 2371
primary angiitis, 2371
vasculitis, 2371
Disability
aging, 1934
Arthritis Impact Measurement Scales, 1603 (ab)
Australia, 1934
Canadian Rheumatology Association Meeting, 1601 (ab), 1603 (ab)
Childhood Health Assessment Questionnaire, 326
disease progression, 1037, 2218
disease severity, 2313
epidemiology, 1934, S43–19
Europe, 1934
fibromyalgia, 270, 372, 2313
Functional Index, 1603 (ab)
functional status, 1037, 1834
Groningen Activity Restriction Scale, 1834
Health Assessment Questionnaire, 1241, 1601 (ab), 1603 (ab), 1834
health services utilization, S43–19
juvenile chronic arthritis, 308
juvenile dermatomyositis, 326
juvenile rheumatoid arthritis, 308
musculoskeletal disorders, 505, 1934
North America, 1934
osteoarthritis, S43–136
outcome assessment, 308, 1241, 1603 (ab)
pain, 270, 1466, 2313, S43–136
predictive factors, 1466, 2313
prognosis, 1037
prognostic factors, 308
psoriatic arthritis, 1601 (ab)
psychosocial factors, 2218
quality of life, 270
reference standards, 1241
rehabilitation, 505
rheumatoid arthritis, 270, 1037, 1241, 1466, 1601 (ab), 1834, 2218
scleroderma, 1603 (ab)
sex, 1834
socioeconomic factors, 505
spine, 1934
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–19, S43–136
trauma, 372
treatment, S43–136
ulcer, 1601 (ab)
Disease activity
aldolase, 563
Bermuda, 1825
biostatistics, 2307
Canadian Rheumatology Association Meeting, 1602 (ab)
central nervous system, 863
cognitive impairment, 863
cyclosporine, 654
disease severity, 189
eosinophilic fasciitis, 563
Escherichia coli, 1825
fatigue, 639
fibromyalgia clinical trials, 2307
functional status, 639, 1602 (ab)
health care costs, 189
HLA, 2034
hydroxychloroquine, 1602 (ab)
indium-III, 478
inflammatory arthritis, 850
interleukin 1 beta, 654
isometric contraction, 473
juvenile chronic arthritis, 295
juvenile dermatomyositis, 193, 320
juvenile rheumatoid arthritis, 295
leukocytes, 478
magnetic resonance imaging, 193
McGill Pain Questionnaire, 2307
methotrexate, 844
muscle strength, 473
Myalgic Score, 2307
natural history, 295
neuropsychologic factors, 863
outcome assessment, 1602 (ab)
outcome measures, 2307
pharmacokinetics, 844
polymyositis/dermatomyositis, 473
prognostic factors, 295
Proteus mirabilis, 1825
rheumatoid arthritis, 639, 844, 850, 1825, 2034
scleroderma, 654
soluble interleukin 2 receptor, 654
Systemic Lupus Disease Activity Measure, 45
systemic lupus erythematosus, 45, 189, 863, 1602 (ab)
systemic lupus erythematosus clinical trials, 1602 (ab)
Taiwan, 2034
Takayasu's arteritis, 478
Tender Point Score, 2307
treatment, 189
United Kingdom, 1825
von Willebrand factor, 193, 320
Disease modifying antirheumatic drugs
gastrointestinal involvement, 2200, 2214
glucocorticoid therapy, 2214
gold, 2214
International League of Associations for Rheumatology, 201
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1797
mortality, 2200, 2214

nonsteroidal antiinflammatory drugs, 2200, 2214
osteoarthritis, 201
outcome assessment, 1797
outcome measures, 201
radiographic progression, 1797
radiography, 1797
rheumatoid arthritis, 2200, 2214
rheumatoid arthritis clinical trials, 1434, 1797
slow acting antirheumatic drugs, 201
West Africa, 1434
World Health Organization, 201
Disease onset
age, 794
ankylosing spondylitis, 794
genetic factors, 794
sex, 794
spondyloarthropathies, 794
Disease outbreaks
antibody formation, 1947
immune response, 1947
lipopolysaccharide, 1947
reactive arthritis, 1947
Salmonella, 1947
Disease progression
adjuvant arthritis, 855
diclofenac, 2013
disability, 1037, 2218
erythrocyte sedimentation rate, 675
functional status, 1037
indomethacin, 2013
inflammation, 675
methotrexate, 241
nonsteroidal antiinflammatory drugs, 2013
one dimensional proton nuclear magnetic resonance imaging, 855
osteoarthritis, 2013, S43–56
predictive factors, 675
prognosis, 1037
psoriatic arthritis, 241, 675
psychosocial factors, 2218
radiography, 241, S43–56
rheumatoid arthritis, 855, 1037, 2218
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–56
Disease severity
age, 1032
disability, 2313
disease activity, 189
fibromyalgia, 2313
health care costs, 189
HLA, 1032, 2027
HLA-DRB1, 2027
pain, 2313
predictive factors, 2313
rheumatoid arthritis, 1032, 2027
rheumatoid factor, 2027
risk factors, 1032
sex, 1032
systemic lupus erythematosus, 189
treatment, 189
Distal interphalangeal joint
denervation, 1211
fingers, 1211
psoriatic arthritis, 1211
D-lactic acid
arthritis, 1504
bacterial infection, 1504
diagnosis, 1504
Dolorimetry
fibromyalgia, 944
myofascial pain, 944
pain, 944
palpation, 944
tender points, 944
Doxycycline
articular cartilage, S43–149
osteoarthritis, S43–149
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–149
Drug administration schedule
deflazacort, 1492
methylprednisolone, 1492
polymyalgia rheumatica, 1492
Drug dose-response relationship
deflazacort, 1660
gold, 1657
methotrexate, 2072
nonsteroidal antiinflammatory drugs, 2072
pharmacokinetics, 2072
polymyalgia rheumatica clinical trials, 1660
prednisolone, 1660
renal function, 2072
rheumatoid arthritis, 1657, 2072
treatment, 1657
Drug induced systemic lupus erythematosus
Hashimoto's thyroiditis, 574
hydrochlorothiazide, 1001
procainamide, 574
Drug prescriptions
Canada, 836
rheumatoid arthritis, 836
second line drugs, 836
treatment outcome, 836
Drugs
analgesic therapy, 1762
anti-alpha beta T cell receptor monoclonal antibody, 2259
antimalarial therapy, 1636
antirheumatic drugs, 980, 982, 983, 989, 995, 998
arthroplasty, 1844
aspirin, 1086
auranofin, 2208
azathioprine, 1636, 1844
bacillus Calmette-Guérin, 1441, 2010
biological products, 1415
bromocriptine, 2084
CAMPATH-1H, 1816
capsaicin, 1447
chlorambucil, 576
chloroquine, 34
colchicine, 1618, 1621
corticosteroids, 881, 1013, 1055, 1097, 2103, 2193
cyclophosphamide, 1812, 2103
cyclosporin A, 1060
cyclosporine, 2163
cytoxan, 1769
danazol, 1867
deflazacort, 1492, 1660
diclofenac, 617, 915, 2013
disease modifying antirheumatic drugs, 201, 2200, 2214
doxycycline, S43–149
erythropoietin, 2166
etidronate, 2183
flurbiprofen, 1726
glucocorticoids, 2214, 2238
gold, 572, 1600 (ab), 1601 (ab), 1657, 1797, 2214
gold salts, 836
granulocyte colony stimulating factor, 1179, 1803
hyaluronic acid, S43–155, S43–158
hydrochlorothiazide, 1001
hydroxychloroquine, 34, 829, 868, 1527, 1602 (ab)
hydroxyurea, 1646
hylan, 1311
immunoconjugate murine anti-CD5 monoclonal antibody, 207
immunosuppressive therapy, 1478
indomethacin, 444, 713, 868, 1941, 2013
interferon-alpha, 1183
intramuscular gold, 829
intravenous cyclophosphamide, 1000
intravenous gamma globulin, 1068
isotretinoin, 2009
magnesium, 953
malic acid, 953
methotrexate, 38, 41, 218, 224, 241, 335, 569, 630, 633, 786, 790, 796, 829, 836, 844, 1000, 1009, 1043, 1104, 1442, 1570, 1574, 1636, 1797, 1844, 1967, 2072, 2189, 2356, 2359, 2370
methylprednisolone, 1492, 2065, 2373
minocycline, 611
minoxidil, 50
misoprostol, 713
nabumetone, 915
naproxen, 2295
nifedipine, 50
nonsteroidal antiinflammatory drugs, 937, 980, 982, 983, 989, 995, 998, 1009, 1130, 1149, 1408, 1603 (ab), 1762, 2013, 2072, 2142, 2200, 2214, 2295
norfloxacin, 793
oral contraceptives, 2159
pentosan polysulfate, S43–146, S43–152
pentoxifylline, 595, 625, 1600 (ab)
phenytoin, 1235
platelet activating factor-ACETHER, 1651
prednisolone, 1660, 2373
prednisone, 342, 829, 868
procainamide, 574
propylthiouracil, 803
RO31-9790, S43–152
salsalate, 617
slow acting antirheumatic drugs, 201, 1442, 2208
steroid therapy, 1442
sulfasalazine, 191, 836, 894, 1601 (ab), 1797
Super Malic®, 953

tamoxifen, 1606
tenidap, 444, 1097, 1726, S43–152
tiaprofenic acid, 1941, S43–152
zileuton, 462
Dunlop-Dotteridge Lecture 1994
ankylosing spondylitis, 740
diagnosis, 740
outcome assessment, 740
Dysentery
Canadian Rheumatology Association Meeting, 1602 (ab)
reactive arthritis, 1602 (ab)
Salmonella typhi, 1602 (ab)
typhoid vaccine, 1602 (ab)
Dyspnea
exercise, 455
pulmonary function, 455
systemic lupus erythematosus, 455

E

Ehlers-Danlos syndrome
anesthesia, 2152
cervical subluxation, 2152
Electrical stimulation
functional status, 1757
knee osteoarthritis, 1757
pain, 1757
Endometrium
cancer, 1606
systemic lupus erythematosus, 1606
tamoxifen, 1606
Endothelium
adhesion molecules, 2126
8-methoxypsoralen, 2126
psoralen and ultraviolet A therapy, 2126
rheumatoid arthritis, 2126
synovitis, 2126
Enzyme linked immunosorbent assay
annexins, 97
anticardiolipin antibodies, 55
antiphospholipid antibody syndrome, 55
autoimmunity diseases, 97
diagnosis, 684
Escherichia coli, 684
genetic factors, 1025
Lyme disease, 684
major histocompatibility complex, 1025
prevalence studies, 55
rheumatoid arthritis, 1025
soluble HLA class I, 1025
Western blot, 758
Eosinophilia
folinic acid, 1373
methotrexate, 1373
pancytopenia, 1373
rheumatoid arthritis, 1373
Eosinophilia-myalgia syndrome
Eosinophilia-myalgia syndrome workshop, 161
L-tryptophan, 161
myoclonus, 157
myokymia, 157
neurologic involvement, 157
treatment, 161
tremor, 157
Eosinophilia-myalgia syndrome workshop
eosinophilia-myalgia syndrome, 161
L-tryptophan, 161
treatment, 161
Eosinophilic fasciitis
aldolase, 563
disease activity, 563
fasciectomy, 1967
fingers, 356
gangrene, 356
hypergammaglobulinemia, 1967
methotrexate, 1967
morphea, 1967
vasculitis, 356
Epidemiology
aged, 2291
aging, 1934
American College of Rheumatology criteria, S43–44
ankylosing spondylitis, 1607
Australia, 1934
Blacks, 1663
Borrelia burgdorferi, 689, 695
Canada, 722
Canadian Rheumatology Association Meeting, 1600 (ab), 1604 (ab)
Caucasians, 1663
China, 795
Chingford Study, 1118, 1509
dermatomyositis, 668
disability, 1934, S43–19
Europe, 1934
fibromyalgia, 722
French Canadians, 1604 (ab)
hand osteoarthritis, 1509
health services, 733
health services utilization, S43–19
hip osteoarthritis, 2291
HLA, 1884
idiopathic inflammatory myositis, 1604 (ab)
juvenile rheumatoid arthritis, 1600 (ab)
Kingston, Canada, 1600 (ab)
knee osteoarthritis, 1118
Lyme disease, 689, 695
mortality, 1600 (ab), 1663
musculoskeletal disorders, 733, 1934
North America, 1934
North American Indians, 1600 (ab)
Ontario Health Survey, 733
osteoarthritis, S43–44
polymyositis, 668
radiography, 2291
reactive arthritis, 252
Reiter's syndrome, 252
rheumatic diseases, 795
rheumatoid arthritis, 1600 (ab)
Russia, 689
sex ratio, 1607
spine, 1934
spondyloarthropathies, 1884
Sweden, 695
systemic lupus erythematosus, 1663
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–19, S43–44
treatment, 689
Epidural lipomatosis
cauda equina, 1771
obesity, 1771
Epstein-Barr virus
lymphoproliferative disorders, 1174
methotrexate, 1174
rheumatoid arthritis, 1174
Erosive osteoarthritis
hydroxychloroquine, 1527
inflammation, 1527
Erythrocyte sedimentation rate
disease progression, 675
inflammation, 675
osteoarthritis clinical trials, 788
predictive factors, 675
psoriatic arthritis, 675
rheumatoid arthritis clinical trials, 788
Erythropoietin
anemia, 2166
aplasia, 2166
systemic lupus erythematosus, 2166
Escherichia coli
Bermuda, 1825
diagnosis, 684
disease activity, 1825
enzyme linked immunosorbent assay, 684
knee, 1776
Lyme disease, 684
Proteus mirabilis, 1825
rheumatoid arthritis, 1825
septic arthritis, 1776
United Kingdom, 1825
Estradiol
arthritis, 421
osteoarthritis, 421
rheumatoid arthritis, 421
Estrogen receptors
arthritis, 421
osteoarthritis, 421
rheumatoid arthritis, 421
Etidronate
menopause, 2183
osteomalacia, 2183
osteoporosis, 2183
Etiology
exercise, S43–3
fibromyalgia, 590
medicolegal factors, 590
osteoarthritis, S43–3
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–3
Europe
aging, 1934
Australia, 1934
disability, 1934
epidemiology, 1934
musculoskeletal disorders, 1934
North America, 1934
spine, 1934
European Quality of Life Measure
OMERACT II Conference, 1197
Quality of Well Being Questionnaire, 1197
rheumatoid arthritis clinical trials, 1197
utility measures, 1197

European Spondylarthropathy Study Group
Amor criteria, 1499
Italy, 1499
prevalence studies, 1499
psoriatic arthritis, 1499
European Spondylarthropathy Study Group criteria
Amor criteria, 246
spondyloarthropathies, 246
Evans' syndrome
danazol, 1867
hemolytic anemia, 1867
systemic lupus erythematosus, 1867
thrombocytopenia, 1867
Exercise
anaerobic threshold, 1483
Canadian Rheumatology Association Meeting, 1604 (ab)
catecholamines, 143
dyspnea, 455
etiology, S43–3
fibromyalgia, 143, 1536, 1604 (ab)
muscle, 1483
muscle fatigue, 143, 1536
nuclear magnetic resonance spectroscopy, 1536
osteoarthritis, S43–3
oxygen, 1483
pain, 1604 (ab)
pulmonary function, 455
sleep disorders, 1604 (ab)
systemic lupus erythematosus, 455, 1483
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–3
Exertion
bone mineral density, 2148
calcium, 2148
osteoporosis, 2148
vitamin D, 2148
Extracellular matrix
alpha V integrin, 16
fibronectins, 817
osteoarthritis, 16
protease inhibitors, 817
rheumatoid arthritis, 16, 817
synoviocytes, 817
synovium, 16
Extremities
gangrene, 363
giant cell arteritis, 363
stroke, 363
temporal arteritis, 363
upper, 363

F

Facial artery
giant cell arteritis, 360
jaw claudication, 360
Facial hemiatrophy
antinuclear antibodies, 73
autoimmunity, 73
linear scleroderma, 73
Factor V mutation
primary antiphospholipid antibody syndrome, 1215
protein C, 1215
Family physicians
analgesic therapy, 1762
Canadian Rheumatology Association Meeting, 1603 (ab)
continuing medical education, 1603 (ab), 1762
diagnosis, 1532
health insurance, 2319
health services accessibility, 2319
iliac crest pain syndrome, 1532
low back pain, 1532
nonsteroidal antiinflammatory drugs, 1762
observer variation, 1532
osteoarthritis, 1762
rheumatoid arthritis, 2319
rheumatology, 1603 (ab)
rheumatology and rheumatologists, 2319
Fasciectomy
eosinophilic fasciitis, 1967
hypergammaglobulinemia, 1967
methotrexate, 1967
morphea, 1967
partial, 1967
Fatigue
disease activity, 639
functional status, 639
rheumatoid arthritis, 639
Fatty acids
antioxidants, 103
psoriatic arthritis, 103
red blood cells, 103
selenium, 103
Fc gamma receptor
anti-Fc gamma receptor autoantibodies, 2241
polymorphonuclear cells, 2241
Sjögren's syndrome, 2241
Felty's syndrome
agranulocytosis, 1803
granulocyte colony stimulating factor, 174, 1179, 1803
neutropenia, 174
rheumatoid arthritis, 174, 1179
sepsis, 1803
vasculitis, 1179
Fibrin
anti-tissue type plasminogen activator antibodies, 1688
systemic sclerosis, 1688
tissue type plasminogen activator, 1688
Fibromyalgia
arthritis, 573
behavior therapy, 717
biopsy, 133
Canada, 722
Canadian Rheumatology Association Meeting, 1603 (ab), 1604 (ab)
carpal tunnel syndrome, 501
catecholamines, 143
clinical trials, 953, 1304
dental amalgam, 2194
depression, 137
diagnosis, 1603 (ab)
disability, 270, 372, 2313
disease severity, 2313
dolorimetry, 944
early, 143
epidemiology, 722
etiology, 590
exercise, 143, 1536, 1604 (ab)
functional status, 1304, 1552
growth hormone, 1138
Health Assessment Questionnaire, 886
Health Assessment Questionnaire for Spondyloarthropathy, 886
health status indicators, 886
hypermobility, 1603 (ab)
insulin like growth factor-I, 1138
medicolegal factors, 590
mental processes, 137
mercury, 2194
muscle fatigue, 1536
musculoskeletal disorders, 573
myofascial pain, 944
nuclear magnetic resonance spectroscopy, 1536
outcome assessment, 525, 1304, 1536
pain, 151, 270, 944, 1552, 1604 (ab), 2313
palpation, 944
population studies, 151
predictive factors, 2313
Problem Elicitation Technique, 1304
psoriatic arthritis, 886
psychological adaptation, 1552
quality of life, 270
rating scale, 1536
reproducibility of results, 1536
rheumatoid arthritis, 270
rheumatology and rheumatologists, 573
salivary glands, 133
sex, 151
Sjögren's syndrome, 133
sleep, 1138
sleep disorders, 1604 (ab)
standard gamble, 1536
tender points, 151, 944
tenderness, 525
trauma, 372
treatment, 713
Fibromyalgia clinical trials
adenosine triphosphate, 953
biostatistics, 2307
disease activity, 2307
magnesium, 953
malic acid, 953
McGill Pain Questionnaire, 2307
Myalgic Score, 2307
outcome measures, 2307
Super Malic®, 953
Tender Point Count, 2307
Fibronectins
chondroitin sulfate, S43–158
extracellular matrix, 817
hyaluronic acid, S43–158
osteoarthritis, S43–158
protease inhibitors, 817
proteoglycans, S43–158

rheumatoid arthritis, 817
synoviocytes, 817
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–158
Fingers
anorexia nervosa, 544
apatite crystals, 2007
calcium pyrophosphate dihydrate crystal deposition disease, 2007
clubbing, 2346
denervation, 1211
distal interphalangeal joint, 1211
eosinophilic fasciitis, 356
gangrene, 356
hypertrophic osteoarthropathy, 2346
osteoarthritis, 2007
osteonecrosis, 544
pachydermodactyly, 2374
peripheral interphalangeal joints, 2374
psoriatic arthritis, 1211
swelling, 2374
Takayasu's arteritis, 2346
vascular insufficiency, 544
vasculitis, 356
Fishes
Mycobacterium marinum, 1607
septic arthritis, 1607
Flow cytometry
interleukin 1 alpha, 600
interleukin 1 beta, 600
mononuclear cells, 600
rheumatoid arthritis, 600
Flurbiprofen
adjuvant arthritis, 1726
metalloproteinase, 1726
tenidap, 1726
tetracycline, 1726
Focal myositis
polymyositis, 188
Folinic acid
eosinophilia, 1373
pancytopenia, 1373
rheumatoid arthritis, 1373
Follicles
rheumatoid arthritis, 394
synovium, 394
T cell receptor V beta, 394
Food
biological availability, 1570
juvenile rheumatoid arthritis, 1570
methotrexate, 630, 1570
pharmacokinetics, 630
rheumatoid arthritis, 630
Fractures
aged, 921
bone mineral density, 921
osteoarthritis, 921
osteoporosis, 921
France
HLA-DRB1, 607
rheumatoid arthritis, 607
southern, 607
French Canadians
Canadian Rheumatology Association Meeting, 1604 (ab)
epidemiology, 1604 (ab)
idiopathic inflammatory myositis, 1604 (ab)
Functional Index
Arthritis Impact Measurement Scales, 1603 (ab)
Canadian Rheumatology Association Meeting, 1603 (ab)
disability, 1603 (ab)
Health Assessment Questionnaire, 1603 (ab)
outcome assessment, 1603 (ab)
scleroderma, 1603 (ab)
Functional status
ankylosing spondylitis, 1304
balneology, 1315
Canadian Rheumatology Association Meeting, 1602 (ab)
disability, 1037, 1834
disease activity, 639, 1602 (ab)
disease progression, 1037
electrical stimulation, 1757
fatigue, 639
fibromyalgia, 1304, 1552
Groningen Activity Restriction Scale, 1834
Health Assessment Questionnaire, 1834
knee arthropathy, 482
knee osteoarthritis, 1757
low back pain, 1315
osteoarthritis, 482
outcome assessment, 482, 1304, 1602 (ab)
pain, 727, 1552, 1757
Problem Elicitation Technique, 1304
prognosis, 1037
psychological adaptation, 1552
rheumatoid arthritis, 432, 482, 639, 1037, 1834
self-assessment, 432
sex, 1834
shoulder, 727
Shoulder Pain and Disability Index, 727
socioeconomic factors, 432
systemic lupus erythematosus, 1602 (ab)
Fund raising
The Arthritis Society, 1604 (ab)
Canadian Rheumatology Association Meeting, 1604 (ab)
rheumatoid arthritis, 1604 (ab)
systemic lupus erythematosus, 1604 (ab)

G

Gamma chain
gamma delta T cells, 812
mononuclear cells, 812
rheumatoid arthritis, 812
synovial fluid, 812
Gamma delta T cells
gamma chain, 812
mononuclear cells, 812
rheumatoid arthritis, 812
synovial fluid, 812
Gangliosides
articular cartilage, S43–133
osteoarthritis, S43–133
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–133
Gangrene
eosinophilic fasciitis, 356
extremities, 363
fingers, 356
giant cell arteritis, 363
stroke, 363
temporal arteritis, 363
vasculitis, 356
Gastroenteritis
cryptosporidiosis, 1962
Cryptosporidium, 1962
pediatric Reiter's syndrome, 1962
Gastroenteropathy
Canadian Rheumatology Association Meeting, 1603 (ab)
half-life, 1603 (ab)
indomethacin, 444
inflammatory arthritis, 444
juvenile rheumatoid arthritis, 1149
leukocyte adhesion, 444
nonsteroidal antiinflammatory drugs, 1149, 1603 (ab)
pharmacokinetics, 1603 (ab)
rheumatoid arthritis, 444
tenidap, 444
Gastrointestinal bleeding
nonsteroidal antiinflammatory drugs, 1471
rheumatoid arthritis, 1471
survival, 1471
Gastrointestinal involvement
disease modifying antirheumatic drugs, 2200, 2214
glucocorticoid therapy, 2214
gold, 2214
mortality, 2200, 2214
nonsteroidal antiinflammatory drugs, 2200, 2214
rheumatoid arthritis, 2200, 2214
Gastropathy
nonsteroidal antiinflammatory drugs, 1471
rheumatoid arthritis, 1471
Gastroprotective agents
nonsteroidal antiinflammatory drugs, S43–26
prescribing practices, S43–26
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–26
ulcer, S43–26
Gelatinase-B
matrix metalloproteinases, 385
rheumatoid arthritis, 385
stromelysin-1, 385
urokinase-type plasminogen activator, 385
Gene mutation
COL2A1, 255
collagen type II, 255
osteoarthritis, 255
osteochondrodysplasia, 255
Gene therapy
collagen, S43–140
cytokines, 1220
inflammation, 1220
osteoarthritis, S43–140
rheumatoid arthritis, 1220
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–140

transgenic mice, S43–140
Genetic factors
age, 794
arthropathy, 2349
camptodactyly, 2349
Caucasians, 1852, 1862
C4AQ0, 1862
disease onset, 794
enzyme linked immunosorbent assay, 1025
haplotypes, 1852
HLA, 1852
major histocompatibility complex, 1025, 1852
pericarditis, 2349
phenotypes, 1862
pleuritis, 2349
rheumatoid arthritis, 1025, 2203
rheumatoid factor, 2203
serositis, 2349
sex, 794
soluble HLA class I, 1025
spondyloarthropathies, 794
systemic lupus erythematosus, 1852, 1862
twins, 2203
Genotypes
anticardiolipin antibodies, 227
C4, 227
Giant cell arteritis
anticardiolipin antibodies, 1694
biopsy, 93
Churg-Strauss syndrome, 2177
extremities, 363
facial artery, 360
gangrene, 363
granulomatous vasculitis, 566
jaw claudication, 360
lung cancer, 367
neoplasms, 566, 2177
polymyalgia rheumatica, 1694
predictive factors, 93
prostate, 566
stroke, 363
temporal arteritis, 363, 367, 2177
temporal artery, 93
vasa vasorum vasculitis, 2177
Gigantism
breast, 1214
systemic lupus erythematosus, 1214
Glomerular mesangium
glomerulonephritis, 427
hematuria, 427
rheumatoid arthritis, 427
Glomerulonephritis
glomerular mesangium, 427
hematuria, 427
rheumatoid arthritis, 427
Glucocorticoid therapy
bone mineral density, 2238
calcitonin, 2238
disease modifying antirheumatic drugs, 2214
gastrointestinal involvement, 2214
gold, 2214
mortality, 2214
nonsteroidal antiinflammatory drugs, 2214
osteoporosis, 2238
PDN-21, 2238
rheumatoid arthritis, 2214
systemic lupus erythematosus, 2238
Gly 26
HLA, 1872
immunogenetics, 1872
scleroderma, 1872
silicone implants, 1872
Tyr 26, 1872
Gold
Canadian Rheumatology Association Meeting, 1601 (ab)
colitis, 572
disease modifying antirheumatic drugs, 2214
drug dose-response relationship, 1657
gastrointestinal involvement, 2214
glucocorticoid therapy, 2214
intramuscular, 1600 (ab)
mortality, 2214
nonsteroidal antiinflammatory drugs, 2214
rheumatoid arthritis, 572, 1600 (ab), 1657, 2214
rheumatoid arthritis clinical trials, 1601 (ab)
self-injections, 1601 (ab)
toxicity, 1600 (ab)
treatment, 1657
Gold sodium thiomalate
anaphylactic reaction, 190
rheumatoid arthritis, 190
Gout
hyperuricemia, 494
nontophaceous interval, 1618
renal disease, 494
Gouty arthritis
calcium pyrophosphate dihydrate crystals, 1604 (ab)
Canada, 908
Canadian Rheumatology Association Meeting, 1604 (ab)
cervical spine, 1604 (ab)
Charcot's joint, 1604 (ab)
cost-benefit analysis, 908
myelopathy, 1604 (ab)
recurrent, 908
urate lowering drugs, 908
Graft versus host disease
anti-alpha beta T cell receptor monoclonal antibody, 2259
anti-DNA antibodies, 2259
lupus nephritis, 2259
murine studies, 2259
Grafting
aneurysm, 183
infection, 183
osteoarthropathy, 183
Granulocyte colony stimulating factor
agranulocytosis, 1803
Felty's syndrome, 174, 1179, 1803
neutropenia, 174
rheumatoid arthritis, 174, 1179
sepsis, 1803
vasculitis, 1179
Granulomatous vasculitis
giant cell arteritis, 566
neoplasms, 566
prostate, 566
Greece
antikeratin antibodies, 2046
HLA-DR1, 2046
rheumatoid arthritis, 2046
Grip Function Test
grip strength, 1559
reproducibility of results, 1559
rheumatoid arthritis, 1559
Grip strength
Grip Function Test, 1559
reproducibility of results, 1559
rheumatoid arthritis, 1559
Groningen Activity Restriction Scale
disability, 1834
functional status, 1834
Health Assessment Questionnaire, 1834
rheumatoid arthritis, 1834
sex, 1834
Growth factors
fibroblast growth factor, S43–129
insulin-like growth factor, S43–129
macrophages, 1624
osteoarthritis, S43–115
polymerase chain reaction, 1624
rheumatoid arthritis, 1624
soluble tumor necrosis factor receptors, S43–115
synovial fibroblasts, S43–115
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–115
transforming growth factor beta, S43–129
vascular endothelial, 1624
Growth hormone
fibromyalgia, 1138
insulin like growth factor-I, 1138
sleep, 1138
Gut
ankylosing spondylitis, 2266, 2273, 2279
inflammation, 2266, 2273, 2279
inflammatory bowel disease, 2266, 2273, 2279
prognosis, 2266, 2273, 2279
spondyloarthropathies, 2266, 2273, 2279
Gut inflammation
psoriatic arthritis, 680
spondyloarthropathies, 680
Gynecomastia
methotrexate, 796, 2189
rheumatoid arthritis, 796, 2189

H

Hairy cell leukemia
polymyositis, 1384
scleroderma, 1384
Half-life
Canadian Rheumatology Association Meeting, 1603 (ab)
gastroenteropathy, 1603 (ab)
nonsteroidal antiinflammatory drugs, 1603 (ab)
pharmacokinetics, 1603 (ab)
Hand osteoarthritis
bone and bones, 2132
Chingford Study, 1509

epidemiology, 1509
evolution, 2132
mechanical stress, 2132
rhesus macaque, 2132
Haplotypes
anticardiolipin antibodies, 227
Caucasians, 1852
genetic factors, 1852
HLA, 227, 1852
major histocompatibility complex, 1852
systemic lupus erythematosus, 1852
Health Assessment Questionnaire
Arthritis Impact Measurement Scales, 1603 (ab)
Canadian Rheumatology Association Meeting, 1601 (ab), 1603 (ab)
childhood, 326
disability, 1241, 1601 (ab), 1603 (ab), 1834
fibromyalgia, 886
Functional Index, 1603 (ab)
functional status, 1834
Groningen Activity Restriction Scale, 1834
Health Assessment Questionnaire for Spondyloarthropathy, 886
health status indicators, 886
outcome assessment, 1241, 1603 (ab)
psoriatic arthritis, 886, 1601 (ab)
reference standards, 1241
rheumatoid arthritis, 1241, 1601 (ab), 1834
scleroderma, 1603 (ab)
sex, 1834
ulcer, 1601 (ab)
Health Assessment Questionnaire for Spondyloarthropathy
fibromyalgia, 886
Health Assessment Questionnaire, 886
health status indicators, 886
psoriatic arthritis, 886
Health care costs
disease activity, 189
disease severity, 189
osteoarthritis, S43–23
systemic lupus erythematosus, 189
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–23
treatment, 189
Health insurance
family physicians, 2319
health services accessibility, 2319
rheumatoid arthritis, 2319
rheumatology and rheumatologists, 2319
Health policy
health status indicators, 1188
OMERACT II Conference, 1188
rheumatoid arthritis clinical trials, 1188
Health services
epidemiology, 733
musculoskeletal disorders, 733
Ontario Health Survey, 733
Health services accessibility
family physicians, 2319
health insurance, 2319
knee arthroplasty, 1209
knee osteoarthritis, 1209
rheumatoid arthritis, 2319
rheumatology and rheumatologists, 2319
Health services utilization
disability, S43–19
epidemiology, S43–19
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–19
Health status indicators
fibromyalgia, 886
Health Assessment Questionnaire, 886
Health Assessment Questionnaire for Spondyloarthropathy, 886
health policy, 1188
OMERACT II Conference, 1185, 1188, 1203
osteoarthritis clinical trials, 1203
psoriatic arthritis, 886
quality of life, 1185
rheumatoid arthritis clinical trials, 1185, 1188, 1203
Heart valve replacement
antiphospholipid antibody syndrome, 802
Hemarthrosis
knee, 552
shoulder, 574
synovium, 552
vascular abnormalities, 552
vitamin C, 574
Hematuria
glomerular mesangium, 427
glomerulonephritis, 427
rheumatoid arthritis, 427
Hemolytic anemia
danazol, 1867
Evans' syndrome, 1867
systemic lupus erythematosus, 1867
thrombocytopenia, 1867
Hepatitis B virus
angiography, 876
arteriography, 876
microaneurysm, 876
polyarteritis nodosa, 876
Hepatitis C virus
cold, 1806
complement activation, 1806
vasculopathy, 1806
Herpes simplex II
systemic lupus erythematosus, 799
Heterotopic ossification
ankylosing spondylitis, 1704
fibrodysplasia ossificans progressiva, 976
total hip arthroplasty, 1704
High molecular weight anionic glycoconjugate
articular cartilage, 1605 (ab)
Canadian Rheumatology Association Meeting, 1605 (ab)
osteoarthritis, 1605 (ab)
transforming growth factor-beta, 1605 (ab)
Hip
HLA-B27, 165
pediatric ankylosing spondylitis, 165
Hip osteoarthritis
aged, 2291
epidemiology, 2291
radiography, 2291
Hispanics
arthroplasty, 1844
azathioprine, 1844
infection, 1844
methotrexate, 1844
predictive factors, 1844
rheumatoid arthritis, 1844
HLA
age, 1032
anti-U1-RNP antibodies, 586
Caucasians, 1852
congenital complete heart block, 541
disease activity, 2034
disease severity, 1032, 2027
epidemiology, 1884
genetic factors, 1852
Gly 26, 1872
haplotypes, 1852
HLA-DRB1, 2027
immunogenetics, 85, 586, 1872
juvenile rheumatoid arthritis, 1356
major histocompatibility complex, 85, 1852
mixed connective tissue disease, 586
neonatal lupus, 541
nucleolus organizer region, 67
outcome assessment, 541
primary antiphospholipid antibody syndrome, 1589
rheumatoid arthritis, 1032, 2027, 2034
rheumatoid factor, 2027
risk factors, 1032
scleroderma, 67, 85, 1872
sex, 1032
silicone implants, 1872
spondyloarthropathies, 1884
systemic lupus erythematosus, 1589, 1852
systemic sclerosis, 67
T cell receptor, 1356
Taiwan, 2034
Tyr 26, 1872
HLA haplotypes
anticardiolipin antibodies, 227
C4 genotypes, 227
HLA-B27
aged, 899
ankylosing spondylitis, 375
anterior uveitis, 1602 (ab)
aortic regurgitation, 332
Canadian Rheumatology Association Meeting, 1602 (ab)
hip, 165
pediatric ankylosing spondylitis, 165
pediatric spondyloarthropathy, 332
pitting edema, 899
RS$_3$PE syndrome, 375
seronegative spondyloarthropathies, 899
spondyloarthropathies, 1602 (ab)
HLA-DR
rheumatoid arthritis, 1450
Taiwan, 1450
HLA-DRB1
disease severity, 2027
France, 607
HLA, 2027
rheumatoid arthritis, 607, 2027

rheumatoid factor, 2027
HLA-DR1
antikeratin antibodies, 2046
Greece, 2046
rheumatoid arthritis, 2046
HLA-DR4 alleles
Canadian Rheumatology Association Meeting, 1601 (ab)
psoriatic arthritis, 1601 (ab)
spondyloarthropathies, 1601 (ab)
Hormones
adrenocorticotropic hormone, 1829
beta-endorphin, 1829
pituitary, 1829
HTLV-1
interleukin 6, 2049
nuclear factor-kappa B, 2049
rheumatoid arthritis, 2049
tax gene, 2049
Human immunodeficiency virus
avascular necrosis of bone, 347
CD4, 347
immunodepression, 2191
methotrexate, 2191
psoriatic arthritis, 2191
systemic lupus erythematosus, 347
T cells, 347
Human upstream binding factor
nucleolus organizer region-90 antigen, 521
pediatric rheumatic diseases, 521
Raynaud's phenomenon, 521
Hyaluronan
adverse effects, 1311
hylan, 1311
knee osteoarthritis, 1311
Hyaluronate
radical scavenger, 400
rheumatoid arthritis, 400
synovial membrane, 400
Hyaluronic acid
articular cartilage, S43–155
canine studies, 262, 1732
chondroitin sulfate, S43–158
fibronectins, S43–158
keratan sulfate, S43–68, S43–155
knee osteoarthritis, 1732
osteoarthritis, 262, S43–68, S43–155, S43–158
ovine studies, S43–155
proteoglycans, S43–158
synovial fluid, 1732, S43–68
synovium, 262
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–68, S43–155, S43–158
Hybridization
insulin-like growth factor, 275
osteoarthritis, 275
rheumatoid arthritis, 275
in situ, 275
Hydrarthrosis
stress fractures, 1804
tibia, 1804
Hydroxychloroquine
anti-La(SSB) antibodies, 868
anti-Ro(SSA) antibodies, 868
Canadian Rheumatology Association Meeting, 1602 (ab)
chloroquine, 34
disease activity, 1602 (ab)
erosive osteoarthritis, 1527
hypergammaglobulinemic purpura, 868
indomethacin, 868
inflammation, 1527
prednisone, 868
renal function, 34
rheumatoid arthritis, 34
systemic lupus erythematosus, 868
systemic lupus erythematosus clinical trials, 1602 (ab)
Hydroxyurea
rheumatoid arthritis clinical trials, 1646
Hylan
adverse effects, 1311
hyaluronan, 1311
knee osteoarthritis, 1311
Hypercalcemia
hyperparathyroidism, 561
Milwaukee shoulder, 561
Hypergammaglobulinemia
eosinophilic fasciitis, 1967
fasciectomy, 1967
methotrexate, 1967
morphea, 1967
Hypergammaglobulinemic purpura
anti-La(SSB) antibodies, 868
anti-Ro(SSA) antibodies, 868
hydroxychloroquine, 868
indomethacin, 868
prednisone, 868
systemic lupus erythematosus, 868
Hyperlipidemia
cholesterol, 450
diet therapy, 450
systemic lupus erythematosus, 450
Hypermobility
Canadian Rheumatology Association Meeting, 1603 (ab)
diagnosis, 1603 (ab)
fibromyalgia, 1603 (ab)
Hyperparathyroidism
hypercalcemia, 561
Milwaukee shoulder, 561
Hypertension
anti-RNA polymerase III antibodies, 557
renal failure, 557
scleroderma, 557
systemic sclerosis, 557
Hypertrophic osteoarthropathy
aortic graft, 2008
clubbing, 2346
fingers, 2346
infection, 2008
Takayasu's arteritis, 2346
Hyperuricemia
colchicine, 1618, 1621
gout, 494
nontophaceous interval gout, 1618, 1621
renal disease, 494
treatment, 1618, 1621
Hypocalcemia
hypoparathyroidism, 2156
pediatric systemic lupus erythematosus, 2156
seizures, 2156
Hypocomplementemia
anti-Clq antibodies, 1669
antiendothelial cell antibodies, 1669
antineutrophil cytoplasmic antibodies, 1669
systemic lupus erythematosus, 1669
urticarial vasculitis, 1669
Hypokalemia
renal acidosis, 2366
renal involvement, 2366
Sjögren's syndrome, 2366
Hypoparathyroidism
hypocalcemia, 2156
pediatric systemic lupus erythematosus, 2156
seizures, 2156

I

Idiopathic inflammatory myositis
Canadian Rheumatology Association Meeting, 1604 (ab)
epidemiology, 1604 (ab)
French Canadians, 1604 (ab)
IgG
anti-beta$_2$ glycoprotein I antibodies, 2233
anticardiolipin antibodies, 2233
antiphospholipid antibodies, 2006
antiphospholipid antibody syndrome, 2006, 2233
murine studies, 2006
systemic lupus erythematosus, 2233
T cells, 2006
Iliac crest pain syndrome
diagnosis, 1532
family physicians, 1532
low back pain, 1532
observer variation, 1532
Iliopsoas
bursitis, 1971
bursography, 1971
pain, 1971
Immune complex arthritis
cartilage, 2250
interleukin 1, 2250
murine studies, 2250
proteoglycan degradation, 2250
proteoglycan synthesis, 2250
tumor necrosis factor-alpha, 2250
Immune response
antibody formation, 1947
disease outbreaks, 1947
lipopolysaccharide, 1947
reactive arthritis, 1947
Salmonella, 1947
Immunoconjugates
CD5, 207
lymphocytes, 207
rheumatoid arthritis, 207
Immunodepression
human immunodeficiency virus, 2191
methotrexate, 2191
psoriatic arthritis, 2191

Immunogenetics
Abe Shore Memorial Lecture, 289
anti-U1-RNP antibodies, 586
Gly 26, 1872
HLA, 85, 586, 1872
major histocompatibility complex, 85
mixed connective tissue disease, 586
pediatric rheumatic diseases, 289
scleroderma, 85, 1872
silicone implants, 1872
Tyr 26, 1872
Immunoglobulin G
aptamers, S43–62
osteoarthritis, S43–62
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–62
Immunosuppressive therapy
corticosteroids, 2193
infection, 2193
neoplasms, 1478
Salmonella, 2193
systemic lupus erythematosus, 1478, 2193
Inclusion body myositis
chlorambucil, 576
Indium-III
disease activity, 478
leukocytes, 478
Takayasu's arteritis, 478
Indomethacin
aged, 713
anti-La(SSB) antibodies, 868
anti-Ro(SSA) antibodies, 868
diclofenac, 2013
disease progression, 2013
gastroenteropathy, 444
hydroxychloroquine, 868
hypergammaglobulinemic purpura, 868
inflammatory arthritis, 444
knee osteoarthritis, 1941
leukocyte adhesion, 444
misoprostol, 713
nonsteroidal antiinflammatory drugs, 2013
osteoarthritis, 2013
prednisone, 868
radiographic progression, 1941
renal dysfunction, 713
rheumatic diseases, 713
rheumatoid arthritis, 444
systemic lupus erythematosus, 868
tenidap, 444
tiaprofenic acid, 1941
Infection
aneurysm, 183
aortic graft, 2008
arthroplasty, 1844
azathioprine, 1844
corticosteroids, 2193
extraintestinal, 2193
grafting, 183
hepatitis B virus, 876
herpes simplex II, 799
herpes zoster, 1254
Hispanics, 1844
human immunodeficiency virus, 347, 351
hypertrophic osteoarthropathy, 2008
immunosuppressive therapy, 2193
Listeria monocytogenes, 786
methotrexate, 1844
osteoarthropathy, 183
predictive factors, 1844
rheumatoid arthritis, 1844
Salmonella, 575, 2193
Streptococcus pyogenes, 529
systemic lupus erythematosus, 2193
urinary tract, 793
Inflammation
ankylosing spondylitis, 2266, 2273, 2279
antigen induced arthritis, 1605 (ab)
Canadian Rheumatology Association Meeting, 1605 (ab)
capsaicin, 1447
cartilage, 1922
C-reactive protein, 1224
disease progression, 675
erosive osteoarthritis, 1527
erythrocyte sedimentation rate, 675
gut, 2266, 2273, 2279
hydroxychloroquine, 1527
inflammatory bowel disease, 2266, 2273, 2279
interleukin 6, 1224
lipopolysaccharide binding protein, 1224
matrix metalloproteinase-3, 2004
neuropeptides, 1447
nitric oxide, 1922
predictive factors, 675
prognosis, 2266, 2273, 2279
psoriatic arthritis, 675
rabbit studies, 1605 (ab)
rheumatoid arthritis, 850, 1224, 1447, 1461, 1631, 1922, 2004
SERP-1 protein, 1605 (ab)
spondyloarthropathies, 2266, 2273, 2279
stromelysin, 2004
synovial fluid, 1224
synovitis, 1461
synovium, 1922
^{99m}technetium labelled immunoglobulin G, 850
^{99m}technetium labelled polyclonal human immunoglobulin G scintigraphy, 1461
triamcinolone hexacetonide, 1631
Inflammatory arthritis
ambulatory care, 1005
chronic, 1005, 1141
disease activity, 850
gastroenteropathy, 444
indomethacin, 444
leukocyte adhesion, 444
outpatient care, 1141
patient care team, 1005
soluble tumor necrosis factor receptors, 382
team management, 1141
^{99m}technetium labelled immunoglobulin G, 850
tenidap, 444
Inflammatory bowel disease
ankylosing spondylitis, 2266, 2273, 2279
gut, 2266, 2273, 2279
inflammation, 2266, 2273, 2279
prognosis, 2266, 2273, 2279
spondyloarthropathies, 2266, 2273, 2279
Inflammatory myopathy
anti-Jo-1 antibodies, 762
pediatric, 762
pulmonary fibrosis, 762
Influenza
autoimmunity, 1802
rheumatoid arthritis, 1802
vaccination, 1802
Insulin-like growth factor
hybridization, 275
osteoarthritis, 275
rheumatoid arthritis, 275
Insulin-like growth factor-I
articular cartilage, 1599 (ab)
bone Gla protein, 1060
Canadian Rheumatology Association Meeting, 1599 (ab)
cyclosporin A, 1060
fibromyalgia, 1138
growth hormone, 1138
osteoarthritis, 1599 (ab)
rheumatoid arthritis, 1060
sleep, 1138
Interferon-alpha
adverse effects, 1183
Behçet's disease, 1183
leukemia, 1183
Interferon-gamma
polymyositis, 1698
tumor necrosis factor-alpha, 1698
Interleukin 1
articular cartilage, 1130
cartilage, 2250
chondrocytes, 1130, S43–104
immune complex arthritis, 2250
interleukin 6, 1130
metalloproteases, S43–123
murine studies, 2250
nonsteroidal antiinflammatory drugs, 1130
osteoarthritis, 1130, S43–104, S43–123
prostaglandins, S43–123
proteoglycan degradation, 2250
proteoglycan synthesis, 2250
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–104, S43–123
tissue inhibitor of metalloproteases, S43–123
transforming growth factor-beta, S43–104
tumor necrosis factor-alpha, 2250
Interleukin 1 alpha
flow cytometry, 600
interleukin 1 beta, 600
mononuclear cells, 600
rheumatoid arthritis, 600
Interleukin 1 beta
cyclosporine, 654
disease activity, 654
flow cytometry, 600
interleukin 1 alpha, 600
mononuclear cells, 600
rheumatoid arthritis, 600
scleroderma, 654
soluble interleukin 2 receptor, 654

Interleukin 1 receptor antagonist
cartilage degradation, 1338
osteoarthritis, 1338
proteoglycans, 1338
rabbit studies, 1338
rheumatoid arthritis, 1338
Interleukin 2
Canadian Rheumatology Association Meeting, 1602 (ab)
lymphokine activated killer cells, 2188
myositis, 2188
neoplasms, 2188
NZB mice, 1602 (ab)
osteoarthritis, 406
reactive arthritis, 406
rheumatoid arthritis, 406
Th1 cells, 1602 (ab)
Interleukin 2 receptor
autoimmunity, 1488
minor salivary glands, 1488
Sjögren's syndrome, 1488
Interleukin 3
antiphospholipid antibody syndrome, 1086
aspirin, 1086
leukotrienes, 1086
Interleukin 4
articular cartilage, 1740
bovine studies, 1740
interleukin 10, 2020
osteoarthritis, 1740
proteoglycans, 1740
rheumatoid arthritis, 2020
synovial cells, 2020
Interleukin 6
articular cartilage, 1130
chondrocytes, 1130
C-reactive protein, 1224
inflammation, 1224
interleukin 1, 1130
lipopolysaccharide binding protein, 1224
nonsteroidal antiinflammatory drugs, 1130
osteoarthritis, 1130
rheumatoid arthritis, 1224
synovial fluid, 1224
Interleukin 7
juvenile rheumatoid arthritis, 1581
Interleukin 8
Behçet's disease, 904
cytokines, 904
Interleukin 10
interleukin 4, 2020
rheumatoid arthritis, 2020
synovial cells, 2020
Interleukin 12
cytokines, 1674
lymphoma, 1674
Sjögren's syndrome, 1674
International League of Associations for Rheumatology
Disease modifying antirheumatic drugs, 201
osteoarthritis, 201
outcome measures, 201
slow acting antirheumatic drugs, 201
World Health Organization, 201
International League of Associations for Rheumatology Task Force for Classification Criteria
pediatric idiopathic arthritides, 1566
Interstitial lung disease
corticosteroid therapy, 881
cyclosporine, 2163
lymphadenopathy, 881
rheumatoid arthritis, 2163
sarcoidosis, 881
systemic sclerosis, 881
Intramuscular gold
Canadian Rheumatology Association Meeting, 1600 (ab)
rheumatoid arthritis, 1600 (ab)
toxicity, 1600 (ab)
Intravenous cyclophosphamide
methotrexate, 1000
pyoderma gangrenosum, 1000
rheumatoid arthritis, 1000
Intravenous gamma globulin
antiphospholipid antibody syndrome, 1068
murine studies, 1068
systemic lupus erythematosus, 1068
Iritis
arthritis, 2010
bacillus Calmette-Guérin, 2010
Ischemia
bowel, 2375
primary Raynaud's phenomenon, 374
primary Sjögren's syndrome, 2375
reperfusion, 374
systemic sclerosis, 374
vasculitis, 2375
Isometric contraction
disease activity, 473
muscle strength, 473
polymyositis/dermatomyositis, 473
Isotretinoin
Achilles tendinitis, 2009
suprapatellar tendinitis, 2009
Italy
Amor criteria, 1499
European Spondylarthropathy Study Group, 1499
prevalence studies, 1499
psoriatic arthritis, 1499

J

Jaw claudication
facial artery, 360
giant cell arteritis, 360
Joint count
juvenile rheumatoid arthritis, 2331
Larsen score, 1983
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1983
observer variation, 2331
outcome assessment, 1983
outcome measures, 2331
radiography, 1983
reproducibility of results, 2331
rheumatoid arthritis clinical trials, 1983
Sharp score, 1983
Joint damage
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1787
outcome assessment, 1787
radiography, 1787
rheumatoid arthritis clinical trials, 1787
Joint effusion
arthritis, 973
breast cancer, 973
metastasis, 973
Joint erosions
joint repair, 1048
mathematical models, 1800
outcome assessment, 1800
radiography, 1048, 1800
rheumatoid arthritis, 1048
rheumatoid arthritis clinical trials, 1800
Sharp's score, 1800
Joint prosthesis
Abe Shore Memorial Lecture, 289
pediatric rheumatic diseases, 289
Joint repair
joint erosions, 1048
radiography, 1048
rheumatoid arthritis, 1048
Joint space
knee, 937
knee osteoarthritis, 807
macroradiography, 807, 937
nonsteroidal antiinflammatory drugs, 937
osteoarthritis clinical trials, 937
Jones criteria
poststreptococcal reactive arthritis, 379
rheumatic fever, 379
Juvenile chronic arthritis
See also juvenile rheumatoid arthritis
disability, 308
disease activity, 295
muscle strength, 1159
muscle thickness, 1159
natural history, 295
outcome assessment, 308
prognostic factors, 295, 308
Juvenile dermatomyositis
Childhood Health Assessment Questionnaire, 326
disability, 326
disease activity, 193, 320
magnetic resonance imaging, 193
neuropathy, 1369
vasculitis, 1369
von Willebrand factor, 193, 320
Juvenile onset mixed connective tissue disease
functional status, 751
musculoskeletal disorders, 751
Juvenile rheumatoid arthritis
See also juvenile chronic arthritis
anterior compartment syndrome, 1377
antinuclear antibodies, 1577
biological availability, 1570
breast feeding, 1166

8-bromo cyclic adenosine monophosphate, 2114
Canada, 745
Canadian Rheumatology Association Meeting, 1600 (ab)
chondrocytes, 2114
classification criteria, 790
computed tomography, 1956
cytokines, 2114
disability, 308
disease activity, 295
epidemiology, 745, 1600 (ab)
food, 1570
gastroenteropathy, 1149
HLA, 1356
interleukin 7, 1581
joint count, 2331
Kingston, Canada, 1600 (ab)
methotrexate, 1009, 1570
Mycoplasma pneumoniae, 745
natural history, 295
nonsteroidal antiinflammatory drugs, 1009, 1149
observer variation, 2331
orthodontic assessment, 1956
outcome assessment, 308
outcome measures, 2331
phospholipase A_2, 2114
popliteal cysts, 1377
predictive factors, 168
prevalence studies, 790
prognostic factors, 295, 308
prolactin, 1577
radiography, 168
reproducibility of results, 2331
rheumatoid arthritis, 2114
synovial cysts, 1953
systemic onset, 168
T cell receptor, 1356
temporomandibular joint, 1956
ultrasonography, 1953

Juvenile spondyloarthropathies
atlantoaxial subluxation, 548
seronegative enthesopathy and arthropathy, 548

Juvenile temporal arteritis
diagnosis, 774

K

Keratan sulfate
articular cartilage, S43–155
hyaluronic acid, S43–68, S43–155
osteoarthritis, S43–68, S43–155
ovine studies, S43–155
synovial fluid, S43–68
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–68, S43–155

Keratinocytes
Canadian Rheumatology Association Meeting, 1599 (ab)
cytomegalovirus, 1599 (ab)
skin manifestations, 1599 (ab)
systemic lupus erythematosus, 1599 (ab)

Keratoconjunctivitis sicca
Canadian Rheumatology Association Meeting, 1604 (ab)
diagnosis, 1604 (ab)
sicca syndrome, 1604 (ab)
Sjögren's syndrome, 1604 (ab)
xerostomia, 1604 (ab)

Kidneys
anticardiolipin antibodies, 2007
cancer, 2007
thrombosis, 2007

Kingston, Canada
Canadian Rheumatology Association Meeting, 1600 (ab)
epidemiology, 1600 (ab)
juvenile rheumatoid arthritis, 1600 (ab)

Knee
Escherichia coli, 1776
hemarthrosis, 552
joint space, 937
macroradiography, 937
nonsteroidal antiinflammatory drugs, 937
osteoarthritis clinical trials, 937
septic arthritis, 1776
synovium, 552

Knee arthropathy
functional status, 482
osteoarthritis, 482
outcome assessment, 482

Knee arthroplasty
health services accessibility, 1209
knee osteoarthritis, 1209
rheumatoid arthritis, 482

Knee osteoarthritis
activities of daily living, 1124
adverse effects, 1311
ambulatory surgery, 1722
arthroscopy, 1722
articular cartilage, 1747
canine studies, 1732
Chingford Study, 1118
complications, 1722
electrical stimulation, 1757
epidemiology, 1118
functional status, 1757
health services accessibility, 1209
hyaluronan, 1311
hyaluronic acid, 1732
hylan, 1311
indomethacin, 1941
joint space, 807
knee arthroplasty, 1209
knee pain scale, 1124
macaca mulatta, 1747
macroradiography, 807
magnetic resonance imaging, 1747
obesity, 2006
pain, 1124, 1757
radiographic progression, 1941
synovial fluid, 1732
tiaprofenic acid, 1941

Knee pain scale
activities of daily living, 1124
knee osteoarthritis, 1124
pain, 1124

L

Lactate dehydrogenase
anticardiolipin antibodies, 649
blood platelets, 649
systemic lupus erythematosus, 649

Lactoferrin
antineutrophil cytoplasmic antibodies, 2304
myeloperoxidase, 2304
reactive arthritis, 2304

Larsen score
joint count, 1983
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1974, 1976, 1983
modified, 1976
outcome assessment, 1974, 1976, 1983
radiography, 1974, 1976, 1983
rheumatoid arthritis clinical trials, 1974, 1976, 1983
Sharp score, 1983

Larva migrans
arthralgia, 497
monoarthritis, 497
panniculitis, 497
vasculitis, 497
visceral, 497

Leukemia
Behçet's disease, 1183
hairy cell, 1384
interferon-alpha, 1183
methotrexate, 2356
myeloid, 2356
polymyositis, 1384
rheumatoid arthritis, 2356
scleroderma, 1384

Leukocyte adhesion
gastroenteropathy, 444
indomethacin, 444
inflammatory arthritis, 444
rheumatoid arthritis, 444
tenidap, 444

Leukocyte differentiation antigens
CD14, 1326
chondrocytes, 1326
osteoarthritis, 1326
rheumatoid arthritis, 1326

Leukocytes
disease activity, 478
indium-III, 478
Takayasu's arteritis, 478

Leukoencephalopathy
central nervous system, 335
methotrexate, 335
polymyositis, 777
rheumatoid arthritis, 335, 777

Leukotrienes
antiphospholipid antibody syndrome, 1086
aspirin, 1086
interleukin 3, 1086
5-lipoxygenase, 462
systemic lupus erythematosus, 462
zileuton, 462

Lichen planus
rheumatoid arthritis, 191
sulfasalazine, 191
Ligaments
ankylosing spondylitis, 2120
atlantoaxial subluxation, 2120
diffuse idiopathic skeletal hyperostosis, 1395
ossification, 1395, 2120
posterior longitudinal, 1395, 2120
retinol, 1395
retinol binding protein, 1395
Linear scleroderma
antinuclear antibodies, 73
autoimmunity, 73
facial hemiatrophy, 73
Lipopolysaccharide
antibody formation, 1947
disease outbreaks, 1947
immune response, 1947
reactive arthritis, 1947
Salmonella, 1947
Lipopolysaccharide binding protein
C-reactive protein, 1224
inflammation, 1224
interleukin 6, 1224
rheumatoid arthritis, 1224
synovial fluid, 1224
Lipoprotein(a)
cerebral infarction, 1210
myocardial infarction, 1210
systemic lupus erythematosus, 1210
5-Lipoxygenase
leukotrienes, 462
systemic lupus erythematosus, 462
zileuton, 462
Listeria monocytogenes
methotrexate, 786
rheumatoid arthritis, 786
Listeriosis
connective tissue disease, 796
Low back pain
balneology, 1315
clinical trials, 1315
diagnosis, 1532
family physicians, 1532
functional status, 1315
iliac crest pain syndrome, 1532
observer variation, 1532
L-tryptophan
eosinophilia-myalgia syndrome, 161
eosinophilia-myalgia syndrome workshop, 161
treatment, 161
Lung cancer
giant cell arteritis, 367
temporal arteritis, 367
Lung disease
methotrexate, 1043
pneumonitis, 1043
rheumatoid arthritis, 1043
risk factors, 1043
Lupus nephritis
adverse effects, 1812
anti-alpha beta T cell receptor monoclonal antibody, 2259
anti-DNA antibodies, 2259
anti-idiotype antibodies, 1075
cyclophosphamide, 1812
graft versus host disease, 2259
murine studies, 2259
renal biopsy, 1211
renal function, 1812
systemic lupus erythematosus, 801, 1075
systemic lupus erythematosus clinical trials, 1812
treatment, 1211
Lyme disease
Borrelia burgdorferi, 689, 695, 758
diagnosis, 571, 684, 758
enzyme linked immunosorbent assay, 684, 758
epidemiology, 689, 695
Escherichia coli, 684
neural networks, 571
pediatric, 758
Russia, 689
Sweden, 695
treatment, 689
Lymphadenopathy
corticosteroid therapy, 881
interstitial lung disease, 881
sarcoidosis, 881
systemic sclerosis, 881
Lymphedema
polymyalgia rheumatica, 370
psoriatic arthritis, 370
rheumatoid arthritis, 214, 370
RS$_3$PE syndrome, 370
scintigraphy, 214
Lymphocytes
CD5, 207
immunoconjugates, 207
rheumatoid arthritis, 207
Lymphokine activated killer cells
interleukin 2, 2188
myositis, 2188
neoplasms, 2188
Lymphoma
angioendotheliomatosis, 1769
central nervous system, 1769
cytokines, 1674
cytoxan, 1769
interleukin 12, 1674
Sjögren's syndrome, 1674
vasculitis, 1769
Lymphoproliferative disorders
Epstein-Barr virus, 1174
methotrexate, 1174
rheumatoid arthritis, 1174
Lysis
C5a, 24
rheumatoid arthritis, 24

M

Macaca mulatta
articular cartilage, 1747
knee osteoarthritis, 1747
magnetic resonance imaging, 1747
Macroglossia
amyloidosis, 1605 (ab)
Canadian Rheumatology Association Meeting, 1605 (ab)
muscle weakness, 1605 (ab)
Macrophages
polymerase chain reaction, 1624
reverse transcription, 1624
rheumatoid arthritis, 1624
vascular endothelial growth factor, 1624
Macroradiography
joint space, 807, 937
knee, 937
knee osteoarthritis, 807
nonsteroidal antiinflammatory drugs, 937
osteoarthritis clinical trials, 937
Magnesium
adenosine triphosphate, 953
fibromyalgia clinical trials, 953
malic acid, 953
Magnetic resonance imaging
adjuvant arthritis, 855
articular cartilage, 1747, S43–52
cartilage, S43–60
core decompression, 1929
disease activity, 193
disease progression, 855
juvenile dermatomyositis, 193
knee osteoarthritis, 1747
macaca mulatta, 1747
one dimensional proton nuclear, 855
osteoarthritis, S43–52, S43–60
osteonecrosis, 1929
primary angiitis, 662
proton, S43–60
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–52, S43–60
von Willebrand factor, 193
Major histocompatibility complex
Caucasians, 1852
enzyme linked immunosorbent assay, 1025
genetic factors, 1025, 1852
haplotypes, 1852
HLA, 85, 1852
immunogenetics, 85
rheumatoid arthritis, 1025
scleroderma, 85
soluble HLA class I, 1025
systemic lupus erythematosus, 1852
Malic acid
adenosine triphosphate, 953
fibromyalgia clinical trials, 953
magnesium, 953
Mastitis
panniculitis, 344
systemic lupus erythematosus, 344
Mathematical models
joint erosions, 1800
outcome assessment, 1800
radiography, 1800
rheumatoid arthritis clinical trials, 1800
Sharp's score, 1800
Matrix metalloproteinases
gelatinase-B, 385

rheumatoid arthritis, 385
stromelysin-1, 385
urokinase-type plasminogen activator, 385
Matrix metalloproteinase-3
inflammation, 2004
plasma, 2004
rheumatoid arthritis, 2004
serum, 2004
stromelysin, 2004
McGill Pain Questionnaire
biostatistics, 2307
disease activity, 2307
fibromyalgia clinical trials, 2307
Myalgic Score, 2307
outcome measures, 2307
Tender Point Count, 2307
Medicolegal factors
etiology, 590
fibromyalgia, 590
Meeting reports
Eosinophilia-Myalgia Syndrome — Guidelines for Patient Care, 161
Canadian Rheumatology Association, 1598
Mexican Society of Rheumatology, 164
Menopause
etidronate, 2183
osteomalacia, 2183
osteoporosis, 2183
Mental processes
depression, 137
fibromyalgia, 137
Mercury
dental amalgam, 2194
fibromyalgia, 2194
Metalloproteases
interleukin 1, S43–123
osteoarthritis, S43–109, S43–123
prostaglandins, S43–123
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–109, S43–123
tissue inhibitor of metalloproteases, S43–123
Metalloproteinases
adjuvant arthritis, 1726
aggrecan, S43–86
collagenases, 2285
flurbiprofen, 1726
osteoarthritis, S43–86
prosthesis, 2285
tenidap, 1726
tetracycline, 1726
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–86
total hip arthroplasty, 2285
Metastasis
arthritis, 973
breast cancer, 973
joint effusion, 973
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium
digital imaging, 2001
disease modifying antirheumatic drugs, 1797
introduction, 1782
joint count, 1983
joint damage, 1787
Larsen score, 1974, 1976, 1983
outcome assessment, 1783, 1787, 1792, 1797, 1974, 1976, 1983, 1990, 1998, 2001
preface, 1781
radiographic progression, 1797
radiography, 1781, 1782, 1783, 1787, 1792, 1797, 1974, 1976, 1983, 1990, 1998, 2001
reproducibility of results, 1998
rheumatoid arthritis clinical trials, 1779, 1781, 1782, 1783, 1787, 1792, 1797, 1974, 1976, 1983, 1990, 1998, 2001
Sharp score, 1792, 1983
welcome address, 1779
Methotrexate
adverse effects, 335, 1009, 1174
age, 218
ankylosing spondylitis, 1104
antimalarial therapy, 1636
arthroplasty, 1844
azathioprine, 1636, 1844
biological availability, 1570
Canada, 1600 (ab)
Canadian Rheumatology Association Meeting, 1600 (ab)
central nervous system, 335
combination therapy, 1636
cytokines, 224
disease activity, 844
disease progression, 241
drug dose-response relationship, 2072
eosinophilia, 1373
eosinophilic fasciitis, 1967
Epstein-Barr virus, 1174
fasciectomy, 1967
food, 630, 1570
gynecomastia, 796, 2189
Hispanics, 1844
human immunodeficiency virus, 2191
hypergammaglobulinemia, 1967
immunodepression, 2191
infection, 1844
intravenous cyclophosphamide, 1000
juvenile rheumatoid arthritis, 1009, 1570, 1574
leukemia, 2356
leukencephalopathy, 335
Listeria monocytogenes, 786
low dose, 2189
lung disease, 1043
lymphoproliferative disorders, 1174
morphea, 1967
nephritis, 1442
nodulosis, 790, 1439, 2359
nonsteroidal antiinflammatory drugs, 1009, 2072
pancytopenia, 1373
pericardial tamponade, 1439
pericarditis, 790
pharmacokinetics, 38, 41, 630, 844, 2072
pleural effusion, 790, 1439
pneumonitis, 1043
predictive factors, 1844
psoriasis, 2359
psoriatic arthritis, 241, 2191, 2359, 2370
pulmonary fibrosis, 1766
pyoderma gangrenosum, 1000
radiographic progression, 2370
radiography, 241
renal disease, 218
renal function, 38, 2072
rheumatoid arthritis, 38, 41, 218, 224, 335, 569, 630, 633, 786, 790, 796, 844, 1000, 1009, 1043, 1174, 1373, 1439, 1600 (ab), 1636, 1766, 1844, 2072, 2189, 2356, 2359
rheumatology and rheumatologists, 1600 (ab)
risk factors, 1043
risk-benefits, 1600 (ab)
secondary amyloidosis, 569
spondyloarthropathies, 1104
steroid therapy, 1442
superoxide, 633
systemic lupus erythematosus, 1442
8-Methoxypsoralen
adhesion molecules, 2126
endothelium, 2126
psoralen and ultraviolet A therapy, 2126
rheumatoid arthritis, 2126
synovitis, 2126
8-Methoxypsoralen and ultraviolet A radiation
systemic sclerosis, 2361
treatment, 2361
Methylprednisolone
bladder, 2373
cell adhesion molecules, 2065
cystitis, 2373
deflazacort, 1492
drug administration schedule, 1492
intravenous, 2065
neutrophils, 2065
polymyalgia rheumatica, 1492
pulse, 2373
rheumatoid arthritis, 2065
selectins, 2065
systemic lupus erythematosus, 2373
vasculitis, 2373
Mexican Society of Rheumatology
meeting report, 164
Microaneurysm
angiography, 876
arteriography, 876
hepatitis B virus, 876
polyarteritis nodosa, 876
Microscopy
connective tissue disease, 2226
nailfold capillaries, 2226
Raynaud's phenomenon, 2226
systemic sclerosis, 2226
Military personnel
reactive arthritis, 252
Reiter's syndrome, 252
Milwaukee shoulder
hypercalcemia, 561
hyperparathyroidism, 561
Minocycline
pharmacokinetics, 611
rheumatoid arthritis, 611

Minor salivary glands
autoimmunity, 1488
interleukin 2 receptor, 1488
Sjögren's syndrome, 1488
Minoxidil
nifedipine, 50
primary Raynaud's phenomenon, 50
Misoprostol
aged, 713
indomethacin, 713
renal dysfunction, 713
rheumatic diseases, 713
Mixed connective tissue disease
anti-U1-RNP antibodies, 586
classification criteria, 586
functional status, 751
HLA, 586
immunogenetics, 586
juvenile onset, 751
Modified Rodnan skin thickness score
observer variation, 1271, 1277, 1281
scleroderma, 1217, 1271, 1277, 1281
skin thickness, 1271, 1277, 1281
Modified San Diego criteria
Copenhagen criteria, 659
primary Sjögren's syndrome, 659
Molecular markers
carboxy terminal type II procollagen, S43–78
chondroitin sulfate, S43–78
osteoarthritis, S43–68
stromelysin, S43–78
tissue inhibitor of metalloproteinases, S43–78
Monarthritis
arthralgia, 497
parvovirus B19, 766
pediatric, 766
visceral larva migrans, 497
Mononuclear cells
flow cytometry, 600
gamma chain, 812
gamma delta T cells, 812
interleukin 1 alpha, 600
interleukin 1 beta, 600
rheumatoid arthritis, 600, 812
synovial fluid, 812
Moraxella
septic arthritis, 578
Morphea
antinuclear antibodies, 2337
eosinophilic fasciitis, 1967
fasciectomy, 1967
hypergammaglobulinemia, 1967
methotrexate, 1967
scleroderma, 2337
Mortality
Blacks, 1663
Canadian Rheumatology Association Meeting, 1600 (ab), 1601 (ab)
cardiovascular disease, 1065
Caucasians, 1663
cause of death, 1259
comorbidity, 1601 (ab)
corticosteroid therapy, 1601 (ab)
disease modifying antirheumatic drugs, 2200, 2214
epidemiology, 1600 (ab), 1663
gastrointestinal involvement, 2200, 2214
glucocorticoid therapy, 2214
gold, 2214
nonsteroidal antiinflammatory drugs, 2200, 2214
North American Indians, 1600 (ab)
predictive factors, 1265
prognosis, 1259
rheumatoid arthritis, 1065, 1600 (ab), 1601 (ab), 2200, 2214
scleroderma, 2100
sex, 1065
socioeconomic factors, 1601 (ab)
systemic lupus erythematosus, 1259, 1265, 1663
systemic sclerosis, 2100
Murine studies
adjuvant arthritis, 124
anti-alpha beta T cell receptor monoclonal antibody, 2259
anti-DNA antibodies, 2259
antiphospholipid antibodies, 2006
antiphospholipid antibody syndrome, 1068, 2006
cartilage, 2250
collagen genes, S43–39
dexamethasone, 124
graft versus host disease, 2259
IgG, 2006
immune complex arthritis, 2250
interleukin 1, 2250
intravenous gamma globulin, 1068
lupus nephritis, 2259
NZB mice, 1602 (ab)
osteoarthritis, S43–39, S43–143
osteochondrodysplasia, S43–39
proteoglycan degradation, 2250
proteoglycan synthesis, 2250
rheumatoid arthritis, 124
synovial membrane, 124
systemic lupus erythematosus, 1068
T cells, 2006
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–39, S43–143
Th1 cells, 1602 (ab)
tumor necrosis factor-alpha, 2250
Muscle
anaerobic threshold, 1483
exercise, 1483
oxygen, 1483
systemic lupus erythematosus, 1483
Muscle fatigue
catecholamines, 143
exercise, 143, 1536
fibromyalgia, 143, 1536
nuclear magnetic resonance spectroscopy, 1536
Muscle involvement
neural cell adhesion molecule, 2246
neurogenic involvement, 2246
systemic sclerosis, 2246
Muscle strength
disease activity, 473
isometric contraction, 473
juvenile chronic arthritis, 1159
muscle thickness, 1159
polymyositis/dermatomyositis, 473
Muscle thickness
juvenile chronic arthritis, 1159
muscle strength, 1159
Muscle weakness
amyloidosis, 1605 (ab)
Canadian Rheumatology Association Meeting, 1605 (ab)
macroglossia, 1605 (ab)
Musculoskeletal disorders
aging, 1934
arthritis, 573
Australia, 1934
cost of illness, 204
disability, 505, 1934
epidemiology, 733, 1934
Europe, 1934
fibromyalgia, 573
health services, 733
North America, 1934
Ontario Health Survey, 733
rehabilitation, 505
rheumatology and rheumatologists, 573
socioeconomic factors, 505
spine, 1934
Myalgia
neuropathy, 282
toxic oil syndrome, 282
Myalgic Score
biostatistics, 2307
disease activity, 2307
fibromyalgia clinical trials, 2307
McGill Pain Questionnaire, 2307
outcome measures, 2307
Tender Point Count, 2307
Myasthenia gravis
scleroderma, 792
Mycobacterium marinum
fishes, 1607
septic arthritis, 1607
Myelodysplastic syndrome
myeloproliferative disorders, 1208
relapsing polychondritis, 1208
Myelopathy
calcium pyrophosphate dihydrate crystals, 1604 (ab)
Canadian Rheumatology Association Meeting, 1604 (ab)
cervical spine, 1604 (ab)
Charcot's joint, 1604 (ab)
gouty arthritis, 1604 (ab)
Myeloperoxidase
antineutrophil cytoplasmic antibodies, 2304
lactoferrin, 2304
reactive arthritis, 2304
Myeloproliferative disorders
myelodysplastic syndrome, 1208
relapsing polychondritis, 1208
Myocardial infarction
antiphospholipid antibody syndrome, 768

cerebral infarction, 1210
lipoprotein(a), 1210
pediatric systemic lupus erythematosus, 768
Raynaud's phenomenon, 768
systemic lupus erythematosus, 1210
Myocarditis
polymyositis/dermatomyositis, 809
Myoclonus
eosinophilia-myalgia syndrome, 157
myokymia, 157
neurologic involvement, 157
tremor, 157
Myofascial pain
dolorimetry, 944
fibromyalgia, 944
pain, 944
palpation, 944
tender points, 944
Myofibroblasts
platelet derived growth factor, 1876
pulmonary fibrosis, 1876
scleroderma, 1876
transforming growth factor-beta 1, 1876
Myokymia
eosinophilia-myalgia syndrome, 157
myoklonus, 157
neurologic involvement, 157
tremor, 157
Myopathy
anti-Jo-1 antibodies, 762
inflammatory, 762
pediatric, 762
pulmonary fibrosis, 762
Myositis
epidemiology, 1604 (ab)
French Canadians, 1604 (ab)
idiopathic inflammatory, 1604 (ab)
interleukin 2, 2188
lymphokine activated killer cells, 2188
neoplasms, 2188

N

Nabumetone
diclofenac, 915
osteoarthritis clinical trials, 915
Nailfold capillaries
Behçet's disease, 1108
connective tissue disease, 2226
microscopy, 2226
Raynaud's phenomenon, 2226
systemic sclerosis, 2226
Naproxen
nonsteroidal antiinflammatory drugs, 2295
pharmacokinetics, 2295
prostaglandins, 2295
rheumatic diseases, 2295
synovial fluid, 2295
Natural history
disease activity, 295
juvenile chronic arthritis, 295
juvenile rheumatoid arthritis, 295
prognostic factors, 295
Necrosis
anticardiolipin antibodies, 1380
antiphospholipid antibody syndrome, 1380
cutaneous, 1380
vascular thrombosis, 1380
Necrotizing vasculitis
cardiac involvement, 78
polyarteritis nodosa, 78
predictive factors, 78
renal involvement, 78
Neonatal lupus
alpha-fetoprotein, 1365
anti-La(SSB) antibodies, 1352
antiphospholipid antibodies, 1365
anti-Ro antibodies, 533
anti-Ro(SSA) antibodies, 1352
autoantibodies, 1352
congenital complete heart block, 533, 541, 1352
HLA, 541
outcome assessment, 533, 541
pregnancy, 1365
Neonatal onset multisystem inflammatory disease
neutrophilic eccrine hidradenitis, 1171
Neoplasms
Churg-Strauss syndrome, 2177
giant cell arteritis, 566, 2177
granulomatous vasculitis, 566
immunosuppressive therapy, 1478
interleukin 2, 2188
lymphokine activated killer cells, 2188
myositis, 2188
prostate, 566
systemic lupus erythematosus, 1478
temporal arteritis, 2177
vasa vasorum vasculitis, 2177
Nephritis
methotrexate, 1442
steroid therapy, 1442
systemic lupus erythematosus, 1442
Neural cell adhesion molecule
muscle involvement, 2246
neurogenic involvement, 2246
systemic sclerosis, 2246
Neural networks
diagnosis, 571
Lyme disease, 571
Neurogenic involvement
muscle involvement, 2246
neural cell adhesion molecule, 2246
systemic sclerosis, 2246
Neurologic involvement
eosinophilia-myalgia syndrome, 157
myoclonus, 157
myokymia, 157
tremor, 157
Neuropathy
juvenile dermatomyositis, 1369
myalgia, 282
toxic oil syndrome, 282
vasculitis, 1369
Neuropeptides
capsaicin, 1447
inflammation, 1447
rheumatoid arthritis, 1447
Neuropsychiatric systemic lupus erythematosus
brain abnormalities, 1247
cognitive impairment, 2187
depression, 2187
single photon emission computed tomography, 1247
Neuropsychologic factors
central nervous system, 863
cognitive impairment, 863
disease activity, 863
systemic lupus erythematosus, 863
Neutropenia
Felty's syndrome, 174
granulocyte colony stimulating factor, 174
rheumatoid arthritis, 174
Neutrophilic eccrine hidradenitis
neonatal onset multisystem inflammatory disease, 1171
Neutrophils
cell adhesion molecules, 2065
methylprednisolone, 2065
rheumatoid arthritis, 2065
selectins, 2065
Nifedipine
minoxidil, 50
primary Raynaud's phenomenon, 50
Nitric oxide
cartilage, 1922
inflammation, 1922
rheumatoid arthritis, 1922
synovium, 1922
Nodules
cholesterol crystals, 338
rheumatoid arthritis, 338
Nodulosis
methotrexate, 790, 1439, 2359
pericardial tamponade, 1439
pericarditis, 790
pleural effusion, 790, 1439
psoriasis, 2359
psoriatic arthritis, 2359
rheumatoid arthritis, 790, 1439, 2359
Nonsteroidal antiinflammatory drugs
adverse effects, 1149
aged, 2142
analgesic therapy, 1762
articular cartilage, 1130
Canadian Rheumatology Association Meeting, 1603 (ab)
chondrocytes, 1130
cognitive impairment, 2142
continuing medical education, 1762
cost-benefit analysis, 1408
diclofenac, 2013
disease modifying antirheumatic drugs, 2200, 2214
disease progression, 2013
drug dose-response relationship, 2072
family physicians, 1762
gastroenteropathy, 1149, 1603 (ab)
gastrointestinal bleeding, 1471
gastrointestinal involvement, 2200, 2214
gastroprotective agents, S43–26
glucocorticoid therapy, 2214

gold, 2214
half-life, 1603 (ab)
indomethacin, 2013
interleukin 1, 1130
interleukin 6, 1130
joint space, 937
juvenile rheumatoid arthritis, 1009, 1149
knee, 937
macroradiography, 937
methotrexate, 1009, 2072
mortality, 2200, 2214
naproxen, 2295
OMERACT II Conference, 1408
osteoarthritis, 1130, 1762, 2013
osteoarthritis clinical trials, 937
outcome assessment, 1408
patient education, 1603 (ab)
pharmacokinetics, 1603 (ab), 2072, 2295
prescribing practices, S43–26
prostaglandins, 2295
renal function, 2072
rheumatic diseases, 2295
rheumatoid arthritis, 1009, 1471, 2072, 2200, 2214
rheumatoid arthritis clinical trials, 1408
survival, 1471
synovial fluid, 2295
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–26
ulcer, S43–26

Nontophaceous interval gout
colchicine, 1618, 1621
hyperuricemia, 1618, 1621
treatment, 1618, 1621

Normal pressure hydrocephalus
central nervous system, 342
prednisone, 342
rheumatoid arthritis, 342

North America
aging, 1934
Australia, 1934
disability, 1934
epidemiology, 1934
Europe, 1934
musculoskeletal disorders, 1934
spine, 1934

North American Indians
Canadian Rheumatology Association Meeting, 1600 (ab)
epidemiology, 1600 (ab)
mortality, 1600 (ab)
rheumatoid arthritis, 1600 (ab)

Nosology
SAPHO syndrome, 2017

Nuclear magnetic resonance spectroscopy
exercise, 1536
fibromyalgia, 1536
muscle fatigue, 1536

Nucleolus organizer region-90 antigens
anti-NOR-90 antibodies, 2371
HLA, 67
human upstream binding factor, 521
pediatric rheumatic diseases, 521, 2371
Raynaud's phenomenon, 521
scleroderma, 67
systemic sclerosis, 67

NZB mice
Canadian Rheumatology Association Meeting, 1602 (ab)
interleukin 2, 1602 (ab)
Th1 cells, 1602 (ab)

O

Obesity
cauda equina, 1771
epidural lipomatosis, 1771
knee osteoarthritis, 2006

Observer variation
diagnosis, 1532
family physicians, 1532
iliac crest pain syndrome, 1532
joint count, 2331
juvenile rheumatoid arthritis, 2331
low back pain, 1532
modified Rodnan skin thickness score, 1271, 1277, 1281
outcome measures, 2331
reproducibility of results, 2331
scleroderma, 1217, 1271, 1277, 1281
skin thickness, 1271, 1277, 1281

Occupations
biomechanical factors, S43–10
osteoarthritis, S43–10
predictive factors, S43–10
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–10

OMERACT II Conference, 980–999, 1185–1207, 1399–1433
acknowledgments, 1433
adverse effects, 982, 983, 989, 995, 998
Arthritis, Rheumatism and Aging Medical Information System, 995
biological products, 1415
biostatistics, 1191, 1412
conclusion, 1431
cost-benefit analysis, 1399, 1403, 1408, 1412, 1415
European Quality of Life Measure, 1197
evaluation, 1420
health policy, 1188
health status indicators, 1185, 1188, 1203
introduction, 980
nonsteroidal antiinflammatory drugs, 1408
osteoarthritis clinical trials, 1193, 1203
outcome assessment, 982, 983, 989, 995, 998, 1185, 1188, 1191, 1193, 1197, 1200, 1399, 1403, 1408, 1412, 1415
pharmacoepidemiology, 989
postmarketing product surveillance, 995
quality of life, 1185, 1191
Quality of Well Being Questionnaire, 1197
rheumatic diseases, 1399
rheumatoid arthritis clinical trials, 982, 983, 989, 995, 998, 1185, 1188, 1191, 1193, 1197, 1200, 1203, 1403, 1408, 1412, 1415
Short Form 36, 1193
utility measures, 1197, 1200
Western Ontario and McMaster Universities Osteoarthritis Index, 1193
workshop report, 998

One dimensional proton nuclear magnetic resonance imaging
adjuvant arthritis, 855
disease progression, 855
rheumatoid arthritis, 855

Ontario Health Survey
arthritis, 733
back disorders, 733
epidemiology, 733
health services, 733
musculoskeletal disorders, 733

Oral contraceptives
pediatric systemic lupus erythematosus, 2159
sex hormones, 2159
skin manifestations, 2159

Orthodontic assessment
computed tomography, 1956
juvenile rheumatoid arthritis, 1956
temporomandibular joint, 1956

Ossification
ankylosing spondylitis, 1704, 2120
atlantoaxial subluxation, 2120
diffuse idiopathic skeletal hyperostosis, 1395
fibrodysplasia ossificans progressiva, 976
heterotopic, 976, 1704
ligaments, 1395, 2120
retinol, 1395
retinol binding protein, 1395
total hip arthroplasty, 1704

Osteoarthritis
activities of daily living, 1124
adverse effects, 1311
aged, 921, 932
aggrecan, S43–71, S43–75, S43–86
alpha V integrin, 16
American College of Rheumatology criteria, S43–42, S43–44
analgesic therapy, 1762
antirheumatic drugs, S43–152
apatite crystals, 2007, S43–101
apoptosis, 926
aptamers, S43–62
arthroscopy, 1722
articular cartilage, 1130, 1514, 1520, 1599 (ab), 1605 (ab), 1740, 1747, 1913, S43–28, S43–52, S43–133, S43–146, S43–149, S43–155
biglycan, 1520
biomechanical factors, S43–10
bone, S43–71
bone mineral density, 921, 932, S43–98
bovine studies, 1740
calcium pyrophosphate dihydrate crystal deposition disease, 2007
calcium pyrophosphate dihydrate crystals, 1514, S43–101
Canadian Rheumatology Association Meeting, 1599 (ab), 1605 (ab)
canine studies, 262, S43–94
cartilage, 702, 926, S43–60, S43–71, S43–75, S43–82, S43–91
cartilage degradation, 1338, 1514

cartilage thickness, 109
cartilage volume, S43–120
CD14, 1326
cell activation, 1599 (ab)
Chingford Study, 1118, 1509
chondrocytes, 1130, 1326, S43–104, S43–152
chondroitin sulfate, S43–158
chondroitinase ABC, 702
clinical trials, 915, 937, 1193, 1203, 1442, S43–49
COL2A1, 255
collagen, S43–34, S43–82, S43–94
collagen genes, S43–28, S43–34
collagen studies, S43–39
collagen type II, 255
complications, 1722
continuing medical education, 1762
corticosteroid therapy, 1013
cytokines, S43–109
decorin, 1520
diclofenac, 2013
disability, S43–136
disease modifying antirheumatic drugs, 201
disease progression, 2013, S43–56
doxycycline, S43–149
electrical stimulation, 1757
epidemiology, 1118, 1509, 2291, S43–44
erosive, 1527
erythrocyte sedimentation rate, 788
estradiol, 421
estrogen receptors, 421
etiology, S43–3
exercise, S43–3
extracellular matrix, 16
familial, 255, S43–28, S43–34, S43–37, S43–39
family physicians, 1762
fibronectins, S43–158
fingers, 2007
fractures, 921
functional status, 482, 1757
gangliosides, S43–133
gene mutation, 255
gene therapy, S43–140
growth factors, S43–115
hand, 1509, 2132, 2291
health care costs, S43–23
health services accessibility, 1209
high molecular weight anionic glycoconjugate, 1605 (ab)
hip, 2291
hyaluronan, 1311
hyaluronic acid, 262, S43–68, S43–155, S43–158
hybridization, 275
hydroxychloroquine, 1527
hylan, 1311
IgG, S43–62
indomethacin, 2013
inflammation, 1527
insulin-like growth factor, 275
insulin-like growth factor-I, 1599 (ab)
interleukin 1, 1130, 1520, S43–104, S43–123
interleukin 1 receptor antagonist, 1338
interleukin 4, 1740
interleukin 6, 1130
International League of Associations for Rheumatology, 201
joint space, 807
keratan sulfate, S43–68, S43–155
knee, 807, 1118, 1311, 1722, 1732, 1747, 1757, 2006
knee arthropathy, 482
knee arthroplasty, 1209
knee pain scale, 1124
leukocyte differentiation antigens, 1326
macaca mulatta, 1747
macroradiography, 807
magnetic resonance imaging, 1747, S43–52, S43–60
metabolic factors, 1118
metalloproteases, S43–109, S43–123
metalloproteinases, S43–86
molecular markers, S43–68
mononuclear cells, 1335
murine studies, S43–39
nonsteroidal antiinflammatory drugs, 708, 1130, 1762, 2013
occupations, S43–10
osteochondrodysplasia, S43–39
osteophytes, S43–143
osteoporosis, 921, 1013, S43–98
outcome assessment, 482, S43–49
outcome measures, 201
ovine studies, S43–155
pain, 1124, 1757, S43–136
patient compliance, 708
pentosan polysulfate, S43–146
plasminogen activators, S43–120
predictive factors, S43–10
prostaglandins, S43–123
protein 29, 421
proteoglycan synthesis, S43–91, S43–143, S43–152
proteoglycans, 702, 1338, 1740, S43–94, S43–158
proteolysis, S43–82
proto-oncogene bcl-2, 926
rabbit studies, 702, 1338, 1913
radiography, 2291, S43–56
radiolabelled probes, S43–62
rheumatoid arthritis, 16, 275
slow acting antirheumatic drugs, 201
soluble tumor necrosis factor receptors, S43–115
spine, 932
subchondral bone, S43–98
synovial fibroblasts, S43–115
synovial fluid, 1335, S43–68, S43–71, S43–75, S43–101
synovium, 16, 262
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–1–160
tissue inhibitor of metalloprotease, S43–123, S43–146
transforming growth factor-beta, 1605 (ab), S43–104, S43–143
transgenic mice, S43–140
treatment, S43–136
tumor necrosis factor receptors, 1599 (ab)
tumor necrosis factor-alpha, 1599 (ab)
ultrasound, 109
urokinase, S43–120
vesicles, 1514
vitamin A, 1913
World Health Organization, 201

Osteoarthritis clinical trials
diclofenac, 915
erythrocyte sedimentation rate, 788
guidelines, 1442
health status indicators, 1203
hip, 915
joint space, 937
knee, 915, 937
macroradiography, 937
nabumetone, 915
nonsteroidal antiinflammatory drugs, 937
OMERACT II Conference, 1193, 1203
outcome assessment, S43–49
rheumatoid arthritis clinical trials, 788, 1193, 1203
Short Form 36, 1193
shoulder, 915
slow acting antirheumatic drugs, 1442
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–49
Western Ontario and McMaster Universities Osteoarthritis Index, 1193

Osteoarthropathy
aneurysm, 183
grafting, 183
hypertrophic, 183
infection, 183

Osteochondrodysplasia
COL2A1, 255
collagen genes, S43–39
collagen type II, 255
familial, 255
gene mutation, 255
murine studies, S43–39
osteoarthritis, S43–39
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–39

Osteomalacia
atypical, 2183
etidronate, 2183
menopause, 2183
osteoporosis, 2183

Osteonecrosis
anorexia nervosa, 544
core decompression, 1929
fingers, 544
magnetic resonance imaging, 1929
vascular insufficiency, 544

Osteophytes
osteoarthritis, S43–143
proteoglycan synthesis, S43–143
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–143
transforming growth factor-beta, S43–143

Osteoporosis
aged, 921

bone mineral density, 440, 921, 1055, 1455, 2148, 2238, S43–98
calcitonin, 2238
calcium, 2148
cortical bone, 440
corticosteroids therapy, 1013, 1055
etidronate, 2183
exertion, 2148
fractures, 921
glucocorticoid therapy, 2238
menopause, 2183
osteoarthritis, 921, 1013, S43–98
osteomalacia, 2183
PDN-21, 2238
rheumatoid arthritis, 440, 1055, 1455
sex hormone, 1455
subchondral bone, S43–98
systemic lupus erythematosus, 2238
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–98
vitamin D, 2148
Outcome assessment
ankylosing spondylitis, 740, 1304, 1609
anti-Ro antibodies, 533
Arthritis Impact Measurement Scales, 1601 (ab), 1603 (ab)
biological products, 1415
biostatistics, 1412
Canadian Rheumatology Association Meeting, 1601 (ab), 1602 (ab), 1603 (ab)
congenital complete heart block, 533, 541
cost-benefit analysis, 1399, 1403, 1408, 1412, 1415
diagnosis, 740
digital imaging, 2001
disability, 308, 1241, 1603 (ab)
disease activity, 1602 (ab)
disease modifying antirheumatic drugs, 1797
Dunlop-Dotteridge Lecture 1994, 740
fibromyalgia, 525, 1304, 1536
Functional Index, 1603 (ab)
functional status, 482, 1304, 1602 (ab)
Health Assessment Questionnaire, 1241, 1603 (ab)
HLA, 541
joint count, 1983
joint damage, 1787
joint erosions, 1800
juvenile chronic arthritis, 308
juvenile rheumatoid arthritis, 308
knee arthropathy, 482
Larsen score, 1974, 1976, 1983
mathematical models, 1800
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1783, 1787, 1792, 1797, 1974, 1976, 1983, 1990, 1998, 2001
neonatal lupus, 533, 541
nonsteroidal antiinflammatory drugs, 1408
OMERACT II Conference, 982, 983, 989, 995, 998, 1185, 1188, 1191, 1193, 1197, 1200, 1399, 1403, 1408, 1412, 1415
osteoarthritis, 482
osteoarthritis clinical trials, S43–49
Problem Elicitation Technique, 1304
prognostic factors, 308
psoriatic arthritis, 1601 (ab)
radiographic progression, 1797
radiography, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 2001
rating scale, 1536
reference standards, 1241
reproducibility of results, 1536, 1998
rheumatic diseases, 1399
rheumatoid arthritis, 482, 1241
rheumatoid arthritis clinical trials, 1403, 1408, 1412, 1415, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 1998, 2001
scleroderma, 1603 (ab)
Sharp score, 1792, 1800, 1983
standard gamble, 1536
systemic lupus erythematosus, 1602 (ab)
tenderness, 525
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–49
Outcome measures
biostatistics, 2307
disease activity, 2307
disease modifying antirheumatic drugs, 201
fibromyalgia clinical trials, 2307
International League of Associations for Rheumatology, 201
joint count, 2331
juvenile rheumatoid arthritis, 2331
McGill Pain Questionnaire, 2307
Myalgic Score, 2307
observer variation, 2331
osteoarthritis, 201
predictive factors, 186
reproducibility of results, 2331
rheumatoid arthritis, 186
slow acting antirheumatic drugs, 201
Tender Point Count, 2307
World Health Organization, 201
Outpatient care
chronic inflammatory arthritis, 1141
team management, 1141
Ovarian abscess
Salmonella, 575
systemic lupus erythematosus, 575
Ovine studies
articular cartilage, S43–155
hyaluronic acid, S43–155
keratan sulfate, S43–155
osteoarthritis, S43–155
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–155
Oxygen
anaerobic threshold, 1483
exercise, 1483
muscle, 1483
systemic lupus erythematosus, 1483

P

Pachydermodactyly
fingers, 2374
peripheral interphalangeal joints, 2374
swelling, 2374
Pain
activities of daily living, 1124
bursitis, 1971
bursography, 1971
Canadian Rheumatology Association Meeting, 1604 (ab)
disability, 270, 1466, 2313, S43–136
disease severity, 2313
dolorimetry, 944
electrical stimulation, 1757
exercise, 1604 (ab)
fibromyalgia, 151, 270, 944, 1552, 1604 (ab), 2313
functional status, 727, 1552, 1757
iliopsoas, 1971
knee osteoarthritis, 1124, 1757
knee pain scale, 1124
myofascial pain, 944
osteoarthritis, S43–136
palpation, 944
population studies, 151
predictive factors, 1466, 2313
psychological adaptation, 1552
psychological factors, 514
quality of life, 270
rheumatoid arthritis, 270, 514, 1466
self-assessment, 514
sex, 151
shoulder, 727
Shoulder Pain and Disability Index, 727
sleep disorders, 1604 (ab)
socioeconomic factors, 514
tender points, 151, 944
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–136
treatment, S43–136
Paleopathology
ankylosing spondylitis, 2327
Central America, 2327
Palpation
dolorimetry, 944
fibromyalgia, 944
myofascial pain, 944
pain, 944
tender points, 944
Pancreas
carcinoma, 2170
panniculitis, 2170
systemic lupus erythematosus, 2170
Pancytopenia
eosinophilia, 1373
folinic acid, 1373
methotrexate, 1373
rheumatoid arthritis, 1373
Panniculitis
arthralgia, 497
carcinoma, 2170
mastitis, 344
pancreas, 2170
systemic lupus erythematosus, 344, 2170
vasculitis, 497
visceral larva migrans, 497
Paraformaldehyde
antineutrophil cytoplasmic antibodies, 2038
antinuclear antibodies, 2038

rheumatoid arthritis, 2038
Paraneoplastic syndromes
adenocarcinoma, 1393
Raynaud's phenomenon, 1393
Parry-Romberg syndrome
See facial hemiatrophy
Parvovirus B19
pediatric monarthritis, 766
Patient care team
ambulatory care, 1005
inflammatory arthritis, 1005
Patient education
Canadian Rheumatology Association Meeting, 1603 (ab)
nonsteroidal antiinflammatory drugs, 1603 (ab)
PDN-21
bone mineral density, 2238
calcitonin, 2238
glucocorticoid therapy, 2238
osteoporosis, 2238
systemic lupus erythematosus, 2238
Pediatric ankylosing spondylitis
hip, 165
HLA-B27, 165
Pediatric idiopathic arthritides
International League of Associations for Rheumatology Task Force for Classification Criteria, 1566
Pediatric Lyme disease
Borrelia burgdorferi, 758
diagnosis, 758
enzyme linked immunosorbent assay, 758
Pediatric mixed connective tissue disease
See also juvenile onset mixed connective tissue disease
Pediatric monarthritis
parvovirus B19, 766
Pediatric reactive arthritis
rheumatic fever, 529
rheumatic heart disease, 529
Streptococcus pyogenes, 529
Pediatric Reiter's syndrome
cryptosporidiosis, 1962
Cryptosporidium, 1962
gastroenteritis, 1962
Pediatric rheumatic diseases
Abe Shore Memorial Lecture, 289
anorexia nervosa, 544
anti-NOR-90 antibodies, 2371
antiphospholipid antibody syndrome, 768
arthropathy, 2349
autoimmunity, 289
biological therapy, 289
camptodactyly, 2349
classification criteria, 1295 (correction), 1445, 1566
congenital heart block, 1352
diet therapy, 1347
dyslipoproteinemia, 1347
fibrosis, 2349
fish oil, 1347
human upstream binding factor, 521
idiopathic arthritides, 1445, 1566
immunogenetics, 289
International League of Associations for Rheumatology Task Force for Classification Criteria, 1566
joint prosthesis, 289
juvenile chronic arthritis, 295, 308, 1159
juvenile dermatomyositis, 320, 326, 1369
juvenile onset mixed connective tissue disease, 751
juvenile rheumatoid arthritis, 295, 308, 790, 1009, 1149, 1166, 1356, 1377, 1574, 1577, 1953, 1956, 2114, 2331
juvenile spondyloarthropathies, 548
juvenile temporal arteritis, 774
Lyme disease, 758
monarthritis, 766
neonatal lupus, 533, 541, 1352, 1365
neonatal onset multisystem inflammatory disease, 1171
nucleolus organizer region-90 antigens, 521, 2371
osteonecrosis, 544
pachydermodactyly, 2374
parvovirus B19, 766
pericarditis, 2349
pleuritis, 2349
Proposal for the Development of Classification Criteria for Idiopathic Arthritides of Childhood, 1445
Raynaud's phenomenon, 521, 768
Reiter's syndrome, 1962
scleroderma, 2337
serositis, 2349
Sjögren's syndrome, 1152
spondyloarthropathies, 332
systemic lupus erythematosus, 768, 1347, 2156, 2344
Pediatric rheumatology
ankylosing spondylitis, 165
juvenile dermatomyositis, 193
juvenile rheumatoid arthritis, 168
Pediatric Sjögren's syndrome
pathology, 1152
Pediatric spondyloarthropathies
aortic regurgitation, 332
HLA-B27, 332
Pediatric systemic lupus erythematosus
See also neonatal lupus
antiphospholipid antibodies, 1438
antiphospholipid antibody syndrome, 768
coronary disease, 1438
hypocalcemia, 2156
hypoparathyroidism, 2156
myocardial infarction, 768
oral contraceptives, 2159
Raynaud's phenomenon, 768
rupture, 2344
seizures, 2156
sex hormones, 2159
skin manifestations, 2159
spleen, 2344
splenomegaly, 2344
Pentosan polysulfate
articular cartilage, S43–146
osteoarthritis, S43–146
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–146
tissue inhibitor of metalloprotease, S43–146
Pentoxifylline
Canadian Rheumatology Association Meeting, 1600 (ab)
rheumatic diseases, 595
rheumatoid arthritis, 595, 625
rheumatoid arthritis clinical trials, 1600 (ab)
tumor necrosis factor-alpha, 625, 1600 (ab)
Pericardial effusion
scleroderma, 1386
vasculitis, 1386
Pericardial tamponade
methotrexate, 1439
nodulosis, 1439
pleural effusion, 1439
rheumatoid arthritis, 1439
Pericarditis
adult Still's disease, 180
arthroplasty, 2349
camptodactyly, 2349
cardiac tamponade, 180
genetic factors, 2349
methotrexate, 790
nodulosis, 790
pleural effusion, 790
pleuritis, 2349
rheumatoid arthritis, 790
serositis, 2349
Peripheral interphalangeal joints
fingers, 2374
pachydermodactyly, 2374
swelling, 2374
Peripheral vascular disease
scleroderma, 469
vasculitis, 469
Pharmacoepidemiology
OMERACT II Conference, 989
Pharmacokinetics
Canadian Rheumatology Association Meeting, 1603 (ab)
disease activity, 844
drug dose-response relationship, 2072
food, 630
gastroenteropathy, 1603 (ab)
half-life, 1603 (ab)
methotrexate, 38, 41, 630, 844, 2072
minocycline, 611
naproxen, 2295
nonsteroidal antiinflammatory drugs, 1603 (ab), 2072, 2295
prostaglandins, 2295
renal function, 38, 2072
rheumatic diseases, 2295
rheumatoid arthritis, 38, 41, 611, 630, 844, 2072
synovial fluid, 2295
Phenotypes
Caucasians, 1862
C4AQ0, 1862
genetic factors, 1862
systemic lupus erythematosus, 1862
Phenytoin
auranofin, 1235
chloroquine, 1235

rheumatoid arthritis, 1235
Pheochromocytoma
vasculitis, 1442
Phospholipase A_2
8-bromo cyclic adenosine monophosphate, 2114
CAMPATH-1H, 1816
chondrocytes, 2114
cytokines, 2114
juvenile rheumatoid arthritis, 2114
rheumatoid arthritis, 1816, 2114
secretory, 1816
tumor necrosis factor-alpha, 1816
Photochemotherapy
rheumatoid arthritis, 3
Pigmentation
adrenocorticotropic hormone, 1603 (ab)
Canadian Rheumatology Association Meeting, 1603 (ab)
scleroderma, 1603 (ab)
Pitting edema
aged, 899
HLA-B27, 899
seronegative spondyloarthropathies, 899
Pituitary hormones
adrenocorticotropic hormone, 1829
beta-endorphin, 1829
cortisol, 1829
prolactin, 1829
rheumatoid arthritis, 1829
Pituitary microadenoma
Cushing's disease, 1964
rheumatoid arthritis, 1964
trans-sphenoidal surgery, 1964
Plasminogen activators
cartilage volume, S43–120
osteoarthritis, S43–120
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–120
urokinase, S43–120
Platelet activating factor antagonists
rheumatoid arthritis, 1651
Platelet activating factor-ACETHER
rheumatoid arthritis, 1651
Platelet derived growth factor
myofibroblasts, 1876
pulmonary fibrosis, 1876
scleroderma, 1876
transforming growth factor-beta 1, 1876
Pleural effusion
methotrexate, 790, 1439
nodulosis, 790, 1439
pericardial tamponade, 1439
pericarditis, 790
rheumatoid arthritis, 790, 1439
Pleuritis
arthropathy, 2349
camptodactyly, 2349
genetic factors, 2349
pericarditis, 2349
serositis, 2349
Pneumonitis
lung disease, 1043
methotrexate, 1043
rheumatoid arthritis, 1043
risk factors, 1043
Polyarteritis
Chinese, 1295
microscopic, 1295
prognosis, 1295
Polyarteritis nodosa
angiography, 876
arteriography, 876
cardiac involvement, 78
hepatitis B virus, 876
human immunodeficiency virus, 351
microaneurysm, 876
necrotizing vasculitis, 78
predictive factors, 78
renal involvement, 78
vasculitis, 351
Polymerase chain reaction
macrophages, 1624
reverse transcription, 1624
rheumatoid arthritis, 1624
vascular endothelial growth factor, 1624
Polymorphonuclear cells
anti-Fc gamma receptor autoantibodies, 2241
Fc gamma receptor, 2241
Sjögren's syndrome, 2241
Polymorphonuclear granulocytes
cartilage destruction, 1436
rheumatoid arthritis, 1436
synovial fluid, 1436
Polymyalgia rheumatica
anticardiolipin antibodies, 1694
CD8, 1020
clinical trials, 1097, 1660
corticosteroids therapy, 1097
deflazacort, 1492
diagnosis, 1020
drug administration schedule, 1492
giant cell arteritis, 1694
lymphedema, 370
methylprednisolone, 1492
rheumatoid arthritis, 1020
T lymphocytes, 1020
tenidap, 1097
Polymyalgia rheumatica clinical trials
deflazacort, 1660
drug dose-response relationship, 1660
prednisolone, 1660
Polymyositis
annexins, 97
classification criteria, 581, 668
dermatomyositis, 668
diagnostic criteria, 581, 668
epidemiology, 668
focal myositis, 188
hairy cell leukemia, 1384
interferon-gamma, 1698
scleroderma, 1384
tumor necrosis factor-alpha, 1698
Polymyositis/dermatomyositis
cardiac involvement, 809
classification criteria (correction), 1807
congestive heart failure, 809
disease activity, 473
isometric contraction, 473
muscle strength, 473
myocarditis, 809
Popliteal cysts
anterior compartment syndrome, 1377
juvenile rheumatoid arthritis, 1377
Population studies
fibromyalgia, 151
pain, 151
sex, 151
tender points, 151
Postmarketing product surveillance
OMERACT II Conference, 995
Poststreptococcal reactive arthritis
Jones criteria, 379
rheumatic fever, 379
Predictive factors
arthroplasty, 1844
azathioprine, 1844
biomechanical factors, S43–10
biopsy, 93
cardiac involvement, 78
disability, 1466, 2313
disease progression, 675
disease severity, 2313
erythrocyte sedimentation rate, 675
fibromyalgia, 2313
giant cell arteritis, 93
Hispanics, 1844
infection, 1844
inflammation, 675
juvenile rheumatoid arthritis, 168
methotrexate, 1844
mortality, 1265
necrotizing vasculitis, 78
occupations, S43–10
osteoarthritis, S43–10
outcome measures, 186
pain, 1466, 2313
polyarteritis nodosa, 78
psoriatic arthritis, 675
radiography, 168
renal involvement, 78
rheumatoid arthritis, 186, 570, 1466, 1844
rheumatoid factor, 570
systemic lupus erythematosus, 1265
temporal artery, 93
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–10
Prednisolone
bladder, 2373
cystitis, 2373
deflazacort, 1660
drug dose-response relationship, 1660
polymyalgia rheumatica clinical trials, 1660
systemic lupus erythematosus, 2373
vasculitis, 2373
Prednisone
anti-La(SSB) antibodies, 868
anti-Ro(SSA) antibodies, 868
central nervous system, 342
cyclophosphamide, 1593
hydroxychloroquine, 868
hypergammaglobulinemic purpura, 868
indomethacin, 868
normal pressure hydrocephalus, 342

progressive multifocal leukoencephalopathy, 1593
rheumatoid arthritis, 342
systemic lupus erythematosus, 868
Wegener's granulomatosis, 1593
Pregnancy
alpha-fetoprotein, 1365
antiphospholipid antibodies, 1365
neonatal lupus, 1365
Prescribing practices
gastroprotective agents, S43–26
nonsteroidal antiinflammatory drugs, S43–26
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–26
ulcer, S43–26
Prevalence studies
Amor criteria, 1499
anticardiolipin antibodies, 55
antiphospholipid antibody syndrome, 55
China, 659
enzyme linked immunosorbent assay, 55
European Spondylarthropathy Study Group, 1499
Italy, 1499
juvenile rheumatoid arthritis, 790
psoriatic arthritis, 1499
Sjögren's syndrome, 659
Primary angiitis
angiography, 662
brain biopsy, 662
central nervous system, 662, 2371
cerebral fluid examination, 662
diagnosis, 662
digital subtraction angiography, 2371
magnetic resonance imaging, 662
vasculitis, 2371
Primary antiphospholipid antibody syndrome
Factor V mutation, 1215
HLA, 1589
protein C, 1215
systemic lupus erythematosus, 1589
Primary Raynaud's phenomenon
ischemia, 374
minoxidil, 50
nifedipine, 50
reperfusion, 374
systemic sclerosis, 374
Primary Sjögren's syndrome
biopsy, 133
bowel, 2375
Copenhagen criteria, 659
C5 deficiency, 1389
ischemia, 2375
modified San Diego criteria, 659
vasculitis, 2375
Problem Elicitation Technique
ankylosing spondylitis, 1304
fibromyalgia, 1304
functional status, 1304
outcome assessment, 1304
Procollagen
carboxy terminal type II, S43–78
Prognosis
ankylosing spondylitis, 2266, 2273, 2279
cause of death, 1259
Chinese, 1295
disability, 1037
disease progression, 1037
functional status, 1037
gut, 2266, 2273, 2279
inflammation, 2266, 2273, 2279
inflammatory bowel disease, 2266, 2273, 2279
mortality, 1259
polyarteritis, 1295
rheumatoid arthritis, 1037, 2186
rheumatoid factor, 2186
spondyloarthropathies, 2266, 2273, 2279
systemic lupus erythematosus, 1259
Prognostic factors
disability, 308
disease activity, 295
juvenile chronic arthritis, 295, 308
juvenile rheumatoid arthritis, 295, 308
natural history, 295
outcome assessment, 308
Progressive multifocal leukoencephalopathy
cyclophosphamide, 1593
prednisone, 1593
Wegener's granulomatosis, 1593
Prolactin
adrenocorticotropic hormone, 1829
antinuclear antibodies, 1577
beta-endorphin, 1829
bromocriptine, 2084
cortisol, 1829
juvenile rheumatoid arthritis, 1577
pituitary hormones, 1829
rheumatoid arthritis, 1829
systemic lupus erythematosus, 2084
Propylthiouracil
alveolar hemorrhage, 803
antineutrophil cytoplasmic antibodies, 803
Prostaglandins
interleukin 1, S43–123
metalloproteases, S43–123
naproxen, 2295
nonsteroidal antiinflammatory drugs, 2295
osteoarthritis, S43–123
pharmacokinetics, 2295
rheumatic diseases, 2295
synovial fluid, 2295
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–123
tissue inhibitor of metalloprotease, S43–123
Prostate
giant cell arteritis, 566
granulomatous vasculitis, 566
neoplasms, 566
Prostatitis
Wegener's granulomatosis, 187
Prosthesis
collagenases, 2285
loosening, 2285
metalloproteinases, 2285
total hip arthroplasty, 2285
Protease inhibitors
extracellular matrix, 817
fibronectins, 817
rheumatoid arthritis, 817
synoviocytes, 817
Protein C
Factor V mutation, 1215
primary antiphospholipid antibody syndrome, 1215
Protein S
anticardiolipin antibodies, 2007
thrombosis, 2007
Protein 29
arthritis, 421
osteoarthritis, 421
rheumatoid arthritis, 421
Proteoglycan degradation
cartilage, 2250
immune complex arthritis, 2250
interleukin 1, 2250
murine studies, 2250
proteoglycan synthesis, 2250
tumor necrosis factor-alpha, 2250
Proteoglycan synthesis
antirheumatic drugs, S43–152
cartilage, 2250, S43–91
chondrocytes, S43–152
immune complex arthritis, 2250
interleukin 1, 2250
murine studies, 2250
osteoarthritis, S43–91, S43–143, S43–152
osteophytes, S43–143
proteoglycan degradation, 2250
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–91, S43–143, S43–152
transforming growth factor-beta, S43–143
tumor necrosis factor-alpha, 2250
Proteoglycans
articular cartilage, 1740
bovine studies, 1740
cartilage, 702
cartilage degradation, 1338
chondroitin sulfate, S43–158
chondroitinase ABC, 702
collagen, S43–94
fibronectins, S43–158
hyaluronic acid, S43–158
interleukin 1 receptor antagonist, 1338
interleukin 4, 1740
osteoarthritis, 702, 1338, 1740, S43–94, S43–158
rabbit studies, 702
rheumatoid arthritis, 1338
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–94, S43–158
Proteolysis
cartilage, S43–82
collagen, S43–82
osteoarthritis, S43–82
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–82
Proteus mirabilis
Bermuda, 1825
disease activity, 1825
Escherichia coli, 1825
rheumatoid arthritis, 1825

United Kingdom, 1825
Proto-oncogene bcl-2
apoptosis, 926
cartilage, 926
osteoarthritis, 926
Pseudogout
acromioclavicular joint, 371
cysts, 371
Psoralen and ultraviolet A therapy
adhesion molecules, 2126
arthroscopy, 29
endothelium, 2126
8-methoxypsoralen, 2126
rheumatoid arthritis, 3, 29, 2126
synovitis, 29, 2126
Psoriasis
methotrexate, 2359
nodulosis, 2359
psoriatic arthritis, 783, 2359
reflex sympathetic dystrophy, 783
rheumatoid arthritis, 2359
trauma, 783
Psoriatic arthritis
Amor criteria, 1499
antioxidants, 103
Arthritis Impact Measurement Scales, 1601 (ab)
arthroscopy, 1722
Canadian Rheumatology Association Meeting, 1601 (ab)
classification criteria, 1499
denervation, 1211
disability, 1601 (ab)
disease progression, 241, 675
distal interphalangeal joint, 1211
erythrocyte sedimentation rate, 675
European Spondylarthropathy Study Group, 1499
fatty acids, 103
fibromyalgia, 886
fingers, 1211
gut inflammation, 680
Health Assessment Questionnaire, 886, 1601 (ab)
Health Assessment Questionnaire for Spondyloarthropathy, 886
health status indicators, 886
HLA-DR4 alleles, 1601 (ab)
human immunodeficiency virus, 2191
immunodepression, 2191
inflammation, 675
Italy, 1499
lymphedema, 370
methotrexate, 241, 2191, 2359, 2370
nodulosis, 2359
outcome assessment, 1601 (ab)
predictive factors, 675
prevalence studies, 1499
psoriasis, 783, 2359
radiographic progression, 2370
radiography, 241
red blood cells, 103
reflex sympathetic dystrophy, 783, 2188
rheumatoid arthritis, 1601 (ab), 2359
selenium, 103
spondyloarthropathies, 680, 1601 (ab)
sulfasalazine, 894, 1601 (ab)
toxicity, 1601 (ab)
trauma, 783
ulcer, 1601 (ab)
Psychological adaptation
fibromyalgia, 1552
functional status, 1552
pain, 1552
Psychological factors
anxiety, 514
depression, 514
pain, 514
rheumatoid arthritis, 514
self-assessment, 514
socioeconomic factors, 514
Psychosocial factors
disability, 2218
disease progression, 2218
rheumatoid arthritis, 2218
Pulmonary fibrosis
anti-Jo-1 antibodies, 762
inflammatory myopathy, 762
methotrexate, 1766
myofibroblasts, 1876
platelet derived growth factor, 1876
rheumatoid arthritis, 1766
scleroderma, 1876
transforming growth factor-beta 1, 1876
Pulmonary function
dyspnea, 455
exercise, 455
systemic lupus erythematosus, 455
Pulmonary hemorrhage
antiphospholipid antibody syndrome, 554
Pulmonary involvement
anticardiolipin antibodies, 62
antiphospholipid antibodies, 62
antiphospholipid antibody syndrome, 62
SAPHO syndrome, 2190
systemic lupus erythematosus, 62
Pulmonary vasculitis
antiphospholipid antibody syndrome, 554
Pyoderma gangrenosum
intravenous cyclophosphamide, 1000
methotrexate, 1000
rheumatoid arthritis, 1000
Pyridinium
bone resorption, 797
creatinine, 797
systemic sclerosis, 797
Pyrophosphatases
alkaline phosphatase, 1907
calcium pyrophosphate dihydrate crystal deposition disease, 1907
spermidine, 1907
spermine, 1907

Q

Quality of life
biostatistics, 1191
disability, 270
fibromyalgia, 270
health status indicators, 1185
OMERACT II Conference, 1185, 1191
pain, 270
rheumatoid arthritis, 270
rheumatoid arthritis clinical trials, 1185, 1191
Quality of Well Being Questionnaire
European Quality of Life Measure, 1197
OMERACT II Conference, 1197
rheumatoid arthritis clinical trials, 1197
utility measures, 1197
Questionnaires
Amor criteria, 1499
Arthritis Impact Measurement Scales, 1603 (ab)
Bath Ankylosing Spondylitis Metrology Index, 1609
Childhood Health Assessment Questionnaire, 326
European Quality of Life Measure, 1197
European Spondylarthropathy Study Group, 1499
Functional Index, 1603 (ab)
Groningen Activity Restriction Scale, 1834
Health Assessment Questionnaire, 1241, 1603 (ab), 1834
knee pain scale, 1124
Lesquesne index, 201
Lupus Activity Index, 2078
McGill Pain Questionnaire, 2307
modified Rodnan skin thickness score, 1217, 1271
Myalgic Score, 2307
Problem Elicitation Technique, 1304
Quality of Well Being Questionnaire, 1197
Short Form 36, 1193
Shoulder Pain and Disability Index, 727
Systemic Lupus Activity Measure, 45, 2078
Systemic Lupus Erythematosus Disease Activity Index, 2078
Tender Point Count, 2307
Western Ontario and McMaster Universities Osteoarthritis Index, 201, 1193

R

Rabbit studies
antigen induced arthritis, 1605 (ab), 1714
articular cartilage, 1714, 1913
Canadian Rheumatology Association Meeting, 1605 (ab)
cartilage, 702
chondroitinase ABC, 702
continuous passive motion, 1714
inflammation, 1605 (ab)
interleukin 1 receptor antagonist, 1338
osteoarthritis, 702, 1338, 1913
proteoglycans, 702
rheumatoid arthritis, 1338, 1714
SERP-1 protein, 1605 (ab)
synovitis, 1714
vitamin A, 1913
Radical scavenger
hyaluronate, 400
rheumatoid arthritis, 400
synovial membrane, 400

Radiographic progression
disease modifying antirheumatic drugs, 1797
indomethacin, 1941
knee osteoarthritis, 1941
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1797
methotrexate, 2370
outcome assessment, 1797
psoriatic arthritis, 2370
radiography, 1797
rheumatoid arthritis clinical trials, 1797
tiaprofenic acid, 1941
Radiography
aged, 2291
avascular necrosis of bone, 1604 (ab)
Canadian Rheumatology Association Meeting, 1598 (ab), 1604 (ab)
classification, S43–50
cortical thickness, 1598 (ab)
diagnosis, 1604 (ab)
digital imaging, 2001
disease modifying antirheumatic drugs, 1797
disease progression, 241, S43–56
epidemiology, 2291
grading, S43–56
hip osteoarthritis, 2291
joint count, 1983
joint damage, 1787
joint erosions, 1048, 1800
joint repair, 1048
joint space, 807, 937
juvenile rheumatoid arthritis, 168
knee osteoarthritis, 807
Larsen score, 1974, 1976, 1983
macroradiography, 807, 937
mathematical models, 1800
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1781, 1782, 1783, 1787, 1792, 1797, 1974, 1976, 1983, 1990, 1998, 2001
methotrexate, 241
osteoarthritis, S43–56
osteoarthritis clinical trials, 937
outcome assessment, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 2001
predictive factors, 168
psoriatic arthritis, 241
radiographic progression, 1797
rheumatoid arthritis, 1048
rheumatoid arthritis clinical trials, 1598 (ab), 1781, 1782, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 1998, 2001
Sharp score, 1598 (ab), 1792, 1800, 1983
systemic lupus erythematosus, 1604 (ab)
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–56
Radiolabelled probes
osteoarthritis, S43–62
Rating scale
fibromyalgia, 1536
outcome assessment, 1536
reproducibility of results, 1536
standard gamble, 1536
Raynaud's phenomenon
adenocarcinoma, 1393
annexins, 97
antiphospholipid antibody syndrome, 768
connective tissue disease, 2226
human upstream binding factor, 521
microscopy, 2226
minoxidil, 50
myocardial infarction, 768
nailfold capillaries, 2226
nifedipine, 50
nucleolus organizer region-90 antigen, 521
paraneoplastic syndromes, 1393
pediatric rheumatic diseases, 521
pediatric systemic lupus erythematosus, 768
primary, 50
systemic sclerosis, 2226
Reactive arthritis
acquired immunodeficiency syndrome, 252
antibody formation, 1947
antineutrophil cytoplasmic antibodies, 2304
beta hemolyticus streptococcus, 1710
Canadian Rheumatology Association Meeting, 1602 (ab)
disease outbreaks, 1947
dysentery, 1602 (ab)
epidemiology, 252
immune response, 1947
lactoferrin, 2304
lipopolysaccharide, 1947
military personnel, 252
myeloperoxidase, 2304
pediatric, 529
poststreptococcal, 379
rheumatic fever, 1710
Salmonella, 1947
Salmonella typhi, 1602 (ab)
typhoid vaccine, 1602 (ab)
Red blood cells
antioxidants, 103
fatty acids, 103
psoriatic arthritis, 103
selenium, 103
Reference standards
disability, 1241
Health Assessment Questionnaire, 1241
outcome assessment, 1241
rheumatoid arthritis, 1241
Reflex sympathetic dystrophy
posttraumatic, 2188
psoriasis, 783
psoriatic arthritis, 783, 2188
trauma, 783
Rehabilitation
disability, 505
musculoskeletal disorders, 505
socioeconomic factors, 505
Reiter's syndrome
acquired immunodeficiency syndrome, 252
epidemiology, 252
military personnel, 252
pediatric, 1962
Relapsing polychondritis
myelodysplastic syndrome, 1208
myeloproliferative disorders, 1208
Renal acidosis
distal tubular, 2366
hypokalemia, 2366
renal involvement, 2366
Sjögren's syndrome, 2366
Renal disease
age, 218
gout, 494
hyperuricemia, 494
methotrexate, 218
rheumatoid arthritis, 218
Renal dysfunction
aged, 713
indomethacin, 713
misoprostol, 713
rheumatic diseases, 713
Renal failure
antineutrophil cytoplasmic antibodies, 791
anti-RNA polymerase III antibodies, 557
hypertension, 557
scleroderma, 557
systemic sclerosis, 557, 791
Renal function
adverse effects, 1812
chloroquine, 34
cyclophosphamide, 1812
drug dose-response relationship, 2072
hydroxychloroquine, 34
lupus nephritis, 1812
methotrexate, 38, 2072
nonsteroidal antiinflammatory drugs, 2072
pharmacokinetics, 38, 2072
rheumatoid arthritis, 34, 38, 2072
systemic lupus erythematosus clinical trials, 1812
Renal involvement
cardiac involvement, 78
hypokalemia, 2366
necrotizing vasculitis, 78
polyarteritis nodosa, 78
predictive factors, 78
renal acidosis, 2366
Sjögren's syndrome, 2366
Reperfusion
ischemia, 374
primary Raynaud's phenomenon, 374
systemic sclerosis, 374
Reproducibility of results
fibromyalgia, 1536
Grip Function Test, 1559
grip strength, 1559
joint count, 2331
juvenile rheumatoid arthritis, 2331
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1998
observer variation, 2331
outcome assessment, 1536, 1998
outcome measures, 2331
rating scale, 1536
rheumatoid arthritis, 1559
rheumatoid arthritis clinical trials, 1998
standard gamble, 1536

Retinol
diffuse idiopathic skeletal hyperostosis, 1395
ligament, 1395
ossification, 1395
retinol binding protein, 1395
Retinol binding protein
diffuse idiopathic skeletal hyperostosis, 1395
ligament, 1395
ossification, 1395
retinol, 1395
Retinopathy
dermatomyositis, 2372
Reverse transcription
macrophages, 1624
polymerase chain reaction, 1624
rheumatoid arthritis, 1624
vascular endothelial growth factor, 1624
Rheumatic diseases
aged, 713
China, 795
clinical trials, 1399
cost-benefit analysis, 1399
epidemiology, 795
indomethacin, 713
misoprostol, 713
naproxen, 2295
nonsteroidal antiinflammatory drugs, 2295
OMERACT II Conference, 1399
outcome assessment, 1399
pentoxifylline, 595
pharmacokinetics, 2295
prostaglandins, 2295
renal dysfunction, 713
synovial fluid, 2295
Rheumatic fever
acute, 379
beta hemolyticus streptococcus, 1710
forme fruste, 379
Jones criteria, 379
pediatric reactive arthritis, 529
poststreptococcal reactive arthritis, 379
reactive arthritis, 1710
rheumatic heart disease, 529
Streptococcus pyogenes, 529
Rheumatic heart disease
pediatric reactive arthritis, 529
rheumatic fever, 529
Streptococcus pyogenes, 529
Rheumatoid arthritis
See also rheumatoid arthritis clinical trials
adhesion molecules, 2126
adjuvant arthritis, 124, 855
adrenocorticotropic hormone, 1829
adverse effects, 335, 572, 611
age, 218, 1032
aging, 1007
alpha V integrin, 16
ambulatory care, 1005
anaphylactic reaction, 190
annexins, 97
anti-annexin V antibodies, 1230
anti-annexin VI antibodies, 1230
antigen induced arthritis, 1714
antikeratin antibodies, 2046
antimalarial therapy, 1636
antineutrophil cytoplasmic antibodies, 2038
antinuclear antibodies, 2038
antiphospholipid antibody syndrome, 1586
anxiety, 644
The Arthritis Society, 1604 (ab)
arthroplasty, 1844
arthroscopy, 29, 1722
articular cartilage, 1714
auranofin, 1235
autoimmunity, 1802
azathioprine, 1636, 1844
Bermuda, 1825
beta-endorphin, 1829
bone Gla protein, 1060
bone marrow transplantation, 1809
bone mineral density, 440, 1055, 1455
8-bromo cyclic adenosine monophosphate, 2114
C5a, 24
CAMPATH-1H, 1816
Canada, 836, 1600 (ab)
Canadian Rheumatology Association Meeting, 1600 (ab), 1601 (ab), 1604 (ab)
caprine arthritis encephalitis virus, 8
caprine studies, 8
capsaicin, 1447
cardiovascular disease, 1065
cartilage, 1922
cartilage degradation, 1338
cartilage destruction, 1436
CD5, 207
CD8, 1020
CD14, 1326
CD69, 413
cell adhesion molecules, 2065
central nervous system, 335, 342
chloroquine, 34, 1235
cholesterol crystals, 338
chondrocytes, 1326, 2114
classification criteria, 1434
clinical observations, 1611
clinical protocols, 1611
clinical trials, 617, 788, 1185, 1188, 1191, 1193, 1197, 1200, 1399, 1434, 1598 (ab), 1600 (ab), 1601 (ab), 1611, 1646, 1779, 1781, 1782, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 1998, 2001, 2208
colitis, 572
combination therapy, 1636
comorbidity, 1601 (ab)
continuous passive motion, 1714
cortical bone, 440
cortical thickness, 1598 (ab)
corticosteroid therapy, 1055, 1601 (ab)
cortisol, 1829
C-reactive protein, 1224
Cushing's disease, 1964
cyclosporin A, 1060
cyclosporine, 2163
cytokines, 224, 2114
cytomegalovirus, 2055
depression, 644
dexamethasone, 124
diagnosis, 789, 1020
diffuse idiopathic skeletal hyperostosis, 2062
disability, 270, 1037, 1241, 1466, 1601 (ab), 1834, 2218
disease activity, 639, 844, 850, 1825, 2034
disease modifying antirheumatic drugs, 2200, 2214
disease progression, 855, 1037, 2218
disease severity, 1032, 2027
drug dose-response relationship, 1657, 2072
drug prescriptions, 829, 836
early, 1020, 1037, 1048
endothelium, 2126
enzyme linked immunosorbent assay, 1025
eosinophilia, 1373
epidemiology, 1600 (ab)
Epstein-Barr virus, 1174, 2055
erythrocyte sedimentation rate, 788
Escherichia coli, 1825
estradiol, 421
estrogen receptors, 421
extracellular matrix, 16, 817
family physicians, 2319
fatigue, 639
Felty's syndrome, 174, 1179
fibromyalgia, 270
fibronectins, 817
flow cytometry, 600
folinic acid, 1373
follicles, 394
food, 630
France, 607
functional status, 432, 482, 639, 1037, 1834
fund raising, 1604 (ab)
gamma chain, 812
gamma delta T cells, 812
gastroenteropathy, 444
gastrointestinal bleeding, 1471
gastrointestinal involvement, 2200, 2214
gelatinase-B, 385
genetic factors, 1025, 2203
glomerular mesangium, 427
glomerulonephritis, 427
glucocorticoid therapy, 2214
gold, 572, 1601 (ab), 1657, 2214
gold sodium thiomalate, 190
granulocyte colony stimulating factor, 174, 1179
Greece, 2046
Grip Function Test, 1559
grip strength, 1559
Groningen Activity Restriction Scale, 1834
gynecomastia, 796, 2189
Health Assessment Questionnaire, 1241, 1601 (ab), 1834
health insurance, 2319
health policy, 829
health services accessibility, 2319
hematuria, 427
herpesvirus 6, 2055
Hispanics, 1844
HLA, 1032, 2027, 2034
HLA-DR, 1450
HLA-DRB1, 607, 2027
HLA-DR1, 2046
hyaluronate, 400

hybridization, 275
hydroxychloroquine, 34
immunoconjugates, 207
indomethacin, 444
infection, 1844
inflammation, 850, 1224, 1447, 1461, 1631, 1922, 2004
influenza, 1802
insulin-like growth factor, 275
insulin-like growth factor-I, 1060
interleukin 1 alpha, 600
interleukin 1 beta, 600
interleukin 1 receptor antagonist, 1338
interleukin 4, 2020
interleukin 6, 1224
interleukin 10, 2020
interstitial lung disease, 2163
intramuscular gold, 1600 (ab)
intravenous cyclophosphamide, 1000
joint erosions, 1048
joint repair, 1048
juvenile rheumatoid arthritis, 2114
knee arthroplasty, 482
leukemia, 2356
leukocyte adhesion, 444
leukocyte differentiation antigens, 1326
leukoencephalopathy, 335
lichen planus, 191
lipopolysaccharide binding protein, 1224
Listeria monocytogenes, 786
lung disease, 1043
lymphedema, 214, 370
lymphocytes, 207
lymphoproliferative disorders, 1174
lysis, 24
macrophages, 1624
major histocompatibility complex, 1025
matrix metalloproteinases, 385
matrix metalloproteinase-3, 2004
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1974, 1976, 1983, 1990, 1998, 2001
methotrexate, 38, 41, 218, 224, 335, 569, 630, 633, 786, 790, 796, 844, 1000, 1009, 1043, 1174, 1373, 1439, 1600 (ab), 1636, 1766, 1844, 2072, 2189, 2356, 2359
8-methoxypsoralen, 2126
methylprednisolone, 2065
minocycline, 611
mononuclear cells, 600, 812
morbidity, 1007
mortality, 1007, 1065, 1600 (ab), 1601 (ab), 2200, 2214
multifocal leukoencephalopathy, 777
murine studies, 124
neuropeptides, 1447
neutropenia, 174
neutrophils, 2065
nitric oxide, 1922
nodules, 338
nodulosis, 790, 1439, 2359
nonsteroidal antiinflammatory drugs, 1009, 1471, 2072, 2200, 2214
normal pressure hydrocephalus, 342
North American Indians, 1600 (ab)
OMERACT II Conference, 980, 982, 983, 989, 995, 1403, 1408, 1412, 1415, 1418, 1420, 1431, 1432
one dimensional proton nuclear magnetic resonance imaging, 855
osteoarthritis, 16, 275
osteoporosis, 440, 1055, 1455
outcome assessment, 482, 1241
outcome measures, 186
outpatient care, 1141
pain, 270, 514, 1466
pancytopenia, 1373
paraformaldehyde, 2038
patient care team, 1005
pentoxifylline, 595, 625, 1600 (ab)
pericardial tamponade, 1439
pericarditis, 790
pharmacokinetics, 38, 41, 611, 630, 844, 2072
phenytoin, 1235
phospholipase A_2, 1816, 2114
pituitary hormones, 1829
pituitary microadenoma, 1964
platelet activating factor antagonists, 1651
platelet activating factor-ACETHER, 1651
pleural effusion, 790, 1439
pneumonitis, 1043
polymerase chain reaction, 1624
polymorphonuclear granulocytes, 1436
polymyalgia rheumatica, 1020
polymyositis, 777
predictive factors, 186, 570, 1466, 1844
prednisone, 342
prognosis, 1037, 2186
prolactin, 1829
protease inhibitors, 817
protein 29, 421
proteoglycans, 1338
Proteus mirabilis, 1825
psoralen and ultraviolet A therapy, 3, 29, 2126
psoriasis, 2359
psoriatic arthritis, 1601 (ab), 2359
psychological factors, 514
psychosocial factors, 2218
pulmonary fibrosis, 1766
pyoderma gangrenosum, 1000
quality of life, 270
rabbit studies, 1338, 1714
radical scavenger, 400
radiography, 1048, 1598 (ab)
reference standards, 1241
renal disease, 218
renal function, 34, 38, 2072
reproducibility of results, 1559
reverse transcription, 1624
rheumatoid factor, 570, 2027, 2186, 2203
rheumatology and rheumatologists, 1600 (ab), 2319
risk factors, 1032, 1043
risk-benefits, 1600 (ab)
Sa autoantibodies, 789
scintigraphy, 214
second line drugs, 829, 836
secondary amyloidosis, 569
selectins, 2065
self-assessment, 432, 514
self-injection, 1601 (ab)
sex, 1032, 1065, 1834
sex hormones, 1455
Sharp score, 1598 (ab)
social factors, 644
socioeconomic factors, 432, 514, 1601 (ab)
soluble HLA class I, 1025
soluble tumor necrosis factor receptors, 382
stromelysin, 2004
stromelysin-1, 385
sulfasalazine, 191
superoxide, 633
survival, 1471
synovial cells, 2020
synovial fluid, 8, 24, 413, 812, 1224, 1436
synovial membrane, 124, 400
synoviocytes, 817
synovitis, 3, 29, 1461, 1714, 2126
synovium, 16, 394, 1922
systemic lupus erythematosus, 1604 (ab)
T cell receptor V beta, 394
T cells, 8, 413
T lymphocytes, 1020
Taiwan, 1450, 2034
team management, 1141
^{99m}technetium labelled immunoglobulin G scintigraphy, 850, 1461
tenidap, 444
toxicity, 1600 (ab)
trans-sphenoidal surgery, 1964
treatment, 1600 (ab), 1657
treatment outcome, 836
triamcinolone hexacetonide, 1631
tumor necrosis factor-alpha, 625, 1600 (ab), 1816
twins, 2203
ulcer, 1601 (ab)
United Kingdom, 1825
urokinase-type plasminogen activator, 385
vaccination, 1802
vascular endothelial growth factor, 1624
vasculitis, 1179

Rheumatoid arthritis clinical trials

auranofin, 2208
biological products, 1415
biostatistics, 1191, 1412
Canadian Rheumatology Association Meeting, 1598 (ab), 1600 (ab), 1601 (ab)
classification criteria, 1434
clinical observations, 1611
clinical protocols, 1611
cortical thickness, 1598 (ab)
cost-benefit analysis, 1403, 1408, 1412, 1415
diclofenac, 617
digital imaging, 2001
disease modifying antirheumatic drugs, 1434, 1797
erythrocyte sedimentation rate, 788
European Quality of Life Measure, 1197
gold, 1601 (ab)
health policy, 1188
health status indicators, 1185, 1188, 1203
hydroxyurea, 1646

joint count, 1983
joint damage, 1787
joint erosions, 1048, 1800
joint repair, 1048
Larsen score, 1974, 1976, 1983
mathematical models, 1800
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1779, 1781, 1782, 1783, 1787, 1792, 1797, 1974, 1976, 1983, 1990, 1998, 2001
nonsteroidal antiinflammatory drugs, 1408
OMERACT II Conference, 982, 983, 989, 995, 998, 1185, 1188, 1191, 1193, 1197, 1200, 1203, 1403, 1408, 1412, 1415
osteoarthritis clinical trials, 788, 1193, 1203
outcome assessment, 1403, 1408, 1412, 1415, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 1998, 2001
pentoxifylline, 1600 (ab)
quality of life, 1185, 1191
Quality of Well Being Questionnaire, 1197
radiographic progression, 1797
radiography, 1048, 1598 (ab), 1781, 1782, 1783, 1787, 1792, 1797, 1800, 1974, 1976, 1983, 1990, 1998, 2001
reproducibility of results, 1998
salsalate, 617
self-injections, 1601 (ab)
Sharp score, 1598 (ab), 1792, 1800, 1983
Short Form 36, 1193
slow acting antirheumatic drugs, 2208
treatment, 1611, 2208
tumor necrosis factor-alpha, 1600 (ab)
utility measures, 1197, 1200
West Africa, 1434
Western Ontario and McMaster Universities Osteoarthritis Index, 1193

Rheumatoid factor
disease severity, 2027
genetic factors, 2203
HLA, 2027
HLA-DRB1, 2027
predictive factors, 570
prognosis, 2186
rheumatoid arthritis, 570, 2027, 2186, 2203
twins, 2203

Rheumatology and rheumatologists
antiphospholipid antibody syndrome, 186
arthritis, 573
Canada, 1600 (ab)
Canadian Rheumatology Association Meeting, 1600 (ab), 1603 (ab)
case reports, 2377
continuing medical education, 1603 (ab)
demography, 805, 959
family physicians, 1603 (ab), 2197, 2319
fibromyalgia, 573
health expenditures, 1
health insurance, 2319
health manpower, 805, 959
health services accessibility, 2197, 2319
medical education, 805, 959
methotrexate, 1600 (ab)
musculoskeletal disorders, 573
rheumatic diseases, 1
rheumatoid arthritis, 1600 (ab), 2319
risk-benefits, 1600 (ab)
treatment, 1600 (ab)

Risk factors
age, 1032
disease severity, 1032
HLA, 1032
lung disease, 1043
methotrexate, 1043
pneumonitis, 1043
rheumatoid arthritis, 1032, 1043
sex, 1032

Risk-benefits
Canada, 1600 (ab)
Canadian Rheumatology Association Meeting, 1600 (ab)
methotrexate, 1600 (ab)
rheumatoid arthritis, 1600 (ab)
rheumatology and rheumatologists, 1600 (ab)

Rodnan skin thickness score
modified, 1217, 1271, 1277

Ro(SSA)
autoantigens, 2092
Sjögren's syndrome, 2092
T cell receptor, 2092
T cells, 2092

RS_3PE syndrome
ankylosing spondylitis, 375
HLA-B27, 375
lymphedema, 370

Rupture
pediatric systemic lupus erythematosus, 2344
spleen, 2344
splenomegaly, 2344

Russia
Borrelia burgdorferi, 689
epidemiology, 689
Lyme disease, 689
treatment, 689

S

Sa autoantibodies
diagnosis, 789
rheumatoid arthritis, 789

Sacroiliitis
adenocarcinoma, 970, 1602 (ab)
Canadian Rheumatology Association Meeting, 1602 (ab)
unilateral, 970

Salivary glands
autoimmunity, 1488
biopsy, 133
fibromyalgia, 133
interleukin 2 receptor, 1488
minor, 1488
Sjögren's syndrome, 133

Salmonella
acute anterior uveitis, 1598 (ab)
antibody formation, 1947
Canadian Rheumatology Association Meeting, 1598 (ab)
corticosteroids, 2193
disease outbreaks, 1947
immune response, 1947
immunosuppressive therapy, 2193
infection, 2193
lipopolysaccharide, 1947
reactive arthritis, 1947
systemic lupus erythematosus, 575, 2193
Yersinia, 1598 (ab)

Salmonella typhi
Canadian Rheumatology Association Meeting, 1602 (ab)
dysentery, 1602 (ab)
reactive arthritis, 1602 (ab)
typhoid vaccine, 1602 (ab)

Salsalate
diclofenac, 617
rheumatoid arthritis clinical trials, 617

SAPHO syndrome
enthesis, 2135
nosology, 2017
prognosis, 2135
psoriasis, 2135
pulmonary involvement, 2190
spondyloarthropathy, 2135

Sarcoidosis
corticosteroid therapy, 881
interstitial lung disease, 881
lymphadenopathy, 881
systemic sclerosis, 881

Scintigraphy
lymphedema, 214
rheumatoid arthritis, 214
^{99m}technetium labelled polyclonal human immunoglobulin G, 1461

Scleroderma
adrenocorticotropic hormone, 1603 (ab)
anti-CENP-B, 1286
anti-centromere antibodies, 1286
antinuclear antibodies, 2337
anti-RNA polymerase III antibodies, 557
Arthritis Impact Measurement Scales, 1603 (ab)
Canadian Rheumatology Association Meeting, 1603 (ab)
clinical trials, 1217, 1271, 1277, 1281
cyclosporine, 654
diffuse cutaneous, 654, 1386
disability, 1603 (ab)
disease activity, 654
familial, 85
Functional Index, 1603 (ab)
Gly 26, 1872
hairy cell leukemia, 1384
Health Assessment Questionnaire, 1603 (ab)
HLA, 67, 85, 1872
hypertension, 557
immunogenetics, 85, 1872
interleukin 1 beta, 654
limited cutaneous, 469, 654
linear, 73
major histocompatibility complex, 85
modified Rodnan skin thickness score, 1217, 1271, 1277, 1281
morphea, 2337
mortality, 2100
myasthenia gravis, 792

myofibroblasts, 1876
nucleolus organizer region-90 antigen, 67
observer variation, 1217, 1271, 1277, 1281
outcome assessment, 1603 (ab)
pediatric, 2337
pericardial effusion, 1386
peripheral vascular disease, 469
pigmentation, 1603 (ab)
platelet derived growth factor, 1876
polymyositis, 1384
pulmonary fibrosis, 1876
renal failure, 557
silica, 1286
silicone implants, 236, 1872
skin thickness, 1217, 1271, 1277, 1281
soluble interleukin 2 receptor, 654
systemic sclerosis, 67, 557, 2100
transforming growth factor-beta 1, 1876
Tyr 26, 1872
vasculitis, 469, 1386
Second line drugs
Canada, 836
drug prescriptions, 836
rheumatoid arthritis, 836
treatment outcome, 836
Secondary amyloidosis
methotrexate, 569
rheumatoid arthritis, 569
Seizures
hypocalcemia, 2156
hypoparathyroidism, 2156
pediatric systemic lupus erythematosus, 2156
Selectins
cell adhesion molecules, 2065
methylprednisolone, 2065
neutrophils, 2065
rheumatoid arthritis, 2065
Selenium
antioxidants, 103
fatty acids, 103
psoriatic arthritis, 103
red blood cells, 103
Self-assessment
functional status, 432
pain, 514
psychological factors, 514
rheumatoid arthritis, 432, 514
socioeconomic factors, 432, 514
Self-injections
Canadian Rheumatology Association Meeting, 1601 (ab)
gold, 1601 (ab)
rheumatoid arthritis clinical trials, 1601 (ab)
Sepsis
agranulocytosis, 1803
Felty's syndrome, 1803
granulocyte colony stimulating factor, 1803
Septic arthritis
emphysematous, 1776
Escherichia coli, 1776
fishes, 1607
knee, 1776
Moraxella, 578
Mycobacterium marinum, 1607
Seronegative enthesopathy and arthropathy
atlantoaxial subluxation, 548
juvenile spondyloarthropathies, 548
Seronegative spondyloarthropathies
aged, 899
HLA-B27, 899
late onset, 899
pitting edema, 899
Serositis
arthropathy, 2349
camptodactyly, 2349
genetic factors, 2349
pericarditis, 2349
pleuritis, 2349
SERP-1 protein
antigen induced arthritis, 1605 (ab)
Canadian Rheumatology Association Meeting, 1605 (ab)
inflammation, 1605 (ab)
rabbit studies, 1605 (ab)
Sex
age, 794, 1032
ankylosing spondylitis, 794
cardiovascular disease, 1065
disability, 1834
disease onset, 794
disease severity, 1032
fibromyalgia, 151
functional status, 1834
genetic factors, 794
Groningen Activity Restriction Scale, 1834
Health Assessment Questionnaire, 1834
HLA, 1032
mortality, 1065
pain, 151
population studies, 151
rheumatoid arthritis, 1032, 1065, 1834
risk factors, 1032
spondyloarthropathies, 794
tender points, 151
Sex hormones
bone mineral density, 1455
oral contraceptives, 2159
osteoporosis, 1455
pediatric systemic lupus erythematosus, 2159
rheumatoid arthritis, 1455
skin manifestations, 2159
Sex ratio
ankylosing spondylitis, 1607
epidemiology, 1607
Sharp score
Canadian Rheumatology Association meeting, 1598 (ab)
cortical thickness, 1598 (ab)
joint count, 1983
joint erosions, 1800
Larsen score, 1983
mathematical models, 1800
Methods of Scoring Radiographic Changes in Rheumatoid Arthritis Symposium, 1792, 1983
outcome assessment, 1792, 1800, 1983
radiography, 1598 (ab), 1792, 1800, 1983
rheumatoid arthritis clinical trials, 1598 (ab), 1792, 1983
Short Form 36
OMERACT II Conference, 1193
osteoarthritis clinical trials, 1193
rheumatoid arthritis clinical trials, 1193
Western Ontario and McMaster Universities Osteoarthritis Index, 1193
Shoulder
functional status, 727
hemarthrosis, 574
hypercalcemia, 561
hyperparathyroidism, 561
Milwaukee, 561
pain, 727
Shoulder Pain and Disability Index, 727
vitamin C, 574
Shoulder Pain and Disability Index
functional status, 727
pain, 727
shoulder, 727
Sicca syndrome
Canadian Rheumatology Association Meeting, 1604 (ab)
diagnosis, 1604 (ab)
keratoconjunctivitis sicca, 1604 (ab)
Sjögren's syndrome, 1604 (ab)
xerostomia, 1604 (ab)
Silica
anti-CENP-B, 1286
anti-centromere antibodies, 1286
scleroderma, 1286
Silicone implants
antinuclear antibodies, 236
autoimmunity, 236
breast, 198, 236
connective tissue disease, 198
Gly 26, 1872
HLA, 1872
immunogenetics, 1872
scleroderma, 236, 1872
Sjögren's syndrome, 198, 236
systemic sclerosis, 198
Tyr 26, 1872
Single photon emission computed tomography
brain abnormalities, 1247
neuropsychiatric systemic lupus erythematosus, 1247
Sjögren's syndrome
annexins, 97
anti-Fc gamma receptor autoantibodies, 2241
autoantigens, 2092
autoimmunity, 1488
biopsy, 133
bowel, 2375
breast, 198
Canadian Rheumatology Association Meeting, 1604 (ab)
connective tissue disease, 198
Copenhagen criteria, 659
cytokines, 1674
C5 deficiency, 1389
diagnosis, 1604 (ab)
Fc gamma receptor, 2241
fibromyalgia, 133
hypokalemia, 2366

interleukin 2 receptor, 1488
interleukin 12, 1674
ischemia, 2375
keratoconjunctivitis sicca, 1604 (ab)
lymphoma, 1674
minor salivary glands, 1488
modified San Diego criteria, 659
pediatric, 1152
polymorphonuclear cells, 2241
prevalence studies, 659
primary, 133, 659, 1389, 2375
renal acidosis, 2366
renal involvement, 2366
Ro(SSA), 2092
salivary glands, 133
sicca syndrome, 1604 (ab)
silicone implants, 198, 236
systemic sclerosis, 198
T cell receptor, 2092
T cells, 2092
vasculitis, 2375
xerostomia, 1604 (ab)
Skin manifestations
Canadian Rheumatology Association Meeting, 1599 (ab)
cytomegalovirus, 1599 (ab)
keratinocytes, 1599 (ab)
oral contraceptives, 2159
pediatric systemic lupus erythematosus, 2159
sex hormones, 2159
systemic lupus erythematosus, 1599 (ab)
Skin thickness
modified Rodnan skin thickness score, 1271, 1277, 1281
observer variation, 1271, 1277, 1281
scleroderma, 1217, 1271, 1277, 1281
Sleep
fibromyalgia, 1138
growth hormone, 1138
insulin like growth factor-I, 1138
Sleep disorders
Canadian Rheumatology Association Meeting, 1604 (ab)
exercise, 1604 (ab)
fibromyalgia, 1604 (ab)
pain, 1604 (ab)
Slow acting antirheumatic drugs
auranofin, 2208
disease modifying antirheumatic drugs, 201
International League of Associations for Rheumatology, 201
osteoarthritis, 201
outcome measures, 201
rheumatoid arthritis clinical trials, 2208
treatment, 2208
World Health Organization, 201
Social factors
anxiety, 644
depression, 644
rheumatoid arthritis, 644
Socioeconomic factors
Canadian Rheumatology Association Meeting, 1601 (ab)
comorbidity, 1601 (ab)
corticosteroid therapy, 1601 (ab)
disability, 505
functional status, 432
mortality, 1601 (ab)
musculoskeletal disorders, 505
pain, 514
psychological factors, 514
rehabilitation, 505
rheumatoid arthritis, 432, 514, 1601 (ab)
self-assessment, 432, 514
Soluble HLA class I
enzyme linked immunosorbent assay, 1025
genetic factors, 1025
major histocompatibility complex, 1025
rheumatoid arthritis, 1025
Soluble interleukin 2 receptor
cyclosporine, 654
disease activity, 654
interleukin 1 beta, 654
scleroderma, 654
Soluble interleukin 2 receptors
osteoarthritis, 406
reactive arthritis, 406
rheumatoid arthritis, 406
Soluble tumor necrosis factor receptors
growth factors, S43–115
inflammatory arthritis, 382
osteoarthritis, 406, S43–115
reactive arthritis, 406
rheumatoid arthritis, 382, 406
synovial fibroblasts, S43–115
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–115
Somatomedin C
See also insulin like growth factor-I
Spermidine
alkaline phosphatase, 1907
calcium pyrophosphate dihydrate crystal deposition disease, 1907
pyrophosphatases, 1907
spermine, 1907
Spermine
alkaline phosphatase, 1907
calcium pyrophosphate dihydrate crystal deposition disease, 1907
pyrophosphatases, 1907
spermidine, 1907
Spine
aged, 932
aging, 1934
Australia, 1934
bone mineral density, 932
disability, 1934
epidemiology, 1934
Europe, 1934
musculoskeletal disorders, 1934
North America, 1934
osteoarthritis, 932
Spleen
pediatric systemic lupus erythematosus, 2344
rupture, 2344
splenomegaly, 2344
Splenomegaly
pediatric systemic lupus erythematosus, 2344
rupture, 2344
spleen, 2344
Spondyloarthropathies
age, 794
Amor criteria, 246
ankylosing spondylitis, 2266, 2273, 2279
anterior uveitis, 1112, 1602 (ab)
aortic regurgitation, 332
bowel inflammation, 1112
Canadian Rheumatology Association Meeting, 1601 (ab), 1602 (ab)
classification criteria, 246
diagnostic criteria, 246
disease onset, 794
epidemiology, 1884
European Spondylarthropathy Study Group criteria, 246
genetic factors, 794
gut, 2266, 2273, 2279
gut inflammation, 680
HLA, 1884
HLA-B27, 332, 1602 (ab)
HLA-DR4 alleles, 1601 (ab)
inflammation, 2266, 2273, 2279
inflammatory bowel disease, 2266, 2273, 2279
methotrexate, 1104
pediatric, 332
prognosis, 2266, 2273, 2279
psoriatic arthritis, 680, 1601 (ab)
sex, 794
Standard gamble
fibromyalgia, 1536
outcome assessment, 1536
rating scale, 1536
reproducibility of results, 1536
Staphylococcus aureus
Bacillus Calmette-Guérin, 1441
bladder cancer, 1441
Steroid therapy
methotrexate, 1442
nephritis, 1442
systemic lupus erythematosus, 1442
Still's disease
adult onset, 180
cardiac tamponade, 180
pericarditis, 180
Streptococcus pyogenes
pediatric reactive arthritis, 529
rheumatic fever, 529
rheumatic heart disease, 529
Stress fractures
hydrarthrosis, 1804
tibia, 1804
Stroke
extremities, 363
gangrene, 363
giant cell arteritis, 363
temporal arteritis, 363
Stromelysin
inflammation, 2004
matrix metalloproteinase-3, 2004
rheumatoid arthritis, 2004
Stromelysin-1
gelatinase-B, 385
matrix metalloproteinases, 385
rheumatoid arthritis, 385

urokinase-type plasminogen activator, 385
Subchondral bone
bone mineral density, S43–98
osteoarthritis, S43–98
osteoporosis, S43–98
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–98
Sulfasalazine
Canadian Rheumatology Association Meeting, 1601 (ab)
lichen planus, 191
psoriatic arthritis, 894, 1601 (ab)
rheumatoid arthritis, 191
toxicity, 1601 (ab)
Superoxide
methotrexate, 633
rheumatoid arthritis, 633
Suprapatellar tendinitis
Achilles tendinitis, 2009
isotretinoin, 2009
Survival
gastrointestinal bleeding, 1471
nonsteroidal antiinflammatory drugs, 1471
rheumatoid arthritis, 1471
Sweden
Borrelia burgdorferi, 695
epidemiology, 695
Lyme disease, 695
Swelling
fingers, 2374
pachydermodactyly, 2374
peripheral interphalangeal joints, 2374
Synovial cells
interleukin 4, 2020
interleukin 10, 2020
rheumatoid arthritis, 2020
Synovial cysts
juvenile rheumatoid arthritis, 1953
ultrasonography, 1953
Synovial fibroblasts
growth factors, S43–115
osteoarthritis, S43–115
soluble tumor necrosis factor receptors, S43–115
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–115
Synovial fluid
aggrecan, S43–71, S43–75
apatite crystals, S43–101
bone, S43–71
calcium pyrophosphate dihydrate crystals, S43–101
canine studies, 1732
caprine arthritis encephalitis virus, 8
caprine studies, 8
cartilage, S43–71, S43–75
cartilage destruction, 1436
CD69, 413
C-reactive protein, 1224
gamma chain, 812
gamma delta T cells, 812
hyaluronic acid, 1732, S43–68
inflammation, 1224
interleukin 6, 1224
keratan sulfate, S43–68
knee osteoarthritis, 1732
lipopolysaccharide binding protein, 1224
mononuclear cells, 812
naproxen, 2295
nonsteroidal antiinflammatory drugs, 2295
osteoarthritis, S43–68, S43–71, S43–75, S43–101
pharmacokinetics, 2295
polymorphonuclear granulocytes, 1436
prostaglandins, 2295
rheumatic diseases, 2295
rheumatoid arthritis, 8, 24, 413, 812, 1224, 1436
T cells, 413
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–68, S43–71, S43–75, S43–101
Synovial membrane
adjuvant arthritis, 124
dexamethasone, 124
hyaluronate, 400
murine studies, 124
radical scavenger, 400
rheumatoid arthritis, 124, 400
Synoviocytes
extracellular matrix, 817
fibronectins, 817
protease inhibitors, 817
rheumatoid arthritis, 817
Synovitis
adhesion molecules, 2126
antigen induced arthritis, 1714
arthroscopy, 29
articular cartilage, 1714
continuous passive motion, 1714
endothelium, 2126
inflammation, 1461
8-methoxypsoralen, 2126
psoralen and ultraviolet A therapy, 29, 2126
rabbit studies, 1714
rheumatoid arthritis, 3, 29, 1461, 1714, 2126
^{99m}technetium labelled immunoglobulin G scintigraphy, 1461
Synovium
alpha V integrin, 16
canine studies, 262
cartilage, 1922
extracellular matrix, 16
follicles, 394
hemarthrosis, 552
hyaluronic acid, 262
inflammation, 1922
knee, 552
nitric oxide, 1922
osteoarthritis, 16, 262
rheumatoid arthritis, 16, 394, 1922
T cell receptor V beta, 394
Syphilis
anticardiolipin antibodies, 1894
antiphospholipid antibody syndrome, 1894
beta$_2$ glycoprotein I, 1894
Systemic Lupus Activity Measure
disease activity, 45
systemic lupus erythematosus, 45
Systemic lupus erythematosus
aging, 1007
anaerobic threshold, 1483
anemia, 2166
annexins, 97
anti-beta$_2$ glycoprotein I antibodies, 2233
anticardiolipin antibodies, 62, 227, 649, 1091, 2233
anti-Clq antibodies, 1669
antiendothelial cell antibodies, 1669
anti-idiotype antibodies, 1075
anti-La(SSB) antibodies, 868
antineutrophil cytoplasmic antibodies, 1669
antiphospholipid antibodies, 62
antiphospholipid antibody syndrome, 62, 1068, 1091, 1899, 2173, 2233
antiribosomal PO protein antibodies, 1681
anti-Ro(SSA) antibodies, 868
aplasia, 2166
The Arthritis Society, 1604 (ab)
arthroscopy, 1722
avascular necrosis of bone, 347, 1604 (ab)
beta$_2$ glycoprotein I, 1091
Blacks, 1663
bladder, 2373
blood platelets, 649
bone marrow transplantation, 1809
bone mineral density, 2238
brain abnormalities, 1247
breast, 1214
bromocriptine, 2084
calciphylaxis, 177
calcitonin, 2238
Canadian Rheumatology Association Meeting, 1599 (ab), 1602 (ab), 1604 (ab)
cancer, 1606
carcinoma, 2170
cardiomyopathy, 177
Caucasians, 1663, 1852, 1862
cause of death, 1259
CD4, 347
central nervous system, 863
central nervous system involvement, 1681
cerebral infarction, 1210
cholesterol, 450
clinical trials, 1602 (ab)
coagulopathy, 2173
cofactors, 1091
cognitive impairment, 863, 2187
congenital complete heart block, 533
corticosteroids, 2193
cyclophosphamide, 1812
cystitis, 2373
cytomegalovirus, 1599 (ab)
C4AQ0, 1862
danazol, 1867
depression, 2187
diagnosis, 1604 (ab)
diet therapy, 450
disease activity, 45, 189, 863, 1602 (ab), 2078
disease severity, 189
drug induced, 574, 1001
dyspnea, 455
endometrium, 1606

epidemiology, 1663
erythropoietin, 2166
Evans' syndrome, 1867
exercise, 455, 1483
familial, 1852, 1862
functional status, 1602 (ab)
fund raising, 1604 (ab)
genetic factors, 1852, 1862
gigantism, 1214
glomerulonephritis, 801
glucocorticoid therapy, 2238
haplotypes, 1852
health care costs, 189
hemolytic anemia, 1867
herpes simplex II, 799
herpes zoster, 1254
HLA, 1589, 1852
human immunodeficiency virus, 347
hydrochlorothiazide, 1001
hydroxychloroquine, 868, 1602 (ab)
hypergammaglobulinemic purpura, 868
hyperlipidemia, 450
hypocomplementemia, 1669
IgG, 2233
immunosuppressive therapy, 1478, 2193
indomethacin, 868
infection, 2193
interstitial lung disease, 967
intravenous gamma globulin, 1068
keratinocytes, 1599 (ab)
lactate dehydrogenase, 649
leukotrienes, 462
5-lipoxygenase, 462
Lupus Activity Index, 2078
lupus nephritis, 801, 1075, 1211
major histocompatibility complex, 1852
mastitis, 344
methotrexate, 967, 1442
methylprednisolone, 2373
morbidity, 1007
mortality, 1007, 1259, 1265, 1663
murine studies, 1068
muscle, 1483
myocardial infarction, 1210
neonatal lupus, 541
neoplasms, 1478
nephritis, 1442
neuropsychiatric, 1247, 2187
neuropsychologic factors, 863
osteoporosis, 2238
outcome assessment, 1602 (ab)
ovarian abscess, 575
oxygen, 1483
pancreas, 2170
panniculitis, 344, 2170
PDN-21, 2238
pediatric, 1347, 1352, 1365, 1438, 2156, 2344
phenotypes, 1862
predictive factors, 1265
prednisolone, 2373
prednisone, 868
primary antiphospholipid antibody syndrome, 1589
prognosis, 1259
prolactin, 2084
pulmonary function, 455
pulmonary involvement, 62
radiography, 1604 (ab)
renal biopsy, 1211
rheumatoid arthritis, 1604 (ab), 1809
risk factors, 1254
Salmonella, 575, 2193
sensitivity and specificity, 2078
single photon emission computed tomography, 1247
skin manifestations, 1599 (ab)
steroid therapy, 1442
Systemic Lupus Activity Measure, 45, 2078
Systemic Lupus Erythematosus Disease Activity Index, 2078
T cells, 347
tamoxifen, 1606
thrombocytopenia, 1867
treatment, 189
urticarial vasculitis, 1669
vasculitis, 177, 2173, 2373
zileuton, 462

Systemic lupus erythematosus clinical trials
adverse effects, 1812
Canadian Rheumatology Association Meeting, 1602 (ab)
cyclophosphamide, 1812
disease activity, 1602 (ab)
hydroxychloroquine, 1602 (ab)
lupus nephritis, 1812
renal function, 1812

Systemic sclerosis
aging, 1007
annexins, 97
anti-CENP-B, 1286
anticentromere antibodies, 1286
antineutrophil cytoplasmic antibodies, 791
anti-RNA polymerase III antibodies, 557
anti-tissue type plasminogen activator antibodies, 1688
bone resorption, 797
breast, 198
connective tissue disease, 198, 2226
corticosteroid therapy, 881
creatinine, 797
disease activity, 1440
familial, 85
fibrin, 1688
hairy cell leukemia, 1384
HLA, 67
hypertension, 557
interstitial lung disease, 881
ischemia, 374
lymphadenopathy, 881
8-methoxypsoralen and ultraviolet A radiation, 2361
microscopy, 2226
modified Rodnan skin thickness score, 1277, 1281
modified skin thickness score, 1271
morbidity, 1007
mortality, 1007, 2100
muscle involvement, 2246
nailfold capillaries, 2226
neural cell adhesion molecule, 2246
neurogenic involvement, 2246
nucleolus organizer region-90 antigen, 67
observer variation, 1217, 1271, 1277, 1281
pediatric scleroderma, 2337
polymyositis, 1384
primary Raynaud's phenomenon, 374
pyridinium, 797
Raynaud's phenomenon, 2226
renal failure, 557, 791
reperfusion, 374
sarcoidosis, 881
scleroderma, 67, 85, 198, 236, 469, 557, 654, 792, 1217, 1271, 1277, 1281, 1286, 1384, 1386, 1603 (ab), 1872, 1876, 2100
silica, 1286
silicone implants, 198, 236
Sjögren's syndrome, 198
skin thickness, 1271, 1277, 1281
thrombomodulin, 1440
tissue type plasminogen activator, 1688
treatment, 2361
vascular damage, 1440

T

T cell receptor
autoantigens, 2092
HLA, 1356
juvenile rheumatoid arthritis, 1356
Ro(SSA), 2092
Sjögren's syndrome, 2092
T cells, 2092

T cell receptor V beta
follicles, 394
rheumatoid arthritis, 394
synovium, 394

T cells
antiphospholipid antibodies, 2006
antiphospholipid antibody syndrome, 2006
autoantigens, 2092
avascular necrosis of bone, 347
caprine studies, 8
CD4, 347
CD69, 413
human immunodeficiency virus, 347
IgG, 2006
murine studies, 2006
rheumatoid arthritis, 8, 413
Ro(SSA), 2092
Sjögren's syndrome, 2092
synovial fluid, 413
systemic lupus erythematosus, 347
T cell receptor, 2092

T lymphocytes
CD8, 1020
diagnosis, 1020
polymyalgia rheumatica, 1020
rheumatoid arthritis, 1020

Taiwan
disease activity, 2034
HLA, 2034
HLA-DR, 1450
rheumatoid arthritis, 1450, 2034

Takayasu's arteritis
clubbing, 2346
disease activity, 478
fingers, 2346
hypertrophic osteoarthropathy, 2346
indium-III, 478

leukocytes, 478
Tamoxifen
cancer, 1606
endometrium, 1606
systemic lupus erythematosus, 1606
Team management
chronic inflammatory arthritis, 1141
outpatient care, 1141
^{99m}Technetium labelled immunoglobulin G scintigraphy
inflammation, 850, 1461
inflammatory arthritis, 850
polyclonal human, 1461
rheumatoid arthritis, 850, 1461
synovitis, 1461
Temporal arteritis
Churg-Strauss syndrome, 2177
diagnosis, 774
extremities, 363
gangrene, 363
giant cell arteritis, 363, 367, 2177
juvenile, 774
lung cancer, 367
neoplasms, 2177
stroke, 363
vasa vasorum vasculitis, 2177
Temporal artery
biopsy, 93
giant cell arteritis, 93
predictive factors, 93
Temporomandibular joint
computed tomography, 1956
juvenile rheumatoid arthritis, 1956
orthodontic assessment, 1956
Tender Point Count
biostatistics, 2307
disease activity, 2307
fibromyalgia clinical trials, 2307
McGill Pain Questionnaire, 2307
Myalgic Score, 2307
outcome measures, 2307
Tender points
dolorimetry, 944
fibromyalgia, 151, 944
myofascial pain, 944
pain, 151, 944
palpation, 944
sex, 151
Tenderness
fibromyalgia, 525
outcome assessment, 525
Tendinitis
Achilles, 2009
isotretinoin, 2009
suprapatellar, 2009
Tenidap
adjuvant arthritis, 1726
flurbiprofen, 1726
gastroenteropathy, 444
indomethacin, 444
inflammatory arthritis, 444
leukocyte adhesion, 444
metalloproteinase, 1726
rheumatoid arthritis, 444
tetracycline, 1726
Tetracycline
adjuvant arthritis, 1726
flurbiprofen, 1726
metalloproteinase, 1726
tenidap, 1726
The Arthritis Society
Canadian Rheumatology Association Meeting, 1604 (ab)
fund raising, 1604 (ab)
rheumatoid arthritis, 1604 (ab)
systemic lupus erythematosus, 1604 (ab)
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–1–160
aggrecans, S43–71, S43–75, S43–86
American College of Rheumatology criteria, S43–42, S43–44
antirheumatic drugs, S43–152
apatite crystals, S43–101
aptamers, S43–62
articular cartilage, S43–13, S43–28, S43–52, S43–129, S43–133, S43–146, S43–149, S43–155
biomechanical factors, S43–10
bone, S43–71
bone mineral density, S43–98
calcium pyrophosphate dihydrate crystal, S43–101
cartilage, S43–60, S43–71, S43–75, S43–78, S43–82, S43–91
cartilage volume, S43–120
chondrocytes, S43–104, S43–152
chondroitin sulfate, S43–158
collagen, S43–34, S43–82, S43–94, S43–140
collagen genes, S43–28, S43–34, S43–37, S43–39
conclusion, S43–160
cytokines, S43–109
disability, S43–16, S43–19, S43–136
disease progression, S43–56
doxycycline, S43–149
epidemiology, S43–16, S43–19, S43–44, S43–50
etiology, S43–3
exercise, S43–3
fibronectins, S43–158
gangliosides, S43–133
gastroprotective agents, S43–26
gene therapy, S43–140
growth factors, S43–115, S43–129
health care costs, S43–23
health services utilization, S43–19
hyaluronic acid, S43–68, S43–155, S43–158
IgG, S43–62
interleukin 1, S43–104, S43–123
International League of Associations for Rheumatology, S43–2
introduction, S43–1
keratan sulfate, S43–68, S43–155
magnetic resonance imaging, S43–52, S43–60
metalloproteases, S43–109, S43–123
metalloproteinases, S43–86
molecular markers, S43–78
murine studies, S43–39
nonsteroidal antiinflammatory drugs, S43–26
obesity, S43–7
occupations, S43–10
osteoarthritis, S43–1–160
osteoarthritis clinical trials, S43–49
osteochondrodysplasia, S43–39
osteophytes, S43–143
osteoporosis, S43–98
outcome assessment, S43–49
ovine studies, S43–155
pain, S43–136
pentosan polysulfate, S43–146
plasminogen activators, S43–120
predictive factors, S43–7, S43–10
prescribing practices, S43–26
prostaglandins, S43–123
proteoglycan synthesis, S43–91, S43–143, S43–152
proteoglycans, S43–94, S43–158
proteolysis, S43–82
radiography, S43–50, S43–56
running, S43–13
soluble tumor necrosis factor receptors, S43–115
spondyloepiphyseal dysplasia, S43–37
subchondral bone, S43–98
synovial fibroblasts, S43–115
synovial fluid, S43–68, S43–71, S43–75, S43–78, S43–101
synovial joint, S43–13
tissue inhibitor of metalloprotease, S43–123, S43–146
transforming growth factor-beta, S43–104, S43–143
transgenic mice, S43–140
treatment, S43–136
ulcer, S43–26
urokinase, S43–120
Women's Health and Aging Study, S43–16
World Health Organization, S43–2
Thrombocytopenia
danazol, 1867
Evans' syndrome, 1867
hemolytic anemia, 1867
systemic lupus erythematosus, 1867
Thrombosis
anticardiolipin antibodies, 2007
cancer, 2007
kidneys, 2007
protein S, 2007
Thyroiditis
drug induced systemic lupus erythematosus, 574
procainamide, 574
Th1 cells
Canadian Rheumatology Association Meeting, 1602 (ab)
interleukin 2, 1602 (ab)
NZB mice, 1602 (ab)
Tiaprofenic acid
indomethacin, 1941
knee osteoarthritis, 1941
radiographic progression, 1941
Tibia
hydrarthrosis, 1804
stress fractures, 1804
Tissue inhibitor of metalloprotease
articular cartilage, S43–146
interleukin 1, S43–123
metalloproteases, S43–123
osteoarthritis, S43–123, S43–146

pentosan polysulfate, S43–146
prostaglandins, S43–123
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–123, S43–146
Tissue type plasminogen activator
anti-tissue type plasminogen activator antibodies, 1688
fibrin, 1688
systemic sclerosis, 1688
Total hip arthroplasty
ankylosing spondylitis, 1704
collagenases, 2285
heterotopic ossification, 1704
metalloproteinases, 2285
prosthesis, 2285
Toxic oil syndrome
myalgia, 282
neuropathy, 282
Toxicity
Canadian Rheumatology Association Meeting, 1600 (ab), 1601 (ab)
intramuscular gold, 1600 (ab)
psoriatic arthritis, 1601 (ab)
rheumatoid arthritis, 1600 (ab)
sulfasalazine, 1601 (ab)
Transforming growth factor-beta
articular cartilage, 1605 (ab)
Canadian Rheumatology Association Meeting, 1605 (ab)
chondrocytes, S43–104
high molecular weight anionic glycoconjugate, 1605 (ab)
interleukin 1, S43–104
osteoarthritis, 1605 (ab), S43–104, S43–143
osteophytes, S43–143
proteoglycan synthesis, S43–143
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–104, S43–143
Transforming growth factor-beta 1
myofibroblasts, 1876
platelet derived growth factor, 1876
pulmonary fibrosis, 1876
scleroderma, 1876
Transgenic mice
collagen, S43–140
gene therapy, S43–140
osteoarthritis, S43–140
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–140
Trans-sphenoidal surgery
Cushing's disease, 1964
pituitary microadenoma, 1964
rheumatoid arthritis, 1964
Trauma
disability, 372
fibromyalgia, 372
psoriasis, 783
psoriatic arthritis, 783
reflex sympathetic dystrophy, 783
Treatment
auranofin, 2208
behavior therapy, 717
Borrelia burgdorferi, 689
Canada, 1600 (ab)
Canadian Rheumatology Association Meeting, 1600 (ab)
clinical observations, 1611
clinical protocols, 1611
colchicine, 1618, 1621
disability, S43–136
disease activity, 189
disease severity, 189
drug dose-response relationship, 1657
early, 2208
eosinophilia-myalgia syndrome, 161
eosinophilia-myalgia syndrome workshop, 161
epidemiology, 689
fibromyalgia, 713
gold, 1657
health care costs, 189
hyperuricemia, 1618, 1621
L-tryptophan, 161
Lyme disease, 689
8-methoxypsoralen and ultraviolet A radiation, 2361
nontophaceous interval gout, 1618, 1621
osteoarthritis, S43–136
pain, S43–136
rheumatoid arthritis, 1600 (ab), 1657
rheumatoid arthritis clinical trials, 1611, 2208
rheumatology and rheumatologists, 1600 (ab)
Russia, 689
slow acting antirheumatic drugs, 2208
systemic lupus erythematosus, 189
systemic sclerosis, 2361
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–136
Treatment outcome
Canada, 836
drug prescriptions, 836
rheumatoid arthritis, 836
second line drugs, 836
Tremor
eosinophilia-myalgia syndrome, 157
myoklonus, 157
myokymia, 157
neurologic involvement, 157
Triamcinolone hexacetonide
inflammation, 1631
rheumatoid arthritis, 1631
Tuberculosis
immunosuppressive therapy, 1321
soft tissue, 1321
Tumor necrosis factor
inflammatory arthritis, 382
osteoarthritis, 406
reactive arthritis, 406
rheumatoid arthritis, 382, 406
soluble receptors, 382, 406
Tumor necrosis factor receptors
Canadian Rheumatology Association Meeting, 1599 (ab)
cell activation, 1599 (ab)
osteoarthritis, 1599 (ab)
tumor necrosis factor-alpha, 1599 (ab)
Tumor necrosis factor-alpha
CAMPATH-1H, 1816
Canadian Rheumatology Association Meeting, 1599 (ab), 1600 (ab)
cartilage, 2250
cell activation, 1599 (ab)
immune complex arthritis, 2250
interferon-gamma, 1698
interleukin 1, 2250
murine studies, 2250
osteoarthritis, 1599 (ab)
pentoxifylline, 625, 1600 (ab)
phospholipase A_2, 1816
polymyositis, 1698
proteoglycan degradation, 2250
proteoglycan synthesis, 2250
rheumatoid arthritis, 625, 1816
rheumatoid arthritis clinical trials, 1600 (ab)
tumor necrosis factor receptors, 1599 (ab)
Twins
genetic factors, 2203
rheumatoid arthritis, 2203
rheumatoid factor, 2203
Typhoid vaccine
Canadian Rheumatology Association Meeting, 1602 (ab)
dysentery, 1602 (ab)
reactive arthritis, 1602 (ab)
Salmonella typhi, 1602 (ab)
Tyr 26
Gly 26, 1872
HLA, 1872
immunogenetics, 1872
scleroderma, 1872
silicone implants, 1872

U

Ulcer
Canadian Rheumatology Association Meeting, 1601 (ab)
disability, 1601 (ab)
gastroprotective agents, S43–26
Health Assessment Questionnaire, 1601 (ab)
nonsteroidal antiinflammatory drugs, S43–26
prescribing practices, S43–26
psoriatic arthritis, 1601 (ab)
rheumatoid arthritis, 1601 (ab)
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–26
Ultrasonography
juvenile rheumatoid arthritis, 1953
synovial cysts, 1953
Ultrasound
cartilage thickness, 109
high frequency, 109
osteoarthritis, 109
Unilateral sacroiliitis
adenocarcinoma, 970
United Kingdom
Bermuda, 1825
disease activity, 1825
Escherichia coli, 1825
Proteus mirabilis, 1825
rheumatoid arthritis, 1825
Urate lowering drugs
Canada, 908

cost-benefit analysis, 908
gouty arthritis, 908
Urokinase
cartilage volume, S43–120
osteoarthritis, S43–120
plasminogen activators, S43–120
receptors, S43–120
Third Symposium on Osteoarthritis: Challenges for the 21st Century, S43–120
Urokinase-type plasminogen activator
gelatinase-B, 385
matrix metalloproteinases, 385
rheumatoid arthritis, 385
stromelysin-1, 385
Urticarial vasculitis
anti-Clq antibodies, 1669
antiendothelial cell antibodies, 1669
antineutrophil cytoplasmic antibodies, 1669
hypocomplementemia, 1669
systemic lupus erythematosus, 1669
Utility measures
European Quality of Life Measure, 1197
OMERACT II Conference, 1197, 1200
Quality of Well Being Questionnaire, 1197
rheumatoid arthritis clinical trials, 1197, 1200
Uveitis
anterior, 1112
bowel inflammation, 1112
spondyloarthropathies, 1112

V

Vaccination
autoimmunity, 1802
influenza, 1802
rheumatoid arthritis, 1802
Vasa vasorum vasculitis
Churg-Strauss syndrome, 2177
giant cell arteritis, 2177
neoplasms, 2177
temporal arteritis, 2177
Vascular abnormalities
hemarthrosis, 552
Vascular disease
peripheral, 469
Vascular endothelial growth factor
macrophages, 1624
polymerase chain reaction, 1624
reverse transcription, 1624
rheumatoid arthritis, 1624
Vascular insufficiency
anorexia nervosa, 544
fingers, 544
osteonecrosis, 544
Vascular thrombosis
anticardiolipin antibodies, 1380
antiphospholipid antibody syndrome, 1380
cutaneous necrosis, 1380
Vasculitis
angioendotheliomatosis, 1769
anti-Clq antibodies, 1669
antiendothelial cell antibodies, 1669
antiphospholipid antibody syndrome, 554, 2173
arthralgia, 497
bladder, 2373
bowel, 2375
cardiac involvement, 78
central nervous system, 1769, 2371
cerebral, 2173
Churg-Strauss syndrome, 2177
coagulopathy, 2173
cystitis, 2373
cytoxan, 1769
digital subtraction angiography, 2371
eosinophilic fasciitis, 356
Felty's syndrome, 1179
fingers, 356
gangrene, 356
giant cell arteritis, 566, 2177
granulocyte colony stimulating factor, 1179
granulomatous, 566
hypocomplementemia, 1669
ischemia, 2375
juvenile dermatomyositis, 1369
lymphoma, 1769
methylprednisolone, 2373
necrotizing, 78
neoplasms, 566, 2177
neuropathy, 1369
panniculitis, 497
pericardial effusion, 1386
peripheral vascular disease, 469
polyarteritis nodosa, 78
prednisolone, 2373
primary angiitis, 2371
primary Sjögren's syndrome, 2375
prostate, 566
pulmonary, 554
renal involvement, 78
rheumatoid arthritis, 1179
scleroderma, 469, 1386
systemic lupus erythematosus, 2173, 2373
temporal arteritis, 2177
urticarial, 1669
vasa vasorum, 2177
visceral larva migrans, 497
Vasculopathy
cold, 1806
complement activation, 1806
hepatitis C virus, 1806
Vesicles
articular cartilage, 1514
calcium pyrophosphate dihydrate crystals, 1514
cartilage degradation, 1514
osteoarthritis, 1514
Viruses
caprine arthritis encephalitis virus, 8
Epstein-Barr virus, 1174
hepatitis C virus, 1806
Visceral larva migrans
arthralgia, 497
monoarthritis, 497
panniculitis, 497
vasculitis, 497
Vitamin A
articular cartilage, 1913
osteoarthritis, 1913
rabbit studies, 1913
Vitamin C
hemarthrosis, 574
shoulder, 574
Vitamin D
bone mineral density, 2148
calcium, 2148
exertion, 2148
osteoporosis, 2148
von Willebrand factor
disease activity, 193, 320
juvenile dermatomyositis, 193, 320
magnetic resonance imaging, 193

W

Wegener's granulomatosis
cyclophosphamide, 1593
prednisone, 1593
progressive multifocal leukoencephalopathy, 1593
prostatitis, 187
West Africa
disease modifying antirheumatic drugs, 1434
rheumatoid arthritis clinical trials, 1434
Western Ontario and McMaster Universities Osteoarthritis Index
OMERACT II Conference, 1193
osteoarthritis clinical trials, 1193
rheumatoid arthritis clinical trials, 1193
Short Form 36, 1193
Workshop report
OMERACT II Conference, 998
World Health Organization
disease modifying antirheumatic drugs, 201
International League of Associations for Rheumatology, 201
osteoarthritis, 201
outcome measures, 201
slow acting antirheumatic drugs, 201

X

Xerostomia
Canadian Rheumatology Association Meeting, 1604 (ab)
diagnosis, 1604 (ab)
keratoconjunctivitis sicca, 1604 (ab)
sicca syndrome, 1604 (ab)
Sjögren's syndrome, 1604 (ab)

Y

Yersinia
acute anterior uveitis, 1598 (ab)
Canadian Rheumatology Association Meeting, 1598 (ab)
Salmonella, 1598 (ab)

Z

Zileuton
leukotrienes, 462
5-lipoxygenase, 462
systemic lupus erythematosus, 462